var title_f39_25_40336="Pelvic outlet view xray";
var content_f39_25_40336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Outlet view for radiograph of pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The outlet view of the pelvis is performed with the x-ray beam oriented 40 degrees caudal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gibbs, MA, Bosse, MJ. Pelvic Ring Fractures. In: Trauma Management: An Emergency Medicine Approach, Ferrara, PC, Colucciello, SA, Marx, JA, Verdile, VP, Gibbs, MA (Eds), Mosby, St. Louis 2001. p. 331. Illustrations used with permission of Elsevier Inc. All rights reserved. Copyright &copy;2001 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40336=[""].join("\n");
var outline_f39_25_40336=null;
var title_f39_25_40337="Syringomyelia with Chiari I malformation";
var content_f39_25_40337=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Syringomyelia associated with a Chiari I malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sagittal T1-weighted MRI reveals syringomyelia (arrows) involving the lower cervical spinal cord in a patient with a Chiari I malformation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40337=[""].join("\n");
var outline_f39_25_40337=null;
var title_f39_25_40338="Patient information: Ankle fracture (The Basics)";
var content_f39_25_40338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83149\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/19/33072\">",
"         Ankle bones",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/13/18647\">",
"          Foods and drinks with calcium and vitamin D",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/51/11058\">",
"         Patient information: Cast and splint care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ankle fracture (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ankle-fracture-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H3919791\">",
"      <span class=\"h1\">",
"       What is an ankle fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A &ldquo;fracture&rdquo; is another word for a broken bone. An ankle fracture is when a person breaks a bone in the ankle. The ankle bones include 2 lower leg bones called the tibia and fibula, and 1 foot bone called the talus (",
"      <a class=\"graphic graphic_figure graphicRef83112 \" href=\"mobipreview.htm?32/19/33072\">",
"       figure 1",
"      </a>",
"      ). There are different kinds of ankle fractures. The type of fracture depends on which bone breaks and how it breaks.",
"     </p>",
"     <p>",
"      Ankle fractures are common in both children and adults.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3919806\">",
"      <span class=\"h1\">",
"       What are the symptoms of an ankle fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of an ankle fracture include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Stiffness",
"       </li>",
"       <li>",
"        Bruising or blistering of the skin",
"       </li>",
"       <li>",
"        Being unable to walk or put weight on the ankle",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      An ankle fracture can also make the ankle look crooked.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3919821\">",
"      <span class=\"h1\">",
"       Is there a test for an ankle fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about the injury and symptoms, and do an exam. He or she will also order an X-ray of the ankle.",
"     </p>",
"     <p>",
"      Some people need other imaging tests, such as a CT or MRI scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3919836\">",
"      <span class=\"h1\">",
"       How are ankle fractures treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of ankle fracture and how severe it is.",
"     </p>",
"     <p>",
"      Treatment for a mild ankle fracture usually involves:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Resting the ankle",
"       </li>",
"       <li>",
"        Raising the ankle above the level of the heart, for example, by propping it up on pillows &ndash; This is helpful only for the first few days after an injury.",
"       </li>",
"       <li>",
"        Putting ice on the ankle &ndash; Put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and the skin. Use the ice (or other cold object) for at least 6 hours after the injury. Some people find it helpful to ice longer, even up to 2 days after an injury.",
"       </li>",
"       <li>",
"        Wearing a splint, brace, or cast &ndash; With some braces and casts, people are able to put weight on their ankle and walk around. With other braces and casts, people are not allowed to put weight on their ankle or walk around.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatment for an ankle fracture also includes medicine to treat the pain. Doctors can prescribe a strong pain medicine if people have a lot of pain or a severe fracture. For mild fractures, doctors usually recommend that people take an over-the-counter pain medicine. Over-the-counter medicines include",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;),",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"     </p>",
"     <p>",
"      A severe ankle fracture is treated with surgery. During surgery, the doctor will put the ankle bones back in position by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using screws, pins, rods, or plates to fix the bones inside the body",
"       </li>",
"       <li>",
"        Putting pins or screws through the skin and into the bones, and then attaching the pins or screws to a bar that is outside the skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors usually recommend that adults work with a physical therapist (exercise expert) after their ankle fracture heals. Physical therapists teach people exercises and stretches to strengthen the muscles and help the joints move more easily. Children usually heal fully without needing physical therapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3919851\">",
"      <span class=\"h1\">",
"       How long do ankle fractures take to heal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ankle fractures take weeks to months to heal, depending on the type of fracture.",
"     </p>",
"     <p>",
"      Healing time also depends on the person. Healthy children usually heal much more quickly than older adults or adults with other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3919866\">",
"      <span class=\"h1\">",
"       Can I do anything to improve the healing process?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to follow all of the doctor&rsquo;s instructions while the fracture is healing. This includes instructions about when to put weight on the ankle.",
"     </p>",
"     <p>",
"      Doctors also usually recommend that people with a fracture:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eat a healthy diet that includes getting enough calcium, vitamin D, and protein (",
"        <a class=\"graphic graphic_figure graphicRef79375 \" href=\"mobipreview.htm?18/13/18647\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Avoid getting their cast or splint wet, if they have a cast or splint that shouldn&rsquo;t get wet.",
"       </li>",
"       <li>",
"        Stop smoking. Fractures can take longer to heal if people smoke.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3919881\">",
"      <span class=\"h1\">",
"       When should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, the doctor or nurse will tell you when to call him or her. In general, you should call him or her if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You (or your child) get a fever, chest pain, or have trouble breathing.",
"       </li>",
"       <li>",
"        Pus drains out of the cut from the surgery, or the skin around the cut looks redder.",
"       </li>",
"       <li>",
"        The pain is severe, or the pain or swelling gets worse.",
"       </li>",
"       <li>",
"        The foot or toes get numb, or the toes look blue or purple.",
"       </li>",
"       <li>",
"        The splint is too tight or too loose.",
"       </li>",
"       <li>",
"        The cast gets damaged or wet, and it&rsquo;s not supposed to get wet.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3919896\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=see_link\">",
"       Patient information: Cast and splint care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/25/40338?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83149 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40338=[""].join("\n");
var outline_f39_25_40338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3919791\">",
"      What is an ankle fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3919806\">",
"      What are the symptoms of an ankle fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3919821\">",
"      Is there a test for an ankle fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3919836\">",
"      How are ankle fractures treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3919851\">",
"      How long do ankle fractures take to heal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3919866\">",
"      Can I do anything to improve the healing process?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3919881\">",
"      When should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3919896\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83149\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/19/33072\">",
"      Ankle bones",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/13/18647\">",
"       Foods and drinks with calcium and vitamin D",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_25_40339="Histology phyllodes tumor";
var content_f39_25_40339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cellular stroma with leaf-like process",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40339=[""].join("\n");
var outline_f39_25_40339=null;
var title_f39_25_40340="Urothelial dysplasia B";
var content_f39_25_40340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40340=[""].join("\n");
var outline_f39_25_40340=null;
var title_f39_25_40341="Salmeterol: Patient drug information";
var content_f39_25_40341=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Salmeterol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     see \"Salmeterol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"     see \"Salmeterol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Serevent&reg; Diskus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Serevent&reg; Diskhaler&reg; Disk;",
"     </li>",
"     <li>",
"      Serevent&reg; Diskus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In patients with asthma, long-acting puffers (inhalers) raised asthma-related deaths. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691447",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used to stop exercise-induced breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to salmeterol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701034",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to milk, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having a breathing attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3378219",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are",
"       <b>",
"        not",
"       </b>",
"       using other asthma drugs. This drug must be used with a long-term asthma-control drug like a breathed in steroid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not only take this drug for your asthma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat an asthma attack. Use a rescue inhaler. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698371",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throat irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor right away if your normal dose does not work as well or if you need to use your inhaler more often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse out mouth after each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a spacer with the puffer (inhaler).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695481",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Never wash the puffer (inhaler). Keep it dry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695121",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If working out or playing sports causes signs, use at least 30 minutes before doing it. Do not take more doses for at least 12 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use more than 2 doses a day.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699412",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store puffer (inhaler) at room temperature. Throw away any part not used after 6 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11857 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-BA627EFD15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40341=[""].join("\n");
var outline_f39_25_40341=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219869\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219870\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018034\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018036\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018035\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018040\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018041\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018043\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018038\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018039\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018044\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018045\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=related_link\">",
"      Salmeterol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=related_link\">",
"      Salmeterol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_25_40342="Colorectal cancer and primary sclerosing cholangitis";
var content_f39_25_40342=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Colorectal cancer and primary sclerosing cholangitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/25/40342/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40342/contributors\">",
"     Kris V Kowdley, MD, FACP, FACG, FASGE, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/25/40342/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40342/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/25/40342/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40342/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/25/40342/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ulcerative colitis (UC) are at increased risk for the development of colorectal carcinoma (CRC). The best established risk factors are long duration and increased anatomic extent of colitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"    </a>",
"    .) In addition, growing evidence suggests that concomitant primary sclerosing cholangitis (PSC) is an independent risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on the epidemiology and pathogenesis of colorectal cancer in patients with PSC and UC while providing recommendations for surveillance and addressing the possibility of chemoprevention. A general discussion on colorectal cancer in patients with inflammatory bowel disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of CRC in patients with UC complicated by PSC has been observed in a number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/1-3,7-9\">",
"     1-3,7-9",
"    </a>",
"    ]. A meta-analysis that included 11 studies concluded that the risk was increased by approximately fourfold in patients with PSC and UC compared to those with UC alone (OR 4.26; 95% CI 2.80-6.48) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following four examples illustrate the range of findings in some of the individual reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 211 patients estimated that the risk of colorectal cancer at 10 and 20 years follow-up was 14 and 31 percent, respectively, in patients with PSC and concomitant IBD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/9\">",
"       9",
"      </a>",
"      ]. In contrast, the corresponding risk was much lower in patients with PSC without IBD (2 and 2 percent, respectively).",
"     </li>",
"     <li>",
"      Another report included 132 patients with UC and PSC who were compared to a random sample of patients with UC without PSC in a historical cohort study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/3\">",
"       3",
"      </a>",
"      ]. Significantly more patients with UC and PSC developed CRC or dysplasia (25 versus 6 percent). Of 17 cancers developing in the PSC group, 76 percent occurred proximal to the splenic flexure and 35 percent presented at an advanced stage. In contrast, only 20 percent of cancers occurred proximal to the splenic flexure in patients with UC without PSC, and none were advanced. Significantly more deaths due to colorectal cancer were observed in patients with PSC (4.5 versus 0 percent). Possible risk factors for CRC in PSC included chronic disease activity and lack of folate supplementation.",
"     </li>",
"     <li>",
"      A similarly designed study included 20 patients with UC and PSC and 25 matched controls with UC but without PSC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/1\">",
"       1",
"      </a>",
"      ]. Colonic dysplasia was observed significantly more often in patients with UC and PSC (45 versus 16 percent). The time course to the development of dysplasia was similar among the two groups. Patients with PSC and UC were much more likely to have synchronous sites of dysplasia than patients with ulcerative colitis alone.",
"     </li>",
"     <li>",
"      A fourth study included 27 patients with UC and PSC who were compared to 1185 patients with UC alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/7\">",
"       7",
"      </a>",
"      ]. All patients had undergone total proctocolectomy. Patients with PSC were much more likely to have had dysplasia detected during surveillance (60 versus 12 percent), and dysplasia or cancer was detected significantly more often in resection specimens (67 versus 12 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of colon cancer has also been studied in patients with PSC and Crohn&rsquo;s disease (CD) involving the colon. A retrospective series that included 35 patients with PSC and colonic CD and 114 patients with colonic CD without PSC did not find an increased risk of dysplasia or colon cancer in patients with PSC and CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/11\">",
"     11",
"    </a>",
"    ]. Among the patients with PSC and CD, there was one patient (3 percent) with dysplasia and no patients with cancer, whereas among the patients with CD alone, there were eight patients (7 percent) with dysplasia (two were indefinite) and two patients (2 percent) with colon cancer.",
"   </p>",
"   <p>",
"    However, because of the low number of patients with CD and PSC studied, it is not possible to conclude definitively that the risk of cancer development in patients with colonic CD and concomitant PSC is lower than for UC. Colonoscopic screening in patients with UC, CD, indeterminate colitis, and even without IBD is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which concomitant PSC increases the risk of colonic neoplasia in patients with UC patients is unknown. Most attention has focused on alterations in the concentration and composition of colonic bile acids. As discussed above, PSC patients have a disproportionately higher likelihood of developing colon cancer proximal to the splenic flexure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. It has been hypothesized that this finding is due to the increased concentration of secondary bile acids in the proximal colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/3\">",
"     3",
"    </a>",
"    ]. Secondary bile acids such as deoxycholic acid and lithocholic acid are cytotoxic to colonic epithelial cells, induce hyperproliferation, and have been implicated in carcinogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In support of this hypothesis is the observation that patients with UC and colonic dysplasia or cancer have higher fecal bile acid concentrations than those without colonic neoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/14\">",
"     14",
"    </a>",
"    ]. Furthermore, ulcerative colitis in PSC tends to be characterized by rectal sparing and \"backwash\" ileitis, suggesting that epithelial injury may be relatively more severe in the proximal colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/15\">",
"     15",
"    </a>",
"    ]. Secondary bile acids may also influence the development of sporadic colonic adenomas and colon cancer since such patients have serum and fecal bile acid profiles that are high in deoxycholic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is increasing evidence that chronic inflammatory activity is the driver of carcinogenesis. PSC-IBD may represent a distinct entity of colitis in which low endoscopic activity may mask an active histologic inflammation that possibly contributes to an increased risk of malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also data suggesting that clinically progressive PSC requiring liver transplant is associated with a milder course of UC (reduced disease activity and less use of steroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and surgery). This is paralleled by less histological activity and reduced incidence of dysplasia and colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colitis in patients with PSC tends to be rectal sparing, is associated with backwash ileitis, has a mild or quiescent course, and is associated with an increased risk of pouchitis in those who undergo a proctocolectomy with ileal pouch anal anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/15,21,22\">",
"     15,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of UC in patients with PSC approaches 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35334?source=see_link\">",
"     \"Epidemiology and pathogenesis of primary sclerosing cholangitis\"",
"    </a>",
"    .) As a result, a 2010 guideline from the American Association for the Study of Liver Diseases (AASLD) recommends a full colonoscopy with biopsies in patients with newly diagnosed PSC and no previous history of symptoms of inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/25\">",
"     25",
"    </a>",
"    ]. Random rectal biopsies should be obtained even if the mucosa appears endoscopically normal since a significant number of patients may not have symptoms of diarrhea or endoscopic evidence of colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the high risk of colonic dysplasia in UC patients with PSC, a 2010 guideline from the AASLD recommends that patients with PSC and IBD undergo surveillance colonoscopy every one to two years from the time of diagnosis of PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients with PSC without IBD should undergo surveillance colonoscopy every five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If available, we suggest that flow cytometry be performed on biopsy samples from each level of the colon to look for DNA aneuploidy, which precedes the development of dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is our approach based upon the findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If surveillance biopsies and flow cytometry show no evidence of dysplasia or aneuploidy, we feel comfortable performing a follow-up colonoscopy after an interval of two to three years. A possible exception would be those patients with greater than 20 years' duration of colitis; in such patients it is reasonable to perform annual surveillance colonoscopy because of the high risk of dysplasia.",
"     </li>",
"     <li>",
"      If surveillance biopsies show no evidence of dysplasia, but flow cytometry is not available, a repeat colonoscopy is recommended annually. If flow cytometry is not available, chromoendoscopy can increase the yield of screening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=see_link\">",
"       \"Chromoendoscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If surveillance biopsies reveal indefinite dysplasia, repeat surveillance colonoscopy is recommended every 6 to 12 months. Prophylactic colectomy may also be discussed with the patient.",
"     </li>",
"     <li>",
"      If low grade dysplasia is detected, a variety of options may be considered, including total colectomy. It would also be reasonable to repeat a surveillance colonoscopy within three to six months to confirm a diagnosis of low grade dysplasia. If there are multiple sites of low grade dysplasia or multiple inflammatory polyps that preclude adequate surveillance, colectomy should be recommended. However, if low-grade dysplasia is present in only one biopsy specimen, repeat surveillance colonoscopy in 6 to 12 months may also be considered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If high grade dysplasia is detected, colectomy should be strongly recommended. Ileal pouch-anal canal anastomosis (IPAA) can be performed safely in the setting of sclerosing cholangitis. The preoperative Model for End-stage Liver Disease score and the use of preoperative immunosuppressive agents are not associated with an increased risk of complications. The likelihood of long-term pouch survival is excellent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHEMOPREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro and animal data suggest that the synthetic bile acid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA) may be chemoprotective against the development of colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The mechanism is unknown but may be due to reductions in the colonic concentration of toxic secondary bile acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/12,14,17,34\">",
"     12,14,17,34",
"    </a>",
"    ]. Furthermore, UDCA inhibited proliferation of colon cancer cell lines and in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/13,32,33,35\">",
"     13,32,33,35",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The possible clinical significance of these observations in humans was supported in a placebo controlled trial that included 52 patients with PSC and ulcerative colitis who had previously participated in a controlled trial of UDCA (13 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per day in divided doses) for PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The average age of participants was 43, the majority had pancolitis, and the median duration of ulcerative colitis was 15 years. During follow-up, colorectal neoplasia developed in three patients who had received UDCA compared with eight initially assigned to placebo (10 versus 35 percent, RR 0.26, 95% CI 0.06-0.92).",
"   </p>",
"   <p>",
"    A similar magnitude of benefit was also suggested in an earlier retrospective case-control study in which the use of UDCA in UC patients with PSC was associated with a decreased risk of colonic dysplasia (odds ratio of 0.18, 95% confidence interval 0.05-0.61) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/38\">",
"     38",
"    </a>",
"    ]. The effect of UDCA was noted after controlling for sex, age at onset of UC, duration of UC, duration of PSC, Child-Pugh class, and use of other medications.",
"   </p>",
"   <p>",
"    Different results were obtained in a nested cohort study using data from a double-blind, placebo-controlled trial of high-dose UDCA (28 to 30",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    in which 56 patients were followed for a total of 235 patient-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/39\">",
"     39",
"    </a>",
"    ]. In this study, patients who received high doses of UDCA had a significantly increased risk of developing colorectal neoplasia (dysplasia or cancer) compared to placebo (hazard ratio 4.4, 95% CI 1.3-20.1).",
"   </p>",
"   <p>",
"    A 2010 guideline issued by the American Association for the Study of Liver diseases recommends against use of UDCA for chemoprevention of colorectal cancer in patients with primary sclerosing cholangitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A protective effect of UDCA on polyp recurrence has also been suggested in patients with primary biliary cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/40\">",
"     40",
"    </a>",
"    ]. A benefit on prevention of recurrent adenomas that contained high-grade dysplasia was described in a controlled trial of patients with sporadic adenomas, although there was not statistically significant benefit on adenoma recurrence overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Folate supplementation may also have a chemoprotective role against the development of CRC. The Nurses' Health study and other epidemiologic studies have shown that folate supplementation was associated with a decreased risk of developing sporadic CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Folate deficiency may lead to hypomethylation of DNA, an early step in colonic carcinogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, folate deficiency may predispose to abnormalities in DNA synthesis and repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only a limited number of studies have looked at the influence of folate supplementation on the development of colonic neoplasia in UC patients with or without concomitant PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/3,45\">",
"     3,45",
"    </a>",
"    ]. Patients with UC may be at particular risk, since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    use is a known cause of folate deficiency. In one case-control study, the adjusted relative risk of developing colonic dysplasia or cancer was 0.47 in",
"    <span class=\"nowrap\">",
"     UC/PSC",
"    </span>",
"    patients who received folate supplementation, although this did not reach statistical significance (95% confidence interval 0.18-1.20) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40342/abstract/3\">",
"     3",
"    </a>",
"    ]. In summary, the full role of folate in the chemoprevention of CRC remains unknown. We recommend folate supplementation of 0.4 to 1.0 mg in all patients with UC who are receiving chronic sulfasalazine therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFECT OF LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have suggested that the risk of colon cancer is increased following liver transplantation, although at least one study suggested that the risk was mainly related to the duration of IBD, not the transplant itself. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41097?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of primary sclerosing cholangitis\", section on 'Liver transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ulcerative colitis (UC) are at increased risk for the development of colorectal carcinoma (CRC). The best established risk factors are long duration and increased anatomic extent of colitis.",
"     </li>",
"     <li>",
"      The prevalence of UC in patients with primary sclerosing cholangitis (PSC) approaches 90 percent. We agree with a 2010 guideline from the American Association for the Study of Liver Diseases (AASLD), which suggests a full colonoscopy with biopsies in patients with newly diagnosed PSC and no previous history of symptoms of inflammatory bowel disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The role of chemoprophylaxis in patients with PSC and inflammatory bowel disease is unproven and thus cannot be recommended routinely. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Chemoprevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3396719743\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Bruce Tung, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/1\">",
"      Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996; 110:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/2\">",
"      Broom&eacute; U, L&ouml;fberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/3\">",
"      Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999; 94:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/4\">",
"      Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997; 41:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/5\">",
"      Gurbuz AK, Giardiello FM, Bayless TM. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis Colon Rectum 1995; 38:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/6\">",
"      D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993; 88:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/7\">",
"      Marchesa P, Lashner BA, Lavery IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997; 92:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/8\">",
"      Lindberg BU, Broom&eacute; U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001; 44:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/9\">",
"      Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/10\">",
"      Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/11\">",
"      Braden B, Halliday J, Aryasingha S, et al. Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2012; 10:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/12\">",
"      Ochsenk&uuml;hn T, Bayerd&ouml;rffer E, Meining A, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999; 85:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/13\">",
"      Martinez JD, Stratagoules ED, LaRue JM, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998; 31:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/14\">",
"      Hill MJ, Melville DM, Lennard-Jones JE, et al. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987; 2:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/15\">",
"      Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/16\">",
"      Bayerd&ouml;rffer E, Mannes GA, Richter WO, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993; 104:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/17\">",
"      Stadler J, Yeung KS, Furrer R, et al. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. Cancer Lett 1988; 38:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/18\">",
"      Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer 1977; 39:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/19\">",
"      J&oslash;rgensen KK, Grzyb K, Lundin KE, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012; 18:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/20\">",
"      Marelli L, Xirouchakis E, Kalambokis G, et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011; 60:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/21\">",
"      Lundqvist K, Broom&eacute; U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/22\">",
"      Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/23\">",
"      Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/24\">",
"      Tung BY, Brentnall TA, Kowdley KV, et al. Diagnosis and prevalence of ulcerative colitis in patients with sclerosing cholangitis (abstract). Hepatology 1996; 24:169A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/25\">",
"      Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/26\">",
"      Fevery J, Henckaerts L, Van Oirbeek R, et al. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study. Liver Int 2012; 32:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/27\">",
"      L&ouml;fberg R, Brostr&ouml;m O, Karl&eacute;n P, et al. DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 1992; 102:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/28\">",
"      Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/29\">",
"      Brentnall TA, Bronner MP, Rubin CE, et al. Natural history and management of low-grade dysplasia in ulcerative colitis (abstract). Gastroenterology 1999; 116:A382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/30\">",
"      L&ouml;fberg R, Brostr&ouml;m O, Karl&eacute;n P, et al. Colonoscopic surveillance in long-standing total ulcerative colitis--a 15-year follow-up study. Gastroenterology 1990; 99:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/31\">",
"      Mathis KL, Benavente-Chenhalls LA, Dozois EJ, et al. Short- and long-term surgical outcomes in patients undergoing proctocolectomy with ileal pouch-anal anastomosis in the setting of primary sclerosing cholangitis. Dis Colon Rectum 2011; 54:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/32\">",
"      Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res 1998; 89:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/33\">",
"      Earnest DL, Holubec H, Wali RK, et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994; 54:5071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/34\">",
"      Rodrigues CM, Kren BT, Steer CJ, Setchell KD. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995; 109:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/35\">",
"      Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats. J Exp Clin Cancer Res 1999; 18:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/36\">",
"      Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/37\">",
"      Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/38\">",
"      Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/39\">",
"      Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/40\">",
"      Serfaty L, De Leusse A, Rosmorduc O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003; 38:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/41\">",
"      Alberts DS, Mart&iacute;nez ME, Hess LM, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005; 97:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/42\">",
"      Glynn SA, Albanes D, Pietinen P, et al. Colorectal cancer and folate status: a nested case-control study among male smokers. Cancer Epidemiol Biomarkers Prev 1996; 5:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/43\">",
"      Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 1998; 129:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/44\">",
"      Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985; 228:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40342/abstract/45\">",
"      Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4055 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40342=[""].join("\n");
var outline_f39_25_40342=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHEMOPREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFECT OF LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3396719743\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35334?source=related_link\">",
"      Epidemiology and pathogenesis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41097?source=related_link\">",
"      Treatment of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_25_40343="Television and media violence";
var content_f39_25_40343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Television and media violence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/25/40343/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40343/contributors\">",
"     Robert D Sege, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/25/40343/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40343/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40343/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/25/40343/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40343/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/25/40343/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although decreased from its peak in the 1990s, violence continues to be a major cause of death and disability for American children. Exposure to television violence is an important and virtually ubiquitous risk factor for youth violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/1\">",
"     1",
"    </a>",
"    ]. Pediatric care providers and parents can work together to decrease the exposure of children to media violence (primary prevention) and, if exposed, to mitigate the effects (secondary prevention).",
"   </p>",
"   <p>",
"    In broad terms, the impact of any influence on health behaviors is the product of the number of persons exposed and the magnitude of the effect of the exposure. This review first explores the ubiquity of exposure of children to television violence, then reviews studies that have established the negative consequences of this exposure, and concludes with suggestions for clinical interventions. Much of the research reviewed was conducted in the 1980s and 1990s, when the influence of media exposure on children was first established. Since then, the variety of media available has exploded, although there is no reason to believe that the exposure has decreased.",
"   </p>",
"   <p>",
"    The association between viewing violence and subsequent violent behavior and prevention of the consequences of media violence are reviewed here. Other types of violence are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40617?source=see_link\">",
"       \"Peer violence and violence prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5784?source=see_link\">",
"       \"Intimate partner violence: Epidemiology and health consequences\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31097?source=see_link\">",
"       \"Childhood exposure to intimate partner violence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=see_link\">",
"       \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24890?source=see_link\">",
"       \"Physical abuse in children: Diagnostic evaluation and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     QUANTITY OF MEDIA VIOLENCE EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents in the United States spend an average of four hours per day watching television, and more than seven hours per day when all types of media are included (eg, video games, computers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/2\">",
"     2",
"    </a>",
"    ]. Children's television is the most violent genre of programming. Whereas violent acts (acts intended to injure or harm others) appear 8 to 12 times per hour on prime-time television, cartoons often show 25 to 50 violent acts per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Movies are another source of violent content. In a review of 77 movies from 1999 and 2000 that were rated PG-13, nearly 90 percent had violent content, and firearms were used in nearly one-third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/5\">",
"     5",
"    </a>",
"    ]. Overall, 2251 acts of violence were observed, 47 percent of which were of lethal magnitude. Seven movies contained more than 100 acts of violence. In another review of 61 G- and PG-rated movies released between 1998 and 2002, 28 percent included characters with guns, 48 percent depicted gun threats, and guns were discharged in 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the consequences of gun use (injury and death) were rarely portrayed. A survey of 6522 United States adolescents aged 10 to 14 years in 2003 indicated that 12.5 percent had seen at least 1 of 40 movies that were rated R for violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Media violence is without consequence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Music videos and video games are additional sources of violent content. In a review of 518 music videos broadcast on television, 462 acts of overt interpersonal violence were portrayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/8\">",
"     8",
"    </a>",
"    ]. Content analysis of 81 randomly selected video games for teenagers found that 98 percent involved intentional violence, 90 percent rewarded or required the player to injure other characters, and 69 percent rewarded or required the player to kill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the data associating video game use with actual violent behavior remain controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The average American child who spends two-thirds of his or her television time watching prime-time television programs and one-third watching cartoons views 10,000 to 12,000 violent acts per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. American children see an estimated 8000 murders and 100,000 acts of violence by the time they finish grade school and twice that many by the time they reach 20 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A random survey of 1051 families conducted in 2005 by the Kaiser Family Foundation demonstrated the continued early and consistent use of television by American families. Over 40 percent of infants less than one year old watch television daily; this proportion climbs to 80 percent by age two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     QUALITY OF MEDIA VIOLENCE EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of viewing violence depends upon the amount, the context in which it is seen, and the social message that accompanies the presentation. Although violence is portrayed in other media (eg, song lyrics, music videos, movies), television violence is best studied. Television violence, because it does not rely on verbal or written language, is understandable to preverbal and preliterate children. Television violence differs from real violence in ways that affect its impact on children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Media violence is socially acceptable",
"    </span>",
"    &nbsp;&mdash;&nbsp;Violence is used more often than patience, negotiation, or compromise to resolve conflict in the media. It is portrayed as an effective, socially acceptable, and normative way to solve problems, is used by heroes as well as villains, and often is rewarded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/4,9,15\">",
"     4,9,15",
"    </a>",
"    ]. In the study of music videos described above, for example, the protagonist of the video was the aggressor in 80 percent of the violent acts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Media violence is without consequence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Violence in the media has a variety of dramatic functions but is rarely seen as painful. In cartoons, violence is meant to be funny; the victim, however seriously injured, reappears intact after the commercial break. In other programs, heroes typically are spared the effects of violence, and villains, even if they are killed, rarely suffer. In the National Television Violence Study, for example, only 16 percent of violent programs showed long-term negative outcomes; 73 percent of violent acts were unpunished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/16\">",
"     16",
"    </a>",
"    ]. In G- and PG-rated movies, injuries and deaths related to firearms are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/6\">",
"     6",
"    </a>",
"    ]. This portrayal of violence without pain is internalized by children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ASSOCIATION BETWEEN VIEWING VIOLENCE AND VIOLENT BEHAVIOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood television viewing is associated with increased risk of subsequent violence. Despite their limitations, multiple studies have demonstrated this effect; taken together, they meet the epidemiologic criteria for causality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/11\">",
"     11",
"    </a>",
"    ]. These criteria include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A temporal relationship between variables",
"     </li>",
"     <li>",
"      Consistency of the association on replication",
"     </li>",
"     <li>",
"      Strength of association",
"     </li>",
"     <li>",
"      Specificity of association",
"     </li>",
"     <li>",
"      A coherent explanation that accounts for the findings",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Temporal relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies describe the temporal relationship between viewing of violence and subsequent violent behavior.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of field studies of children in controlled environments (eg, boarding school) who were assigned to view films that were violent or nonviolent and then monitored for a period of time by trained observers for aggressive or violent behavior demonstrated a clear and consistent association between the viewing of violent films and short-term violent or aggressive behavior [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      These field studies do not show which children are particularly vulnerable to the effect of viewing violence, the duration of the effect, the effect of television viewed in private, or a dose-response relationship.",
"     </li>",
"     <li>",
"      A cohort of eight-year-old children from a county of New York State were followed for 22 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. The socioeconomic status, parenting styles, size of family, and the quantity and quality of television viewing were among the variables studied. Compared with their peers, boys who were reported to view and prefer violent television programming at age eight were approximately twice as likely to be arrested for a violent crime by age 30 years. A weaker association was found between viewing television violence at age 18 years and subsequent violence history by age 30, suggesting that eight-year-old children are more susceptible to media violence than are 18-year-old adolescents. No relationship was found between aggressive behavior at age eight and subsequent viewing of television violence at age 19.",
"      <br/>",
"      <br/>",
"      This study is limited by the lack of randomization and experimental manipulation and the inability to control for potential confounding variables.",
"     </li>",
"     <li>",
"      Population studies examined homicide trends in the United States, white South Africa, and Canada before, during, and after the introduction of television in each country [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. The homicide rate doubled in each of these countries 10 to 12 years after the introduction of television.",
"      <br/>",
"      <br/>",
"      These studies are limited by their inability to control for other contemporary trends or events (eg, the Vietnam War, the struggle over apartheid) that might also account for the homicide trends.",
"     </li>",
"     <li>",
"      In a controlled trial, third- and fourth-grade children at one school received an 18-lesson, 6-month curriculum to reduce television, videotape, and video game use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/25\">",
"       25",
"      </a>",
"      ]. Compared with control children, children in the intervention school had decreased verbal aggression and decreased peer ratings of aggression. This study demonstrates the efficacy of television reduction as a violence prevention strategy, lending further support to the causal role of television in youth violence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Consistency of association",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly every study examining the relationship between television or other media violence and subsequent violent behavior has demonstrated a positive association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/11,19,26-36\">",
"     11,19,26-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Strength and specificity of association",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most studies, the association of television violence and subsequent violent behavior is significant and persists when a variety of other variables known to influence violent behavior are controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/11,28,29\">",
"     11,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Coherent explanation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The explanation to account for the association between viewing violence and subsequent violent conduct has two components. The first one is based upon the ways in which children learn how to behave. The second one is related to the desensitization to and normalization of violence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Imitation and reinforcement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social learning begins at an early age through imitation and positive or negative reinforcement of behaviors. As described above, several aspects of televised violence render its imitation appealing to children:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The effectiveness",
"     </li>",
"     <li>",
"      The rewards that heroes receive for its use",
"     </li>",
"     <li>",
"      The lack of consequences",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Support for this explanation comes from an early experimental study of preschool children who were shown one of three versions of a short film in which an actor hits and kicks a clown doll [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/37\">",
"     37",
"    </a>",
"    ]. In the first version, the film ends after the violence; in the second, the actor is rewarded after the attack; and in the third, the actor is punished after the attack. The children were led to a room containing an identical clown doll after they viewed the film. The children who saw the first and second versions of the film tended to attack the doll in the same way that the actor had. The children who saw the third version did not attack the doll as often.",
"   </p>",
"   <p>",
"    Additional support is provided by comparison of the portrayal of violence in American and Japanese television. In Japan, where violence more often is perpetrated by the villain and the consequences of violence (eg, suffering for the hero) are emphasized, society is less violent than in America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Media violence, including violent video games, systematically desensitizes young people to violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/40\">",
"     40",
"    </a>",
"    ]. The combination of ubiquitous violence and the successful use of violence by heroes in the media desensitize American children to the horror of killing.",
"   </p>",
"   <p>",
"    The normalization of and desensitization to violence has three effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased likelihood of aggression",
"     </li>",
"     <li>",
"      Increased likelihood of being a victim",
"     </li>",
"     <li>",
"      The bystander effect",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who are exposed repeatedly to media violence accept violence as a normal part of life and a way to solve problems. They learn that objecting to violence may lead to more serious violence. They may resign themselves to violence, fail to seek help, and become more susceptible to becoming victims. Bystanders who feel that physical violence is a normal part of life encourage others to fight or refrain from intervening to prevent a fight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/42\">",
"     42",
"    </a>",
"    ]. In contrast, when children learn sanctions against aggression, aggressive behavior decreases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MODULATORS OF EFFECTS OF VIOLENCE VIEWING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual qualities of the viewer interact with the violence that is portrayed to produce a particular outcome in behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Some individuals are strongly affected by certain program elements, whereas other elements have no effect. The circumstances that increase the likelihood that television violence will have behavioral consequences include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/1,44\">",
"     1,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The violence works for the protagonist",
"     </li>",
"     <li>",
"      The violence is justified",
"     </li>",
"     <li>",
"      The violence is pertinent to the viewer's life circumstance (eg, the perpetrator is similar to the viewer)",
"     </li>",
"     <li>",
"      The viewer is susceptible (eg, viewer is angry or provoked before the viewing)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect on individuals is influenced by temperamental and environmental variables. Children who identify with violent media characters are likely to use aggression in their lives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/28\">",
"     28",
"    </a>",
"    ]. To the extent that children who witness aggressive solutions to interpersonal problems identify with the aggressive character, they fantasize about the aggressive behavior and remember the aggressive characters that they observe. The aggressive behavior then becomes habitual and interferes with social and academic success, leading to more regular television viewing, thus perpetuating a cycle of aggression, academic and social failure, violence viewing, and aggressive fantasizing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EFFECTS OF MEDIA VIOLENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Television violence produces four types of harmful effects on viewers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/42,45-48\">",
"     42,45-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased tendency for viewers of large amounts of television to behave violently toward others (aggressor effect) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An increased fearfulness of becoming a victim of violence, with a resultant increase in self-protective behavior",
"     </li>",
"     <li>",
"      An increased callousness and desensitization toward actual violence (bystander effect)",
"     </li>",
"     <li>",
"      A cycle in which aggressive children who watch television violence identify with violent characters, act like those characters, and seek out more and more violent programming",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeated exposure to television violence produces subtle shifts in how adult Americans view the world and contributes to a pessimistic perspective. Adults who watch large amounts of television are more likely to view the world with feelings of danger, mistrust, intolerance, gloom, and hopelessness than do adults with less television exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/50\">",
"     50",
"    </a>",
"    ]. Similar results are found in preschool children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This pessimistic world view has implications for policy making and individual actions. As an example, more Americans now own handguns than did a decade ago, despite the well-documented increased personal risk of injury or death associated with handgun ownership and the decline in the overall rate of violent crime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADVOCACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric care providers can address the problem of media violence and associated violent behavior at three levels: the family, the community and school, and the legislative and regulatory approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Family and individual",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric care providers discuss parenting practices and offer anticipatory guidance at most health supervision visits. The provision of advice regarding television viewing fits well into this practice.",
"   </p>",
"   <p>",
"    The television viewing history has three main questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Where are the televisions located in the household?",
"     </li>",
"     <li>",
"      How much television does the child watch after school, after dinner, and on weekends?",
"     </li>",
"     <li>",
"      What are some of the child's favorite shows?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parents should be educated about the adverse consequences of television viewing (eg, exposure to violence, obesity, and decreased school achievement) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/33,54-57\">",
"     33,54-57",
"    </a>",
"    ] and then advised about ways to decrease the exposure and the effects of media violence. Specific and efficient advice maximizes the effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/11,58-61\">",
"     11,58-61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limit children's total media time to less than one to two hours per day",
"     </li>",
"     <li>",
"      Remove television sets from children's bedrooms",
"     </li>",
"     <li>",
"      Discourage television viewing for children younger than two years",
"     </li>",
"     <li>",
"      Monitor the shows that are viewed by children and adolescents",
"     </li>",
"     <li>",
"      View programs and discuss the content with children:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Is this real or pretend?",
"     </li>",
"     <li>",
"      Is this how we do things at home?",
"     </li>",
"     <li>",
"      What do you think would happen if you did that?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use controversial programming to initiate discussions about family values, violence, sexuality, and drugs",
"     </li>",
"     <li>",
"      Encourage alternative entertainment for children (eg, reading, athletics, hobbies, and creative play)",
"     </li>",
"     <li>",
"      Use devices to block unauthorized television viewing if necessary (eg, a lock for the television's electrical plug)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medical care settings should set an example for the above recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/58,61,62\">",
"     58,61,62",
"    </a>",
"    ]. Reading programs using volunteers should be implemented in waiting rooms and inpatient units. Televisions in hospitals, offices, and clinic waiting areas should be tuned to nonviolent programming and display a sign that says: \"This television is tuned to a public television channel so that children can watch nonviolent shows.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     School and community",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric care providers who are consultants to schools, hospitals, or parent groups should emphasize the importance of diminishing the exposure of children to televised violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/58,62\">",
"     58,62",
"    </a>",
"    ]. As an example, pediatric health care providers can support community-based \"television turn-offs\" and media literacy programs to teach children critical viewing skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Legislation and regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term goals of legislative and regulatory advocacy include decreased frequency and different characterization of violence (eg, with consequences) and the promotion of alternative strategies for conflict resolution.",
"   </p>",
"   <p>",
"    Pediatric care providers should be aware of policies and proposed policy changes in government and industry regulation and should try to focus their advocacy efforts on simple measures that do not impinge on the First Amendment rights of broadcasters. Pediatric care providers should work with the entertainment industry to encourage responsible programming and compliance with the major broadcast networks' standards regarding television violence. These standards proscribe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/61,63\">",
"     61,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gratuitous or excessive depictions of violence",
"     </li>",
"     <li>",
"      Depictions of violence as glamorous",
"     </li>",
"     <li>",
"      Depictions of violence as an acceptable solution to human conflict",
"     </li>",
"     <li>",
"      Depictions of violence designed to shock or stimulate the audience",
"     </li>",
"     <li>",
"      Scenes showing excessive gore, pain, or physical suffering",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the standards urge that the consequences of televised violence be portrayed and that portrayals of callousness or indifference to suffering experienced by the victims of violence be avoided.",
"   </p>",
"   <p>",
"    The Children's Television Act of 1990 and the Revision of Programming Policies for Television Broadcast Stations called for an increase in the quality of children's programming [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Broadcasters are required to air educational and informational programming at least three hours per week, to limit the amount of advertising during children's programming, and to label the shows",
"    <span class=\"nowrap\">",
"     E/I",
"    </span>",
"    (educational and informational) on the screen. Pediatric advocates can use the provisions of these acts to work with their local broadcast stations to develop violence-free programming [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/61,66\">",
"     61,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Telecommunications Act of 1996 gave the broadcasting industry an opportunity to establish voluntary ratings for programming that contains sexual, violent, or other content that parents may consider inappropriate for children (",
"    <a class=\"graphic graphic_table graphicRef65107 \" href=\"mobipreview.htm?36/28/37324\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/67\">",
"     67",
"    </a>",
"    ]. Although parent and industry raters may disagree on what is appropriate viewing for children of various ages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/68\">",
"     68",
"    </a>",
"    ], the rating system is a first step in helping parents choose programming for their children. The rating system and the \"v-chip\" enable parents to prevent certain programming from entering their homes.",
"   </p>",
"   <p>",
"    The FCC has adopted rules requiring all new television sets with screens larger than 33 cm to be equipped with v-chips (",
"    <a class=\"external\" href=\"file://www.fcc.gov/vchip/\">",
"     www.fcc.gov/vchip/",
"    </a>",
"    ). However, reports indicate that less than half of purchasers of these televisions are aware of the v-chip, and only a tiny minority use them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40343/abstract/69\">",
"     69",
"    </a>",
"    ]. So, for the time being, parental, rather than electronic, controls will mediate the exposure of children to television violence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477663690\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children and adolescents in the United States spend an average of 6.5 hours per day watching television, playing video games, or using computers. Children&rsquo;s television (particularly cartoons), movies, music videos, and video games are potential sources of violent content. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Quantity of media violence exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effect of viewing violence depends upon the amount, the context in which it is seen, and the social message that accompanies the presentation. Televised violence differs from real violence in ways that affect its impact on children and adolescents. Media violence often is perceived as socially acceptable and without consequence. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Quality of media violence exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite their limitations, multiple studies have demonstrated that childhood television viewing is associated with increased risk of subsequent violence by demonstrating a temporal relationship; consistency, strength, and specificity of the association; and a coherent explanation for the association. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Association between viewing violence and violent behavior'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individual qualities of the viewer interact with the violence that is portrayed to produce a particular outcome in behavior. Some individuals are strongly affected by certain program elements, whereas other elements have no effect. The effect on individuals is influenced by temperamental and environmental variables. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Modulators of effects of violence viewing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of increased exposure to media violence may include (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Effects of media violence'",
"      </a>",
"      above): &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased tendency to behave violently toward others (aggressor effect)",
"     </li>",
"     <li>",
"      Increased fearfulness of becoming a victim, with a resultant increase in self-protective behavior",
"     </li>",
"     <li>",
"      Increased callousness and desensitization toward actual violence (bystander effect)",
"     </li>",
"     <li>",
"      A cycle in which aggressive children who watch television violence identify with violent characters, act like those characters, and seek out more and more violent programming",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric care providers can address the problem of media violence and associated violent behavior at three levels: the family, the community and school, and the legislative and regulatory approaches. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Advocacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/1\">",
"      Comstock G, Strasburger VC. Deceptive appearances: television violence and aggressive behavior. J Adolesc Health Care 1990; 11:31.",
"     </a>",
"    </li>",
"    <li>",
"     Rideout VJ, Foehr UG, Roberts DF. Generation M2: Media in the lives of 8- to 18-year olds. Kaiser Family Foundation, Menlo Park, CA 2010. file://www.kff.org/entmedia/upload/8010.pdf (Accessed on June 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/3\">",
"      Dietz WH, Strasburger VC. Children, adolescents, and television. Curr Probl Pediatr 1991; 21:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/4\">",
"      Yokota F, Thompson KM. Violence in G-rated animated films. JAMA 2000; 283:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/5\">",
"      Webb T, Jenkins L, Browne N, et al. Violent entertainment pitched to adolescents: an analysis of PG-13 films. Pediatrics 2007; 119:e1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/6\">",
"      Ramsey LT, Pelletier AR. Update on firearm use in G- and PG-rated movies. JAMA 2004; 292:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/7\">",
"      Worth KA, Gibson Chambers J, Nassau DH, et al. Exposure of US adolescents to extremely violent movies. Pediatrics 2008; 122:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/8\">",
"      Rich M, Woods ER, Goodman E, et al. Aggressors or victims: gender and race in music video violence. Pediatrics 1998; 101:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/9\">",
"      Haninger K, Thompson KM. Content and ratings of teen-rated video games. JAMA 2004; 291:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/10\">",
"      Olson CK. Media violence research and youth violence data: why do they conflict? Acad Psychiatry 2004; 28:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/11\">",
"      Sege R, Dietz W. Television viewing and violence in children: the pediatrician as agent for change. Pediatrics 1994; 94:600.",
"     </a>",
"    </li>",
"    <li>",
"     Gerbner G, Signorielli N. Violence profile 1967 through 1988-89: Enduring Patterns. Annenberg School for Communication, Philadelphia 1990.",
"    </li>",
"    <li>",
"     Donnerstein E, Slaby RG, Eron LD. The mass media and youth aggression. In: A Psychosocial Perspective on Violence and Youth, Eron LD, Gentry JH, Schlegel P (Eds), American Psychological Association Press, Washington, DC 1996. p.219.",
"    </li>",
"    <li>",
"     Rideout, Hamel. The media family: electronic media in the lives of infants, toddlers, pre-schoolers and their parents. The Kaiser Family Foundation May 2006. Available at: www.kff.org/entmedia/7500.cfm (Accessed on October 04, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/15\">",
"      Willis E, Strasburger VC. Media violence. Pediatr Clin North Am 1998; 45:319.",
"     </a>",
"    </li>",
"    <li>",
"     National Television Violence Study, Vol 1 1996; vol 2 1997. Sage, Thousand Oaks, CA.",
"    </li>",
"    <li>",
"     Public Health Service. Smoking and Health: Report of the advisory committee to the Surgeon General. U.S. Government Printing Office. Washington, DC 1964.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/18\">",
"      Evans AS. Causation and disease: a chronological journey. The Thomas Parran Lecture. 1978. Am J Epidemiol 1995; 142:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/19\">",
"      Wood W, Wong FY, Chachere JG. Effects of media violence on viewers' aggression in unconstrained social interaction. Psychol Bull 1991; 109:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/20\">",
"      Turner CW, Hesse BW, Peterson-Lewis S. Naturalistic studies of the long-term effects of television violence. J Soc Issues 1986; 42:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/21\">",
"      Huesmann LR, Eron LD. Cognitive processes and the persistence of aggressive behavior. Aggressive Behavior 1984; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/22\">",
"      Huesmann LR. Psychological processes promoting the relation between exposure to media violence and aggressive behavior by the viewer. J Social Issues 1986; 42:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/23\">",
"      Centerwall BS. Exposure to television as a risk factor for violence. Am J Epidemiol 1989; 129:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/24\">",
"      Centerwall BS. Television and violence. The scale of the problem and where to go from here. JAMA 1992; 267:3059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/25\">",
"      Robinson TN, Wilde ML, Navracruz LC, et al. Effects of reducing children's television and video game use on aggressive behavior: a randomized controlled trial. Arch Pediatr Adolesc Med 2001; 155:17.",
"     </a>",
"    </li>",
"    <li>",
"     Surgeon General's Scientific Advisory Committee on Television and Social Behavior. Television and growing up: The impact of televised violence. U.S. Government Printing Office, Washington, DC 1972.",
"    </li>",
"    <li>",
"     National Institute of Mental Health. Television and behavior, Volume 1: Summary report. U.S. Government Printing Office, Washington, DC 1982.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/28\">",
"      Huesmann LR, Moise-Titus J, Podolski CL, Eron LD. Longitudinal relations between children's exposure to TV violence and their aggressive and violent behavior in young adulthood: 1977-1992. Dev Psychol 2003; 39:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/29\">",
"      Christakis DA, Zimmerman FJ. Violent television viewing during preschool is associated with antisocial behavior during school age. Pediatrics 2007; 120:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/30\">",
"      Ybarra ML, Diener-West M, Markow D, et al. Linkages between internet and other media violence with seriously violent behavior by youth. Pediatrics 2008; 122:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/31\">",
"      Anderson CA, Sakamoto A, Gentile DA, et al. Longitudinal effects of violent video games on aggression in Japan and the United States. Pediatrics 2008; 122:e1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/32\">",
"      Manganello JA, Taylor CA. Television exposure as a risk factor for aggressive behavior among 3-year-old children. Arch Pediatr Adolesc Med 2009; 163:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/33\">",
"      Council on Communications. Policy Statement--Media Education. Pediatrics 2010; 126:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/34\">",
"      Paik H, Comstock G. The effects of television violence on antisocial behavior: a meta-analysis. Communication Research 1994; 21:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/35\">",
"      Anderson CA, Shibuya A, Ihori N, et al. Violent video game effects on aggression, empathy, and prosocial behavior in eastern and western countries: a meta-analytic review. Psychol Bull 2010; 136:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/36\">",
"      Bensley L, Van Eenwyk J. Video games and real-life aggression: review of the literature. J Adolesc Health 2001; 29:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/37\">",
"      BANDURA A, ROSS D, ROSS SA. Imitation of film-mediated agressive models. J Abnorm Soc Psychol 1963; 66:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/38\">",
"      Media violence. American Academy of Pediatrics Committee on Communications. Pediatrics 1995; 95:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/39\">",
"      Iwao S, de Sola Pool I, Hagiwara S. Japanese and U.S. Media: Some Cross-Cultural Insights into TV Violence. J Commun 1981; 31:28.",
"     </a>",
"    </li>",
"    <li>",
"     Grossman D. On Killing: The psychological cost of learning to kill in war and society, Little Brown and Company, Boston 1995.",
"    </li>",
"    <li>",
"     American Psychological Association Commission on Violence and Youth. Violence &amp; youth: Psychology's response. Washington, DC 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/42\">",
"      Drabman RS, Thomas MH. Does watching violence on television cause apathy? Pediatrics 1976; 57:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/43\">",
"      Henry D, Guerra N, Huesmann R, et al. Normative influences on aggression in urban elementary school classrooms. Am J Community Psychol 2000; 28:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/44\">",
"      Hogan MJ. Adolescents and media violence: six crucial issues for practitioners. Adolesc Med Clin 2005; 16:249.",
"     </a>",
"    </li>",
"    <li>",
"     Slaby, R. Television violence: Effects and remedies. Testimony before the Subcommittee on Crime and Criminal Justice of the U.S. House of Representatives' Committee on Judiciary Affairs. U.S. Government Printing Office. Washington, DC 1992.",
"    </li>",
"    <li>",
"     Commission for the Prevention of Youth Violence. Youth and Violence: Medicine, Nursing, and Public Health: Connecting the dots to prevent violence. December 2000. Available at: www.ama-assn.org/ama/upload/mm/386/fullreport.pdf (Accessed on April 20, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/47\">",
"      Rich JA, Stone DA. The experience of violent injury for young African-American men: the meaning of being a \"sucker\". J Gen Intern Med 1996; 11:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/48\">",
"      Singer MI, Slovak K, Frierson T, York P. Viewing preferences, symptoms of psychological trauma, and violent behaviors among children who watch television. J Am Acad Child Adolesc Psychiatry 1998; 37:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/49\">",
"      Villani S. Impact of media on children and adolescents: a 10-year review of the research. J Am Acad Child Adolesc Psychiatry 2001; 40:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/50\">",
"      Gerbner G, Gross L, Morgan M, Signorielli N. The \"mainstreaming\" of America: Violence profile number 11. J Commun 1980; 33:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/51\">",
"      Singer JS, Rapaczynski W. Family patterns and television viewing as predictors of children's beliefs and aggression. J Commun 1984; 37:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/52\">",
"      Denno DM, Grossman DC, Britt J, Bergman AB. Safe storage of handguns. What do the police recommend? Arch Pediatr Adolesc Med 1996; 150:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/53\">",
"      Kellermann AL, Rivara FP, Rushforth NB, et al. Gun ownership as a risk factor for homicide in the home. N Engl J Med 1993; 329:1084.",
"     </a>",
"    </li>",
"    <li>",
"     Walsh D, Goldman LS, Brown R, American Medical Association. Physician Guide to Media Violence, American Medical Association, Chicago 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/55\">",
"      Strasburger VC. \"Sex, Drugs, Rock 'n' Roll,\" and the Media-Are the Media Responsible for Adolescent Behavior? Adolesc Med 1997; 8:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/56\">",
"      Dietz WH. Television, Obesity, and Eating Disorders. Adolesc Med 1993; 4:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/57\">",
"      Morgan M. Television and School Performance. Adolesc Med 1993; 4:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/58\">",
"      American Academy of Pediatrics. Committee on Public Education. American Academy of Pediatrics: Children, adolescents, and television. Pediatrics 2001; 107:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/59\">",
"      Children, adolescents, and television. American Academy of Pediatrics Committee on Communications. Pediatrics 1995; 96:786.",
"     </a>",
"    </li>",
"    <li>",
"     Caring for your baby and young child: Birth to age 5, Shelov SP, Hannemann RE (Eds), Bantam, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/61\">",
"      Council on Communications and Media. From the American Academy of Pediatrics: Policy statement--Media violence. Pediatrics 2009; 124:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/62\">",
"      DiMaggio DM, Sharif I, Hoffman-Rosenfeld J. TV guides: exposure of hospitalized children to inappropriate programming. Ambul Pediatr 2003; 3:98.",
"     </a>",
"    </li>",
"    <li>",
"     Standards for the Depiction of Violence in Television Programs. National Association of Broadcasters, Washington, DC December 1992.",
"    </li>",
"    <li>",
"     Children's Television Act. 47 USC 303a, 303b, 394.",
"    </li>",
"    <li>",
"     Revision of Programming Policies for Television Broadcast Stations. Federal Communications Commission, FCC 96-335 (MM Docket 93-48), Washington, DC August 8, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/66\">",
"      Charren P, Gelber A, Arnold M. Media, children, and violence: a public policy perspective. Pediatrics 1994; 94:631.",
"     </a>",
"    </li>",
"    <li>",
"     Telecommunications Act of 1996. Pub L No. 104-104, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40343/abstract/68\">",
"      Walsh DA, Gentile DA. A validity test of movie, television, and video-game ratings. Pediatrics 2001; 107:1302.",
"     </a>",
"    </li>",
"    <li>",
"     Kaiser Family Foundation. Available at: www.kkf.org (Accessed on October 10, 2006).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 597 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40343=[""].join("\n");
var outline_f39_25_40343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H477663690\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      QUANTITY OF MEDIA VIOLENCE EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      QUALITY OF MEDIA VIOLENCE EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Media violence is socially acceptable",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Media violence is without consequence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ASSOCIATION BETWEEN VIEWING VIOLENCE AND VIOLENT BEHAVIOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Temporal relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Consistency of association",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Strength and specificity of association",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Coherent explanation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Imitation and reinforcement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MODULATORS OF EFFECTS OF VIOLENCE VIEWING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EFFECTS OF MEDIA VIOLENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADVOCACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Family and individual",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      School and community",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Legislation and regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477663690\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/597|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/28/37324\" title=\"table 1\">",
"      Television guidelines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31097?source=related_link\">",
"      Childhood exposure to intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5784?source=related_link\">",
"      Intimate partner violence: Epidemiology and health consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40617?source=related_link\">",
"      Peer violence and violence prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_25_40344="Oxcarbazepine: Drug information";
var content_f39_25_40344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxcarbazepine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/38/39525?source=see_link\">",
"    see \"Oxcarbazepine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/46/16104?source=see_link\">",
"    see \"Oxcarbazepine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxtellar XR&trade;;",
"     </li>",
"     <li>",
"      Trileptal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxcarbazepine&reg;;",
"     </li>",
"     <li>",
"      Trileptal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adjunctive therapy, partial seizures (epilepsy):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release (Trileptal&reg;): Initial: 600 mg daily in 2 divided doses; dose may be increased by as much as 600 mg/day increments at weekly intervals; recommended daily dose: 1200 mg daily in 2 divided doses. Although daily doses &gt;1200 mg daily were somewhat more efficacious, most patients were unable to tolerate 2400 mg daily (due to CNS effects).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release (Oxtellar XR&trade;): Initial: 600 mg once daily; dosage may be increased by 600 mg/day increments at weekly intervals. Recommended daily dose is 1200-2400 mg once daily. Although daily doses &gt;1200 mg daily were somewhat more efficacious, most patients were unable to tolerate 2400 mg daily (due to CNS effects).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conversion to monotherapy, partial seizures (epilepsy):",
"     </b>",
"     Patients receiving concomitant antiepileptic drugs (AEDs): Oral:  Immediate release (Trileptal&reg;): Initial: 600 mg daily in 2 divided doses while simultaneously reducing the dose of concomitant AEDs. Withdraw concomitant AEDs completely over 3-6 weeks, while increasing the oxcarbazine dose in increments of 600 mg daily at weekly intervals, reaching the maximum oxcarbazine dose (2400 mg daily) in about 2-4 weeks (lower doses have been effective in patients in whom monotherapy has been initiated).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Initiation of monotherapy, partial seizures (epilepsy):",
"     </b>",
"     Patients not receiving prior AEDs: Oral: Immediate release (Trileptal&reg;): Initial: 600 mg daily in 2 divided doses. Increase dose by 300 mg daily every third day to a dose of 1200 mg daily. Higher dosages (2400 mg daily) have been shown to be effective in patients converted to monotherapy from other AEDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conversion from immediate release (Trileptal&reg;) to extended release (Oxtellar XR&trade;):",
"     </b>",
"     Higher doses of Oxtellar XR&trade; may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant antiepileptic drugs (AEDs):",
"     </b>",
"     Concomitant use with enzyme-inducing antiepileptic drugs (eg, carbamazepine, phenobarbital, phenytoin):  Extended release (Oxtellar XR&trade;): Consider initiating dose at 900 mg once daily.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F204810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/46/16104?source=see_link\">",
"      see \"Oxcarbazepine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adjunctive treatment, partial seizures (epilepsy):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-3 years: Immediate release (Trileptal&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 8-10 mg/kg/day, not to exceed 600 mg daily, given in 2 divided daily doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: The target maintenance dose should be achieved over 2-4 weeks, and is dependent upon patient weight (should not exceed 60 mg/kg/day given in 2 divided daily doses).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;20 kg: Consider initiating dose at  16-20 mg/kg/day; maximum maintenance dose should be achieved over 2-4 weeks and should not exceed 60 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 4-16 years: Immediate release (Trileptal&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 8-10 mg/kg/day, not to exceed 600 mg daily, given in 2 divided daily doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: The target maintenance dose should be achieved over 2 weeks, and is dependent upon patient weight, according to the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20-29 kg: 900 mg daily in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     29.1-39 kg: 1200 mg daily in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;39 kg: 1800 mg daily in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 6-17 years: Extended release (Oxtellar XR&trade;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 8-10 mg/kg once daily (not to exceed 600 mg daily in the first week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: The target maintenance dose should be achieved over 2-3 weeks with dose increases of 8-10 mg/kg/day increments at weekly intervals. Target maintenance dose depends on weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     20-29 kg: 900 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     29.1-39 kg: 1200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;39 kg: 1800 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conversion to monotherapy, partial seizures (epilepsy):",
"     </b>",
"     Patients receiving concomitant antiepileptic drugs (AEDs): Children 4-16 years: Oral: Immediate release (Trileptal&reg;): Initial: 8-10 mg/kg/day in twice daily divided doses, while simultaneously initiating the dose reduction of concomitant antiepileptic drugs; the concomitant drugs should be withdrawn over 3-6 weeks. Oxcarbazepine dose may be increased by a maximum of 10 mg/kg/day at weekly intervals. See below for recommended total daily dose by weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Initiation of monotherapy, partial seizures (epilepsy):",
"     </b>",
"     Patients not receiving prior AEDs: Children 4-16 years: Oral:  Immediate release (Trileptal&reg;): Initial: 8-10 mg/kg/day in twice daily divided doses; doses may be titrated by 5 mg/kg/day every third day. See below for recommended total daily dose by weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Range of maintenance doses by weight during monotherapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     20 kg: 600-900 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     25-30 kg: 900-1200 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     35-40 kg: 900-1500 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     45 kg: 1200-1500 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     50-55 kg: 1200-1800 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     60-65 kg: 1200-2100 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     70 kg: 1500-2100 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conversion from immediate release (Trileptal&reg;) to extended release (Oxtellar XR&trade;):",
"     </b>",
"     Children &ge;6 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant antiepileptic drugs (AEDs):",
"     </b>",
"     Children &ge;6 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release (Trileptal&reg;): Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extended release (Oxtellar XR&trade;):",
"     <i>",
"      Initial:",
"     </i>",
"     300 mg or 450 mg once daily should be considered; dosage may be increased by 300-450 mg daily increments at weekly intervals to desired clinical response; do not exceed 2400 mg daily.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F204797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Immediate release (Trileptal&reg;), Extended release (Oxtellar XR&trade;): Therapy should be initiated at one-half the usual starting dose (300 mg daily in adults) and increased slowly to achieve desired clinical response (eg, 300-450 mg daily at weekly intervals).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     ESRD (on dialysis): Immediate release formulations should be used instead of extended release formulation.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F204798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release (Trileptal&reg;): Use caution (not studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release (Oxtellar XR&trade;): Not recommended (not studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 300 mg/5 mL (250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trileptal&reg;: 300 mg/5 mL (250 mL) [contains ethanol, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 150 mg, 300 mg, 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trileptal&reg;: 150 mg, 300 mg, 600 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxtellar XR&trade;: 150 mg, 300 mg, 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12617171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Trileptal&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM246799.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM246799.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Oxtellar XR&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM326087.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM326087.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F204766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Immediate release:",
"     </b>",
"     Administer twice daily without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Suspension:",
"     </i>",
"     Prior to using for the first time, firmly insert the plastic adapter provided with the bottle. Cover adapter with child-resistant cap when not in use. Shake bottle for at least 10 seconds, remove child-resistant cap, and insert the oral dosing syringe provided to withdraw appropriate dose. Dose may be taken directly from oral syringe or may be mixed in a small glass of water immediately prior to swallowing. Rinse syringe with warm water after use and allow to dry thoroughly. Discard any unused portion after 7 weeks of first opening bottle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Extended release:",
"     </b>",
"     Administer once daily on an empty stomach at least 1 hour before or 2 hours after food. Swallow whole; do not cut, crush, or chew the tablets.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxtellar XR&trade;: Adjunctive therapy in the treatment of partial seizures in patients with epilepsy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trileptal&reg;: Monotherapy or adjunctive therapy in the treatment of partial seizures in patients with epilepsy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F204821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bipolar disorder; treatment of neuropathic pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6224110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       OXcarbazepine may be confused with carBAMazepine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Trileptal&reg; may be confused with TriLipix&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F204823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported in adults with doses of up to 2400 mg/day (includes patients on monotherapy, adjunctive therapy, and those not previously on AEDs); incidence in children was similar.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (22% to 49%), somnolence (20% to 36%), headache (13% to 32%), ataxia (5% to 31%), fatigue (12% to 15%), vertigo (6% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (7% to 36%), nausea (15% to 29%), abdominal pain (10% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait (5% to 17%), tremor (3% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia (14% to 40%), nystagmus (7% to 26%), abnormal vision (4% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (&le;2%), leg edema (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Nervousness (2% to 5%), amnesia (4%), abnormal thinking (&le;4%), insomnia (2% to 4%), fever (3%), speech disorder (1% to 3%),  abnormal feelings (&le;2%), EEG abnormalities (&le;2%), agitation (1% to 2%), confusion (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4%), acne (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyponatremia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (5% to 7%), dyspepsia (5% to 6%), constipation (2% to 6%), taste perversion (5%), xerostomia (3%), gastritis (1% to 2%), weight gain (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Micturition (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (3% to 6%), back pain (4%), falling down (4%), abnormal coordination (1% to 4%), dysmetria (1% to 3%), sprains/strains (&le;2%), muscle weakness (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal accommodation (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (7%), rhinitis (2% to 5%), chest infection (4%), epistaxis (4%), sinusitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Aggressive reaction, alopecia, amylase increased, anaphylaxis, angioedema, anxiety, aphasia, aplastic anemia, biliary pain, bradycardia, bruising, cardiac failure, cerebral hemorrhage, chest pain, cholelithiasis, colitis, conjunctival hemorrhage, consciousness decreased, convulsions aggravated, delirium, delusion, dysphagia, dysphonia, dyspnea, dystonia, dysuria, emotional lability, enteritis, erythema multiforme, erythematosus rash, esophagitis, eye edema, extrapyramidal disorder, GGT increased, gingival bleeding, gingival hyperplasia, hematuria, hemianopia, hemiplegia, hematemesis, hypersensitivity reaction, hypertension, hypocalcemia, hypochondrium pain, hypoesthesia, hypokalemia, hysteria, laryngismus, leukopenia, leukorrhea, lipase increased, liver enzymes elevated, maculopapular rash, manic reaction, multiorgan hypersensitivity (eosinophilia, arthralgia, rash, fever, lymphadenopathy), muscle contractions (involuntary), mydriasis, neuralgia, oculogyric crisis, orthostatic hypotension, palpitation, pancreatitis, pancytopenia, panic disorder, paralysis, paroniria, photophobia, photosensitivity reaction, pleurisy, priapism, purpura, psychosis, ptosis, renal pain, rigors, scotoma, sialoadenitis, Stevens-Johnson syndrome, stupor, suicidal behavior/ideation, syncope, systemic lupus erythematosus, tachycardia, tetany, thrombocytopenia, toxic epidermal necrolysis, ulcerative stomatitis, urinary tract pain, urticaria, vitiligo, weight loss, xerophthalmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxcarbazepine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F204751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Agranulocytosis, leukopenia, and pancytopenia have been reported with use (rare); discontinuation and conversion to alternate therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Use has been associated with CNS-related adverse events, most significant of these were cognitive symptoms including psychomotor slowing, difficulty with concentration, and speech or language problems, somnolence or fatigue, and coordination abnormalities, including ataxia and gait disturbances. Caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Potentially serious, sometimes fatal, dermatologic reactions (eg, Stevens-Johnson, toxic epidermal necrolysis) have been reported in adults and children; monitor for signs and symptoms of skin reactions; discontinuation and conversion to alternate therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Rare cases of anaphylaxis and angioedema have been reported, even after initial dosing; permanently discontinue should symptoms occur. Use caution in patients with previous hypersensitivity to carbamazepine (cross-sensitivity occurs in 25% to 30% of patients). Potentially serious, sometimes fatal multiorgan hypersensitivity reactions have also been reported; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; discontinuation and conversion to alternate therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyponatremia: Clinically-significant hyponatremia (serum sodium &lt;125 mmol/L) may develop during use; consider monitoring serum sodium (particularly during the first 3 months of therapy) especially in patients at risk for hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; patients should be instructed to notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Single-dose studies show that half-life of the primary active metabolite is prolonged 3-4 fold and AUC is doubled in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute; dose adjustment required in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral contraceptives: May reduce the efficacy of oral contraceptives; nonhormonal contraceptive measures are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F204818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: OXcarbazepine may decrease the serum concentration of Cobicistat.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): OXcarbazepine may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): OXcarbazepine may decrease the serum concentration of Contraceptives (Progestins).  Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the serum concentration of OXcarbazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: OXcarbazepine may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin-Phenytoin: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: OXcarbazepine may decrease the serum concentration of Perampanel. Perampanel may increase the serum concentration of OXcarbazepine.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with oxcarbazepine.  Patients receiving this combination should be followed closely for response, especially with any changes to oxcarbazepine therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of PHENobarbital. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: OXcarbazepine may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: OXcarbazepine may enhance the serotonergic effect of Selegiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the serum concentration of OXcarbazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F204785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease oxcarbazepine levels. Avoid evening primrose (seizure threshold decreased). Avoid valerian, St John's wort, kava kava, gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies oxcarbazepine as pregnancy category C. Oxcarbazepine, the active metabolite MHD and the inactive metabolite DHD, crosses the placenta and can be detected in the newborn. An increased risk in the overall rate of major congenital malformations has not been observed following maternal use of oxcarbazepine. Available studies have not been large enough to determine if there is an increased risk of specific defects. In general, the risk of teratogenic effects is higher with AED polytherapy than monotherapy. Plasma concentrations of MHD gradually decrease due to physiologic changes which occur during pregnancy; patients should be monitored during pregnancy and postpartum. Oxcarbazepine may decrease plasma concentrations of hormonal contraceptives.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to oxcarbazepine during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F204802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F204773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oxcarbazepine and the active 10-hydroxy metabolite (MHD) are found in breast milk (small amounts). According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F204771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (OXcarbazepine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/5 mL (250 mL): $206.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Trileptal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/5 mL (250 mL): $264.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Oxtellar XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $357.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $496.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $909.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (OXcarbazepine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $145.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $264.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $487.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Trileptal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $285.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $522.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $959.57",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F204760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizure frequency; serum sodium as deemed necessary (particularly during first 3 months of therapy); symptoms of CNS depression (dizziness, headache, somnolence); hypersensitivity reactions. Additional  serum sodium monitoring recommended during maintenance treatment in patients receiving other medications known to decrease sodium levels, in patients with signs/symptoms of hyponatremia, and in patients with an increase in seizure frequency or severity. Monitor for suicidality (eg, suicidal thoughts, depression, behavioral changes). Serum levels of concomitant antiepileptic drugs during titration as necessary.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F204775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actinium (CR, DO, GT, HN, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Barzepin (ID);",
"     </li>",
"     <li>",
"      Carbox (PH);",
"     </li>",
"     <li>",
"      Deprectal (MX);",
"     </li>",
"     <li>",
"      Lonazet (CO);",
"     </li>",
"     <li>",
"      Neurtrol (TW);",
"     </li>",
"     <li>",
"      Oxalepsy (PK);",
"     </li>",
"     <li>",
"      Oxetol (MX);",
"     </li>",
"     <li>",
"      Oxpin (KP);",
"     </li>",
"     <li>",
"      Oxrate (IN);",
"     </li>",
"     <li>",
"      Oxypine (TW);",
"     </li>",
"     <li>",
"      Pharozepine (ID);",
"     </li>",
"     <li>",
"      Prolepsi (ID);",
"     </li>",
"     <li>",
"      Timox (DE);",
"     </li>",
"     <li>",
"      Trexapin (IL);",
"     </li>",
"     <li>",
"      Trileptal (AE, AR, AT, AU, BE, BG, BH, BO, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IQ, IR, IT, JO, KW, LB, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PR, PY, QA, RU, SA, SE, SV, SY, TH, TR, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Trileptin (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F204750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pharmacological activity results from both oxcarbazepine and its monohydroxy metabolite (MHD). Precise mechanism of anticonvulsant effect has not been defined. Oxcarbazepine and MHD block voltage-sensitive sodium channels, stabilizing hyperexcited neuronal membranes, inhibiting repetitive firing, and decreasing the propagation of synaptic impulses. These actions are believed to prevent the spread of seizures. Oxcarbazepine and MHD also increase potassium conductance and modulate the activity of high-voltage activated calcium channels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F204768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: MHD: V",
"     <sub>",
"      d",
"     </sub>",
"     : 49 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, serum: MHD: ~40% (primarily to albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive to 10-monohydroxy metabolite (MHD; active); MHD is further glucuronidated or oxidized to a 10,11-dihydroxy metabolite (DHD; inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release: Decreased in children &lt;8 years; increased in elderly &gt;60 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release: Parent drug: 2 hours; MHD: 9 hours; renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30 mL/minute): MHD: 19 hours; Extended release: Parent drug: 7-11 hours; MHD: 9-11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance of MHD is increased in younger children (~80% in children 2-4 years of age) and approaches that of adults by ~13 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum (median): Immediate release: Tablets: 4.5 hours; Oral suspension: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (95%, &lt;1% as unchanged oxcarbazepine, 27% as unchanged MHD, 49% as MHD glucuronides); feces (&lt;4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Carrazana E and Mikoshiba I, &ldquo;Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain,&rdquo;",
"      <i>",
"       J Pain Symptom Manage",
"      </i>",
"      , 2003, 25(5 Suppl):31-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/25/40344/abstract-text/12694990/pubmed\" id=\"12694990\" target=\"_blank\">",
"        12694990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Irving GA, &ldquo;Contemporary Assessment and Management of Neuropathic Pain,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2005, 28;64(12 Suppl 3):21-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/25/40344/abstract-text/15642898/pubmed\" id=\"15642898\" target=\"_blank\">",
"        15642898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myllynen P, Pienimaki P, Jouppila P, et al, &ldquo;Transplacental Passage of Oxcarbazepine and its Metabolites",
"      <i>",
"       in vivo",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2001, 42(11):1482-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/25/40344/abstract-text/11879354/pubmed\" id=\"11879354\" target=\"_blank\">",
"        11879354",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pratoomsri W, Yatham LN, Bond DJ, et al, \"Oxcarbazepine in the Treatment of Bipolar Disorder: A Review,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2006, 51(8):540-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/25/40344/abstract-text/16933591/pubmed\" id=\"16933591\" target=\"_blank\">",
"        16933591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rey E, Bulteau C, Motte J, et al, &ldquo;Oxcarbazepine Pharmacokinetics and Tolerability in Children With Inadequately Controlled Epilepsy,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2004, 44(11):1290-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/25/40344/abstract-text/15496647/pubmed\" id=\"15496647\" target=\"_blank\">",
"        15496647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2005, 66(7):870-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/25/40344/abstract-text/16013903/pubmed\" id=\"16013903\" target=\"_blank\">",
"        16013903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9467 Version 53.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C0D21FD3A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40344=[""].join("\n");
var outline_f39_25_40344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204790\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204791\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204825\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204795\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204810\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204796\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204797\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204798\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204762\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204747\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617171\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204766\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204765\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204821\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6224110\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204823\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204769\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204751\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204818\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204756\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204785\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204758\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204772\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204802\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204773\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204771\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204760\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204775\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204750\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204768\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9467\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9467|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/38/39525?source=related_link\">",
"      Oxcarbazepine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/46/16104?source=related_link\">",
"      Oxcarbazepine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_25_40345="Treatment of metastatic and recurrent head and neck cancer";
var content_f39_25_40345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of metastatic and recurrent head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/25/40345/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40345/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40345/contributors\">",
"     Everett E Vokes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/25/40345/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40345/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/25/40345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/25/40345/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/25/40345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with recurrent or metastatic head and neck squamous cell cancer is generally poor. The median survival in most series is six to nine months depending upon patient and disease-related factors.",
"   </p>",
"   <p>",
"    Systemic therapy is indicated in conjunction with best supportive care for most patients with metastatic or advanced recurrent head and neck cancer. The choice of a systemic regimen is influenced by whether patients have received prior treatment as part of a combined modality approach to functional organ preservation as part of their initial management or whether they had been previously received systemic therapy for metastatic or incurable locoregional disease.",
"   </p>",
"   <p>",
"    Treatment options include single agent therapy and combination regimens using either conventional cytotoxic chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    molecularly targeted agents, combined with best supportive care. The approach to patients requiring palliative systemic therapy is reviewed here, along with the management of oligometastatic disease. The use of chemotherapy as a component of initial definitive therapy is discussed separately, as is the use of systemic chemotherapy in other malignancies of the head and neck region:",
"   </p>",
"   <p>",
"    The use of chemotherapy as a component of initial definitive therapy is discussed separately, as is the use of systemic chemotherapy in other malignancies of the head and neck region:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16280?source=see_link\">",
"       \"Treatment of recurrent and metastatic nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11816?source=see_link\">",
"       \"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link\">",
"       \"Head and neck sarcomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H644766211\">",
"    <span class=\"h1\">",
"     LOCALLY RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with locally recurrent head and neck cancer present a therapeutic challenge. Treatment options are limited and morbidity can be substantial. Nevertheless, selected patients with recurrent disease may achieve long-term survival. The treatment of locally recurrent disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9559?source=see_link\">",
"     \"Treatment of locally recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACTIVE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both conventional cytotoxic drugs and molecularly targeted compounds have activity in metastatic and recurrent head and neck cancer. The most widely used agents include platinum compounds (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/1-8\">",
"     1-8",
"    </a>",
"    ], taxanes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/9-12\">",
"     9-12",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/4,9,13\">",
"     4,9,13",
"    </a>",
"    ], 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/14\">",
"     14",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/15\">",
"     15",
"    </a>",
"    ]. The platinum agents are used both as single agents and to form the backbone for most combination regimens.",
"   </p>",
"   <p>",
"    Other agents that may possess activity but have been less extensively evaluated include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/16\">",
"     16",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/17-21\">",
"     17-21",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/22,23\">",
"     22,23",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/24\">",
"     24",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Carboplatin versus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is often considered to be less effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in head and neck cancer, there is little direct evidence. Carboplatin may be preferred in some cases since it is associated with less neurotoxicity, nephrotoxicity, and nausea and vomiting compared with cisplatin, although carboplatin causes more myelosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar response rates for single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    &nbsp;and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    &nbsp;have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/29,33\">",
"     29,33",
"    </a>",
"    ]. Adequately powered, randomized trials directly comparing cisplatin to carboplatin as single agents and in multidrug regimens are lacking in this patient population. Of the three studies that have compared the combination of cisplatin or carboplatin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    &nbsp;for induction chemotherapy in patients with locally advanced disease, only one showed a statistically increased response rate and survival with the use of a cisplatin-based rather than carboplatin-based regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/30\">",
"     30",
"    </a>",
"    ]. Similarly, indirect evidence from the phase III trial assessing the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    in combination with a platinum-based regimen supports the use of carboplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/34\">",
"     34",
"    </a>",
"    ]. In that trial, there was a similar improvement in progression-free survival attributable to cetuximab in patients treated with cisplatin plus fluorouracil&nbsp;and those given carboplatin plus fluorouracil, and there was no apparent difference in results between patients treated with the two platinum regimens. &nbsp;",
"   </p>",
"   <p>",
"    A SWOG trial showed similar survival for a regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus 5-fluorouracil in the metastatic recurrent setting, with a non-statistically significant improvement in response rate (32 versus 21 percent) and overall survival (7 versus 5 months) for the cisplatin-containing regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors have been identified as predictive of favorable survival in patients with metastatic or recurrent head and neck cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/13,14,35-37\">",
"     13,14,35-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ambulatory performance status (ECOG 0 or 1 versus 2)&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Poorly differentiated histology",
"     </li>",
"     <li>",
"      Response to chemotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, factors associated with a poor prognosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight loss",
"     </li>",
"     <li>",
"      Poor performance status",
"     </li>",
"     <li>",
"      Prior radiation therapy",
"     </li>",
"     <li>",
"      Active smoking",
"     </li>",
"     <li>",
"      Significant comorbidity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Elderly adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence suggests that healthy elderly patients with metastatic and recurrent head and neck cancer have survival outcomes comparable to younger patients, but may experience increased toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of age in determining the efficacy and tolerability of palliative chemotherapy was retrospectively reviewed using data from two cooperative group phase III trials that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    &nbsp;doublets in patients with metastatic and recurrent head and neck cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Objective response rates, median time to progression, and two-year survival were similar in patients greater than versus less than age 70 years. The elderly patients, however, experienced significantly higher rates of grade 3 to 5 thrombocytopenia, diarrhea, and renal complications. Furthermore, the elderly patients included in these trials may represent a highly selected subset with better performance status and less comorbidity compared with the general population of elderly patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVIOUSLY UNTREATED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of appropriate therapy for patients with advanced head and neck cancer who have not received prior systemic therapy is affected by the patient&rsquo;s performance status and comorbidities. This includes patients who initially present with advanced disease and are not candidates for definitive therapy, as well as those who develop metastatic or incurable locally recurrent disease following local treatment (surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT) without chemotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a good performance status and without serious comorbidity, doublet cytotoxic chemotherapy regimens, generally with a platinum-based regimen, increase the objective response rate compared with single agent chemotherapy, although no improvement in overall survival has been demonstrated.",
"     </li>",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus 5-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      increases overall survival compared with cisplatin plus 5-fluorouracil alone. However, whether the sequential use of single agent cetuximab when patients progress following chemotherapy alone can achieve the same prolongation of survival is not known.",
"     </li>",
"     <li>",
"      For patients with a poor performance status or significant comorbidities,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or cisplatin based combinations are generally contraindicated. Typically this utilizes single agent therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23915663\">",
"    <span class=\"h2\">",
"     Combination cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of combination chemotherapy regimens without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    have been evaluated in patients with advanced head and neck cancer, most of which include a platinum compound. Although these regimens significantly improve response rates, no improvement in overall survival has been demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Platinum and fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV day 1) and 5-FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day continuous infusion for four days) is a standard combination chemotherapy regimen for use in the palliative setting. In phase III trials, this regimen produced response rates around 30 percent, which is significantly better than with single agent cisplatin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/5,13,14,40\">",
"     5,13,14,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a Southwest Oncology Group (SWOG) trial randomly assigned 261 patients with advanced head and neck cancer to one of three regimens:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus fluorouracil, or single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/13\">",
"     13",
"    </a>",
"    ]. The overall response rate was greater for the two combination regimens compared with methotrexate (32 and 21 percent versus 10 percent, respectively). However, the median survival was similar with all three regimens (6.6, 5.0, and 5.6 months, respectively). The percentage of patients with any grade 3 or 4 toxicity was greatest for those treated with the cisplatin regimen compared with carboplatin regimen or single agent methotrexate (33 versus 26 and 16 percent, respectively).",
"   </p>",
"   <p>",
"    Another option for patients in whom quality of life is an important consideration is weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (AUC 1.5), 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    which is well tolerated and is a reasonable alternative to high dose regimens. However, this regimen has not been compared in randomized trials with more intense regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34523328\">",
"    <span class=\"h3\">",
"     Platinum plus taxane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    have been combined with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    in various combination regimens. None of these regimens have demonstrated superiority compared with cisplatin plus 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The most extensive data on the role of a platinum-taxane regimen come from a phase III trial conducted by the Eastern Cooperative Oncology Group (ECOG), in which 204 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    or cisplatin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/40\">",
"     40",
"    </a>",
"    ]. With a median follow-up of eight months, there were no statistically significant differences in overall survival (median survival 8.7 versus 8.1 months and one-year survival rate 41 versus 32 percent) or objective response rate (27 versus 26 percent). Gastrointestinal and hematologic toxicities were more common in patients receiving cisplatin plus 5-fluorouracil.",
"   </p>",
"   <p>",
"    Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    &nbsp;(75 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    &nbsp;(70 to 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    given every three weeks have been evaluated in phase II studies that included both previously treated and chemotherapy na&iuml;ve patients. Overall response rates ranged from 32 to 55 percent, with median response durations around five months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. These higher response rates were associated with severe side effects in up to 70 percent of patients. Weekly therapy with this combination may have similar efficacy and a more favorable toxicity profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/45\">",
"     45",
"    </a>",
"    ]. Docetaxel plus cisplatin has not been compared with cisplatin plus 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    in a randomized, phase III trial.",
"   </p>",
"   <p>",
"    The substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    &nbsp;for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    &nbsp;simplifies administration and is associated with less nephrotoxicity, neurotoxicity, and emesis. Carboplatin has also been combined with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    &nbsp;or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    &nbsp;in phase II trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Reported response rates ranged from 25 to 43 percent. These combinations have not been adequately assessed in randomized trials. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Carboplatin versus cisplatin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194223436\">",
"    <span class=\"h3\">",
"     Cisplatin plus pemetrexed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    may have activity in some patient subsets, this regimen is not recommended for the initial treatment of patients with recurrent or metastatic head and neck cancer.",
"   </p>",
"   <p>",
"    In a phase III trial, 795 patients were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    or cisplatin alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/28\">",
"     28",
"    </a>",
"    ]. Overall survival, the primary endpoint of the trial, was not significantly improved with the combination compared with cisplatin alone (median 7.3 versus 6.3 months, HR 0.87, 95% CI 0.75-1.02). In preplanned subset analyses, overall survival was significantly improved in patients with performance status 0 or 1 and in those with an oropharyngeal primary; however these results require confirmation and comparison with the current standard of care (platinum-based combination).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230876253\">",
"    <span class=\"h3\">",
"     Three or four drug regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three or four drug regimens have been associated with high response rates but also with significant toxicity, particularly neutropenic fever, in patients with recurrent or metastatic head and neck cancer. Regimens that have been studied in phase II studies include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/49-51\">",
"     49-51",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , cisplatin, plus fluorouracil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/52,53\">",
"     52,53",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , plus cisplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/54\">",
"     54",
"    </a>",
"    ], and paclitaxel,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , plus cisplatin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. There is no evidence that these regimens are superior to single agent or doublet chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anti-EGFR monoclonal antibodies plus platinum-based chemotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175776916\">",
"    <span class=\"h3\">",
"     Cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    , a monoclonal antibody targeting the epidermal growth factor (EGFR) receptor, has demonstrated activity in patients with head and neck cancer. The addition of cetuximab to a platinum-based doublet regimen has resulted in a significant increase in overall survival compared to doublet chemotherapy alone.",
"   </p>",
"   <p>",
"    In a phase III trial, 442 patients with recurrent or metastatic head and neck cancer were assigned to a first-line regimen of platinum (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [area under the concentration x time curve [AUC] of 5 day 1]) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for four days) every three weeks with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for the initial dose, followed by subsequent weekly 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/34\">",
"     34",
"    </a>",
"    ]. Overall, 39 percent of patients had received systemic cytotoxic chemotherapy at least six months prior to randomization as part of their initial definitive management. Chemotherapy was given for a maximum of six cycles, although cetuximab could be continued as maintenance until disease progression or toxicity. Crossover to include cetuximab was not allowed in the chemotherapy arm of the trial.",
"   </p>",
"   <p>",
"    Chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    significantly prolonged overall survival compared with chemotherapy alone (median 10.1 versus 7.4 months, hazard ratio for death 0.80, 95% CI 0.64-0.99). Significant improvements were also seen in the progression-free survival and objective response rates (median 5.6 versus 3.3 months and 36 versus 20 percent, respectively). Crossover was not allowed; thus this trial does not exclude the possibility that sequential use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    followed by cetuximab at the time of failure would be equivalent in survival with the three-drug regimen.",
"   </p>",
"   <p>",
"    The overall incidence of severe (grade 3 or 4) adverse events with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    regimen was not significantly increased compared with chemotherapy alone (82 versus 76 percent). However, treatment with cetuximab resulted in a significant increase in the incidence of severe hypomagnesemia (5 versus 1 percent), severe skin reactions (9 versus &lt;1 percent), and sepsis (4 versus &lt;1 percent). Severe infusion-related reactions to cetuximab occurred in 3 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    is approved for first-line use in combination with platinum-based chemotherapy in both Europe and the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175776923\">",
"    <span class=\"h3\">",
"     Panitumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the SPECTRUM phase III trial, 657 patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    , another monoclonal antibody targeting the EGFR receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/58\">",
"     58",
"    </a>",
"    ]. There was a statistically nonsignificant trend toward increase in overall survival with the addition of panitumumab (median 11.1 versus 9.0 months, HR 0.87, 95% CI 0.73-1.05). &nbsp;",
"   </p>",
"   <p>",
"    In a preplanned analysis of this trial presented at the 2012 ASCO meeting, responses were correlated with HPV status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/59\">",
"     59",
"    </a>",
"    ]. Tissue was available to determine HPV status by p16 immunohistochemistry in 443 cases (67 percent).This preliminary analysis suggested that there may be a greater benefit in terms of progression-free and overall survival for the HPV negative patients compared with those who are HPV positive. Further analyses are ongoing.",
"   </p>",
"   <p>",
"    Conclusions regarding the sensitivity of HPV positive tumors to EGFR monoclonal antibodies in patients with locoregionally advanced disease rather than recurrent or metastatic disease cannot be extrapolated from these data, as patients with recurrent or metastatic HPV positive disease may represent a distinct subtype from the untreated patient with locoregionally advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23915954\">",
"    <span class=\"h1\">",
"     PREVIOUS SYSTEMIC THERAPY AS PART OF INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    induction chemotherapy is frequently used in combination with radiation therapy for definitive therapy in patients who present with locoregional disease. Although such treatment has the potential to cure some patients, many will eventually relapse, either with recurrent disease in the head and neck region or with distant metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients who relapse may be candidates for salvage therapy with curative intent, using either surgery or reirradiation. However, most patients who recur ultimately require palliative systemic therapy. The optimal regimen for these patients has not been defined in randomized trials.",
"   </p>",
"   <p>",
"    Factors that need to be considered in choosing a treatment include the response to initial chemoradiotherapy regimen, the specific agents originally used, and the interval between initial treatment and evidence of progressive disease. In addition, the overall condition of the patient, and the presence or absence of comorbidities should be integrated into the patient treatment plan.",
"   </p>",
"   <p>",
"    Patients who had a relatively prolonged period of disease control following their initial chemoradiotherapy and whose overall condition is good may be candidates for retreatment with a platinum-based combination. In the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    trial in which the tested therapies were the initial management of recurrent or metastatic disease, 61 percent of patients had received no prior systemic therapy while 39 percent had received prior induction chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concurrent chemoradiotherapy at least six months before randomization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/34\">",
"     34",
"    </a>",
"    ]. There was no significant difference in progression-free survival between those who had received prior systemic therapy and those who had not. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Anti-EGFR monoclonal antibodies plus platinum-based chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast, patients who failed to respond to their initial treatment regimen or relapsed shortly thereafter are presumed to be refractory to those agents and should be managed with second line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SECOND-LINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic chemotherapy agents, monoclonal antibodies, and small molecule targeted agents have all been evaluated as second-line therapy. Key factors in choosing a treatment regimen include the prior treatment history, the patient performance status and comorbidities, and potential toxicities of a proposed regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23915983\">",
"    <span class=\"h2\">",
"     Cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After failure of first-line chemotherapy, objective responses to second-line cytotoxic chemotherapy are uncommon, particularly when contemporary response criteria are applied, and there is no evidence that second line treatment prolongs survival. As an example, a phase III trial compared weekly intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    , an epidermal growth factor receptor tyrosine kinase inhibitor in a heavily pretreated population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/21\">",
"     21",
"    </a>",
"    ]. The overall response rate to methotrexate was 4 percent in 152 patients treated with methotrexate, and the median overall survival was 6.7 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/21\">",
"     21",
"    </a>",
"    ]. Other single agents have produced higher response rates but this has generally been associated with increased toxicity, and these agents have not been shown to affect survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/3-5,9\">",
"     3-5,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who are a candidate for second-line cytotoxic chemotherapy, the choice of agent is based upon prior treatment history and the overall condition of the patient. Toxicity profiles for different chemotherapy agents vary widely and may be an important consideration when choosing a regimen.",
"   </p>",
"   <p>",
"    As an example, single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    causes more mucositis than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (38 versus 0 percent) but less vomiting (10 versus 87 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/3\">",
"     3",
"    </a>",
"    ]. When weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    was compared to methotrexate, docetaxel was associated with grade 3 or 4 neutropenia (12.5 percent), febrile neutropenia (1 percent), anemia (19 percent), mucositis (9 percent), and ungual (nail) toxicity (pain and ungual loss, 9 percent), whereas methotrexate was associated with grade 3 or 4 anemia (15 percent) and mucositis (5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    also has shown evidence of activity in previously treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and may represent an option for some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23915990\">",
"    <span class=\"h2\">",
"     Anti-EGFR monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), which is overexpressed in most squamous head and neck cancers. The activity of cetuximab in patients refractory to platinum-based chemotherapy has been demonstrated in several multicenter, phase II trials, all of which observed an objective response rate of approximately 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/15,60,61\">",
"     15,60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25473?source=see_link\">",
"     \"Treatment protocols for squamous cell carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    is illustrated by a series of 103 patients with progressive disease following two to six cycles of platinum-based therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/15\">",
"     15",
"    </a>",
"    ]. Cetuximab was given with an initial dose of 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    followed by 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly. Overall, 17 patients (13 percent) had an objective response, including 8 of 79 (10 percent) who had had progression with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    chemotherapy and 9 of 51 (18 percent) who had had stable disease. The median survival from the initiation of cetuximab therapy was 7.5 months.",
"   </p>",
"   <p>",
"    Weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    at a dose of 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    remains the standard of care; in another study, cetuximab at a dose of 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    given every two weeks was well tolerated and had similar efficacy (response rate 11 percent) in a series of 35 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/62\">",
"     62",
"    </a>",
"    ]. Further dose escalation (750",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    on the every two week schedule did not result in any improvement in efficacy in another 26 patients (response rate 8 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    is approved by the United States Food and Drug Administration for second line therapy in patients with recurrent or metastatic head and neck cancer.",
"   </p>",
"   <p>",
"    Zalutumumab is another monoclonal antibody that targets the EGFR. In a randomized, phase III trial, 286 patients who had progressed on platinum-based chemotherapy were randomly assigned in a 2:1 ratio to zalutumumab or best supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/63\">",
"     63",
"    </a>",
"    ]. There was a statistically nonsignificant increase in overall survival with zalutumumab compared with best supportive care (6.7 versus 5.2 months, hazard ratio 0.77, 95% CI 0.57-1.05). The percentage of patients surviving at 12 months was longer with zalutumumab (22 versus 12 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23915998\">",
"    <span class=\"h2\">",
"     Other targeted agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other small molecule tyrosine kinase inhibitors have been tested in patients with advanced head and neck cancer, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    . None of these have demonstrated clinically significant activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/17,19-21,64\">",
"     17,19-21,64",
"    </a>",
"    ]. Several newer agents, such as BIBW 2992, are currently being evaluated in phase III trials in patients with recurrent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastatic squamous cell carcinoma of the head and neck.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     Gefitinib",
"    </a>",
"    is the most extensively studied. In a phase III trial, 482 patients were randomly assigned to treatment with gefitinib (at one of two dose levels) or weekly intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/21\">",
"     21",
"    </a>",
"    ]. Most patients had received one or more chemotherapy regimens, including a platinum compound. The median overall survival was approximately six months on all treatment regimens, and the objective response rates ranged from 3 to 8 percent. In a second phase III trial, the combination of gefitinib plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    was compared with placebo plus docetaxel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/65\">",
"     65",
"    </a>",
"    ]. Although the addition of gefitinib was well tolerated, there was no statistically significant difference in overall survival between the two treatment arms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624594020\">",
"    <span class=\"h1\">",
"     OLIGOMETASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with head and neck cancer with one or a limited number of distant metastases at presentation or relapse may benefit from aggressive treatment that includes eradication of all known sites of disease.",
"   </p>",
"   <p>",
"    The most extensive data come from small series of patients with oligometastatic disease in the lungs, in whom disease in the primary site and regional lymph nodes has been completely controlled. In this setting, surgical metastasectomy can result in prolonged disease-free survival in a significant percentage of appropriately selected patients. Data on oligometastatic disease involving sites other than the lung are more limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series that included 97 patients with squamous cell carcinoma from primary sites other than the oral cavity, the five-year overall survival rate was 32 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/66\">",
"       66",
"      </a>",
"      ]. Similarly, in a series of 83 patients from one institution, the five-year survival was 34 percent for the 41 patients with squamous cell carcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The primary site is an important factor influencing outcome. Patients with oligometastatic disease from a primary tumor of the oral cavity appear to have a significantly worse prognosis. As an example, in one series of 23 patients with a primary lesion of the oral tongue, 22 (96 percent) relapsed, with a median time to death of 10 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/68\">",
"       68",
"      </a>",
"      ]. Similar poor results were seen in another series of 17 patients with oral cavity primary tumors, in which there were no five-year survivors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other approaches to disease eradication, such as stereotactic body radiation therapy, have also been used to treat one or a limited number of pulmonary metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/25/40345/abstract/69\">",
"     69",
"    </a>",
"    ]. However, long-term follow-up data are more limited compared with surgical resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link&amp;anchor=H5#H5\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Lung tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No clinical trials have been conducted to assess the role of adjuvant chemotherapy following surgical resection of all metastatic disease sites, and adjuvant systemic therapy cannot be routinely recommended in this situation. Although an occasional patient who has not received prior systemic therapy might benefit from such an approach, there may be significant risks associated with such an approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with metastatic or recurrent head and neck squamous cell carcinoma, the prognosis is generally poor. Carefully selected patients with good performance status and locally recurrent disease may benefit from salvage surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reirradiation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of patients who have not received prior systemic treatment for squamous cell head and neck cancer is influence by the patient&rsquo;s performance status, comorbidities, and related prognostic factors:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For otherwise healthy patients with a good performance status and favorable prognostic features, we suggest combination chemotherapy using a platinum compound (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      , with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      , or a platinum plus a taxane, rather than single agent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although the addition of cetuximab increases overall survival compared with a platinum plus fluorouracil, there is no evidence that this is more effective than using cetuximab sequentially as second-line therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Previously untreated patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have not received previous treatment for recurrent or metastatic head and neck cancer but whose condition is not adequate to permit combination chemotherapy, we suggest single agent therapy with a taxane, a platinum (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Active agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe comorbidities or poor performance status may be best treated with supportive care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients whose initial definitive therapy included systemic therapy with a platinum-based regimen with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a platinum-based combination for those who had a relatively prolonged period of disease control following their initial chemoradiotherapy and whose overall condition is good (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Previously untreated patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23915954\">",
"       'Previous systemic therapy as part of initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest single agent therapy for patients who recur or develop metastases during or shortly after their initial chemoradiotherapy if their overall condition is acceptable (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with severe comorbidities",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor performance status may be best treated with supportive care. (See",
"      <a class=\"local\" href=\"#H23915954\">",
"       'Previous systemic therapy as part of initial treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Second-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have progressed after initial palliative systemic treatment for recurrence or metastasis, we suggest single agent therapy with a taxane, platinum compound (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The choice of agent should be based upon the history of prior treatment and the overall condition of the patient. Patients with severe comorbidities",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor performance status may be best treated with supportive care. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Second-line therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25473?source=see_link\">",
"       \"Treatment protocols for squamous cell carcinoma of the head and neck\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/1\">",
"      Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/2\">",
"      Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/3\">",
"      Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 1983; 52:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/4\">",
"      A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. Br J Cancer 1990; 61:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/5\">",
"      Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/6\">",
"      Veronesi A, Zagonel V, Tirelli U, et al. High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J Clin Oncol 1985; 3:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/7\">",
"      Forastiere AA, Takasugi BJ, Baker SR, et al. High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 1987; 19:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/8\">",
"      Havlin KA, Kuhn JG, Myers JW, et al. High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot study. Cancer 1989; 63:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/9\">",
"      Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004; 40:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/10\">",
"      Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/11\">",
"      Colevas AD, Posner MR. Docetaxel in head and neck cancer: a review. Am J Clin Oncol 1998; 21:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/12\">",
"      Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998; 82:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/13\">",
"      Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/14\">",
"      Jacobs C, Lyman G, Velez-Garc&iacute;a E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/15\">",
"      Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/16\">",
"      Gedlicka C, Kornfehl J, Turhani D, et al. Salvage therapy with oral etoposide in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer Invest 2006; 24:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/17\">",
"      Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980.",
"     </a>",
"    </li>",
"    <li>",
"     Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&amp;N Ca) (abstract #5331). J Clin Oncol 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/19\">",
"      Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11:8418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/20\">",
"      Kirby AM, A'Hern RP, D'Ambrosio C, et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 2006; 94:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/21\">",
"      Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009; 27:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/22\">",
"      Raguse JD, Gath HJ, Bier J, et al. Gemcitabine in the treatment of advanced head and neck cancer. Clin Oncol (R Coll Radiol) 2005; 17:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/23\">",
"      Catimel G, Vermorken JB, Clavel M, et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/24\">",
"      Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010; 102:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/25\">",
"      Pivot X, Raymond E, Laguerre B, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001; 85:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/26\">",
"      Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011; 29:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/27\">",
"      Fury MG, Haque S, Stambuk H, et al. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer 2011; 117:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/28\">",
"      Urba S, van Herpen CM, Sahoo TP, et al. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer 2012; 118:4694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/29\">",
"      Al-Sarraf M, Metch B, Kish J, et al. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep 1987; 71:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/30\">",
"      De Andr&eacute;s L, Brunet J, L&oacute;pez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995; 13:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/31\">",
"      Welkoborsky HJ, Bleier R, Wissen-Siegert I. [Antineoplastic effectiveness and unwanted side effects of polychemotherapy of extensive oro- and hypopharyngeal cancers--results of a prospective therapy study with 5-FU/cisplatin versus 5-FU/carboplatin]. Laryngorhinootologie 1992; 71:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/32\">",
"      Ebeling O, Eckel HE, Volling P, et al. [Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up]. HNO 1994; 42:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/33\">",
"      Eisenberger M, Hornedo J, Silva H, et al. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 1986; 4:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/34\">",
"      Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/35\">",
"      Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/36\">",
"      Recondo G, Armand JP, Tellez-Bernal E, et al. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope 1991; 101:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/37\">",
"      Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/38\">",
"      Argiris A, Li Y, Murphy BA, et al. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 2004; 22:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/39\">",
"      Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/40\">",
"      Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:3562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/41\">",
"      Sch&ouml;ffski P, Catimel G, Planting AS, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999; 10:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/42\">",
"      Glisson BS, Murphy BA, Frenette G, et al. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002; 20:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/43\">",
"      Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 2000; 11:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/44\">",
"      Baur M, Kienzer HR, Schweiger J, et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial. Cancer 2002; 94:2953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/45\">",
"      Guntinas-Lichius O, Appenrodt S, Veelken F, Krug B. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 2006; 116:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/46\">",
"      Stathopoulos GP, Rigatos S, Papakostas P, Fountzilas G. Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. Eur J Cancer 1997; 33:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/47\">",
"      Clark JI, Hofmeister C, Choudhury A, et al. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 2001; 92:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/48\">",
"      Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest 2007; 25:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/49\">",
"      Worden FP, Moon J, Samlowski W, et al. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer 2006; 107:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/50\">",
"      Hussain M, Gadgeel S, Kucuk O, et al. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 1999; 86:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/51\">",
"      Benasso M, Ponzanelli A, Merlano M, et al. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group. Acta Oncol 2006; 45:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/52\">",
"      Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol 2000; 23:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/53\">",
"      Baghi M, Hambek M, Wagenblast J, et al. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 2006; 26:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/54\">",
"      Okuno SH, Mailliard JA, Suman VJ, et al. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck. Cancer 2002; 94:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/55\">",
"      Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/56\">",
"      Shin DM, Khuri FR, Glisson BS, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 2001; 91:1316.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cancer.gov/cancertopics/druginfo/fda-cetuximab (Accessed on January 18, 2012).",
"    </li>",
"    <li>",
"     Vermorken JB, Stohlmacher J, Davidenko I, et al. Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients with recurrent and/or metastatic squamous cell carcionma of the head and neck receiving chemotherapy with or without panitumumab (abstract #LBA26). Ann Oncol 2010; viii12.",
"    </li>",
"    <li>",
"     Stoehlmacher-Williams J, et al. Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial (abstract #5504). J Clin Oncol 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/60\">",
"      Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/61\">",
"      Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/62\">",
"      Fury MG, Sherman E, Lisa D, et al. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw 2012; 10:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/63\">",
"      Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011; 12:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/64\">",
"      Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/65\">",
"      Argiris A, Ghebremichael M, Gilbert J, et al. Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/66\">",
"      Shiono S, Kawamura M, Sato T, et al. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann Thorac Surg 2009; 88:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/67\">",
"      Liu D, Labow DM, Dang N, et al. Pulmonary metastasectomy for head and neck cancers. Ann Surg Oncol 1999; 6:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/68\">",
"      Mochizuki T, Okumura S, Ishii G, et al. Surgical resection for oral tongue cancer pulmonary metastases. Interact Cardiovasc Thorac Surg 2010; 11:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/25/40345/abstract/69\">",
"      Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 2008; 72:398.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3364 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9089A68DA0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40345=[""].join("\n");
var outline_f39_25_40345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H644766211\">",
"      LOCALLY RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACTIVE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Carboplatin versus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Elderly adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVIOUSLY UNTREATED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23915663\">",
"      Combination cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Platinum and fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34523328\">",
"      - Platinum plus taxane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194223436\">",
"      - Cisplatin plus pemetrexed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1230876253\">",
"      - Three or four drug regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anti-EGFR monoclonal antibodies plus platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175776916\">",
"      - Cetuximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175776923\">",
"      - Panitumumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23915954\">",
"      PREVIOUS SYSTEMIC THERAPY AS PART OF INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SECOND-LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23915983\">",
"      Cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23915990\">",
"      Anti-EGFR monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23915998\">",
"      Other targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H624594020\">",
"      OLIGOMETASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3364\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3364|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11816?source=related_link\">",
"      Malignant salivary gland tumors: Treatment of recurrent and metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9559?source=related_link\">",
"      Treatment of locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16280?source=related_link\">",
"      Treatment of recurrent and metastatic nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25473?source=related_link\">",
"      Treatment protocols for squamous cell carcinoma of the head and neck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_25_40346="Rosacea papules";
var content_f39_25_40346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67890%7EDERM%2F53889%7EDERM%2F78747%7EDERM%2F63008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=36\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67890%7EDERM%2F53889%7EDERM%2F78747%7EDERM%2F63008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=36\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules are present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and centrofacial erythema are present in this patient with rosacea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory papules and pustules are present on the nose and cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Papulopustular rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDRWF2m2yRSdPlO3OMnv7VNHbOsitNAsaBtrozYBHvjmty3nguopTEGUM370feZU7bRTdttPcC3laW4DtwQfLKEDg1zcqO3nexi2+ntLNKVcoi53RZwcexqeCyWJ0khtYnD9HmOSCfT6VoW/nRswnikmMJONpAZkH97PUU13W9jhaCJoreQ7gJm4BJ4x7UWQXbZWulmuEGT5zYwAmdy0gsEuEgW1VA/3ZHwRtPr6itYiWwu2DRW80hXCTQnaM9Mk1NLapErypL5qOuHQdUccg561XKQ59jCtLYxyyJI/mSnJaMkgNj0PpVu3Fmly0q6c7QMByi8xn1GfetGLUFt7fyNTFud8W77RsG+QemexFRi88yNLezu2FpKQUV1ww9ceoNUoroEpMddXtr5zDUg8cgQmPZH88gPTA7026SEWS3MSLHchVaPy48gkjo/bNWjZMieZbXdo9ygLjzPuxJ7ntVmJILtgl9uhPkb4G5IZvX8TVJGTaKunS/8truzQTSDbEy425zzx/WsqXTLuWWScXbRQyz7I4tuDJ/e+gFXJ5LmGz+zvPDHJB8kkhXJ5P3R6GkurhdPaaW2uWYRIoIYBgqf7PuTRcFdbdRbry0+0TrFBHHakqHUfec4+QY/nWfqd81paT35aJbq5ARLXHK++KravqkH2eeCVmdo9vlKh2jf1LMKzUubexuob++82a8kZnETHhF7frUuVtjSMOrGXcUm9IUM9zqd0BnzWyEQ+/p7UmpXNxKkNhYBFiiwXZADznjLdxmpJrqCJY1JmDyyGSa4AwxGOij09KgUtPIy28DW1kjBjvOCQPVqzZvDuxsrGEC3tZgZpv8AWyYPyAf7VS2+yG3guDGDCA2xWBxKf7x9ear28U/kI6KWWdiSOmVHb3rXm+0aldIjxpEIxtCKPlhXuTUt6FpEGnW883llJG+0SA4XZ/BjnFdFY6Wkkduk+I1ckpk44H8TVW0rT2uL8RWLNM4baGHQ+/0rtrCwXTIm80mW7zhy4+VMn7o9TSir6sKk1HRFW9vFW3t9M0uX5iAs06qV2e3vWvJaixsEfZHNsUrvGPmyPU96ltdKtrbTHlmWEzSZ2Fvvkdse9Zk9uy28ck0TSSrIXIZ/kQenua0sc909F0KdrA/2NA0TZJzMeOQDz+AqppsqTXs3mNCy2wPk4I2jPcn2rduGezitpJRD83OC+AFPRSBXHXVuLa9lR1BaUMBtOQrE8fQc1ElZXNab5rmlcTNPbQLMBHLknn+Lvuz3zTZZkFndFyTJNFiMnB596gtxO0MVisYeWEl1ZuuB1HvUc0ctxFcSqNkaLlwQOBnGfz9KnXc0SWzM0RgSQkK7seiqvb1FUld5rpIoEHzNjB65q5MrmFCGw4U7MdcZ7VmIxjYNnaUP3h3rI6N00StAyXF7G0uYosjcBwTV6W3WPRkmyVkwoAA6knnP4VTEKLYwTRSs0zylXXGR7VYmuZJkKTvuCHoOMHFUrLcTu2UGnVGixksOckfKtEQ33RZCdrHjAxnNV7wCOMNksRy/p+NP0YiSeJWLb2cc9QPSs0m3Y0eiuam8s4QKNsfX3x1qyABuabzDbn5QwP3e4FUrmAQvKsq4MbESKDja1RGTZAySDPO4EHjOKewlrsXpXV8NsHHyg+1QOxDRoh245z6VJEw+zByFZicDJ6/hUSEZOMFx0yP50ikXNMvHsrzzojglSh3DP1qKRyNz7gWPbNRsCFwBkEckdSagaRhuBHNF9AVm7luKVQCXXKH09asTXAdUEfyjHQelZ0ErJgcAZB9cVeYxPt8p8ux+fcMYPtTWopKzHec7t8rY45/wpzOET5UZWHOe/uKdaoLmSRigyn8I4H5U4RqrxrOfLU87wM5H0p2JvZkGZlCp5Z2ucg45xWtr1jFp01l+8d96qGHQgEZqC4O4YVH64VmPWp9M+zjzBes01zGAU3c9O3NawRlKXUufZbc2trbyXF0wBLxrGcbfw7Gu00OwstNsRcW8jtLGu1snqT2IrkbW5hGqxzOBtjc4Cjhs+9aVrql3NJNlMKc8xfeA/rW8Zo5KkJS0udFuQrIkkssvmt82E4z6A1BcaDIwZ7G4MUmMYLZP0zWFBdNAogS7WV1OERHIyeuTWnFqd7feXCY1R1ycK+CxHvT5kzNwlHYpahDcXVmJZIgskR2lkOctXLNLJHdM7gMOn4+9dTc3CwQsX82FmbDBuQT71zFwY3cEAiNqyqI6aPU055o59NjkBLMjZdSfu+gHtWReOkq7zkkcfQUiKzTsgcLkevFUrokMT0fnOO9Q27XNIxs9CC7iDAFXy4/hrGlcK3lnO/PWteS5ZTD5sYynGcdRWHqgU3nmRZ27s4pPVG0d7MjLkOQWzg4p8gDJll474pkm4KG4IJ4oJYoynKtRZDlsAcC0ZM4KkMKyjL5TkyDcprTkjIjOAG4wTWLc8OFOM5xT6GSjchnjSZmZPkOM47Z9qzbuEggNkE+orQKhw6d16e9VL+CYRRyuGw4wjHkGmjOSsc3qUYQKIwT2bjqawpWbLgDBxgiuluRtLZyT0OayZ5o4oJI2tY2dhhZeQQM+laR1MppowpNjQFJEJbqCP60VauCu8yQRgKAAVzn8aK1RzuKPo9lZbxmWMwuynep4ycZJFdDaQLqelB7kCKQR5W4x9xscKB1rNhmuIdMRbmKKSHPltIxyVHpjr3qutjJFqUdtFOTE5J++VHTisL2N2r6GnZ+a6yNBNG1xHHidpBgqp4/KqU1jJcwSi1jUyW6BiDn5x9K044obnR5ZoUSK4iyv3vmkI7H1qLzbySES2z/ZZEAErMMhmI7GrVmZ3a2KVzMIYIWkSJ3lIwM8qR/CR71bCl5klaGERzHaVIx5Z7e9QahGtz5N0gWC6SXaQfvhh6+uaiSb/SvtY/eblAMfO4P6/hTvrYLaXLkGnq0snnBJlQjbFJ1LHqM+tXNSs5boJNbaaIhgIyZA8oDuD61nxX06yGe8JaEZjtygGHb+LPfNWYroSQStlor6WTEVq5yAOm9s/XNWmjOSle5UeKO9uw8KC1aDCmOU8zAdFI7nNXJ5r2e+trW4HlWyjzp5EADRgfw57CqU8ONTkxcqWsxv3ysCsr46g+lMsrm4uLfVS9zDFZbw105X55DjovtST11Kaurks6wTalbNpdu72kBeRvNbcZn7ZP8AjWRdaiI792bynkRjPLCi5Td2DH0HpTiiul3NH5v2rpAI/uKpHJb0qA3SWtlDb20MLXly4O1BkkZ4yfwNS31KUehSnlnjP2V4CkZxc3MhXBGemfQe1Miha51SMWdqmMFFlmGcnqSaZLLqM11O0Uo815DJKWGQMevrirYh1DT7WERsiyTKcP13Kc5NTuzW1l5kEdtNcao0Sot4YDh5M4APt7Ulza3MhImmWVEjJKK21QM96m0rT5pFWKLMZbBDBvvD6dPep7e2S8ubhDORbwnLMVJMhB5zUFrcXT0eKAGJYZHkQorNk+Sp64HrWtaW2LMWdgWUyLm4kIxtH93nqadbyf2nqK3HlLBZxqxVFAyV9TXQ6QIJTHfTE29nGCdh++//ANc9qLCu47lywsYrayKrGYbS3i8y4lH8bY4UVc0Ca51i8W6nRVtrZh8rDHy/T1rSt4mu7DyzCILKR96qxy2OOtWRbrJFdPYXBt1ZiWyMdOD+Fa8pzOd733IJ0F9dNIyiC3WTYWfGSe2Pasu6unthLE6IbQZDSbiQD2P0rbhWWKz+1Bizk7dzHBP+0O34VkeIFnvrO4VSIgigqDgs56kDHA47U2hL4rPYx5wb+2W4iQtEmVV4wDvIHBqjqVnD/YcTOxNwiliiZBDHufXmpNF06W1t1RmLORvPlnhe/J9ah1CWBltbZZGYMAzSE8sM/cxUPVG8dJaFWy48mMhvOZSY3zzuJxgD261BNeu9nNDKRiMjATAJ55z61p39lFDfQQwyGQ/KQx4IXHJ/pWLe24VWdRhWyV2jO7npnt61lJNG8ZRkypbAtOvl+Yjh+4zgVFrNusV1kbhEW25x1psbTRSsdxLEg7s/pW3LfRXdhFbTsAyg8DpnHU1C1TuattNNHPwlgSkbDg7qcwby22At8pLHvU0ZCuiuF2ngMB2qsm4XjxxsSuSOmc4rM080Ubo5XaoOWxWpYW8SWTXcNwsc0LrmMg5+v07VSvgJp2cKy5wMVMkTeVHvCkIDiReePQ1cdGKeqViW5nlnneW4yZJjufJ60w487arFlAzzUSggHPp0FPhIYLvBLHtUNlrQsQx+duO7a5OQD39qUR8EKGAzg59agBKPsAxIvTBqZArK0jEZHT5sFjRuHqNl/dxsFb5ieuaTy28rziwxgbjQYtkhSfI9CvSo2TCspyTjoKLDTXQLTfcMyxqSQOo549asqW8nKOhb7wIOfwqrpNy9ncBkwdysuOgPHerGmLDCZftBUyMpK8Zw1VFKyJk3qya2mlif923zdct71o2FxGk6SXSCfaCAGOAvpVCGMlHZB+7OA5POKmWNTEfnLKDtGOpFCRLsy47uGURsAyPuyORntUqGeOS4luNjtMgVnYdM96rxTMlnIiou48Fm7Y9D60XDsLaISNvVh0PGKt6IztqSadci3kMWAx+6Gc5X64rQ3W8FwIBcNMx6iM4BHpVGXT/sdpFcvKpDAMsanJFbGh+Hpbq3OpufLijy6fLksauEWRNwSu3oX9MsZvNfKGR0UlOmUX60+8+YRmGJ5gPv7Dhgfb0p7Ti1lTYk/LDzJJVCqPYVel1ZYLWaS0cQ+Y2cBNwPrtreySscjk7mJdXkjbBfIXOdpJrGnfdlFcBN2FBrQa7k84SPG88G/wCZWIBf8e1Zl1/x8yAx+Wu7oT0FYyR0QdiKGQxzBXCllOQc1C+2SVpmwR0I+tF5GPMIBB44wapyv5Y4IyOvPX2qTZK+qGToB8quCCeCe1ULyE7DwCRzkelSSyhlBPHpioDcYcEqSMEHnrQjRJopgF1C5yMcCpbeLeH+Zdy/wk8mp5I0EJlQgAjBXPNVQjBQc4x0NJ7hLVBIMHBLAjsB/OsG/Ro7lX5KA966CaeS4xuXJRcFgOoqheeXKGXnkcHpVGUW0ZLLiVpEI2nnircd0rae9ndLuty4kQDgg9wD2qBUMY+vFMkTzICufxPaiLswqRUjHuol88oE3ICcBj2+tYN3b5zhwcfpXSOQ2AeHAwazJpjE7CMrtkG1srmqRjJHLTnaW+XD9D9KKnv1ClxjDdz7UVomYuOp9P2QinkuVXrFk7H9+9V57c/bUuUP7thtTdnarj3qzeqkSpexQqk+S2/JIYY4GKhSZjoRRnZCAJPKx0yf4R6+9R5D8yJJo/t8kd6DGFCsXPABI7U+yMkWo3KxjfH5Ymg3tgJzycGpxKmoW8m5ljghPmCMjJLDjLHtVK1vbaS0iS4BN5K5EsknZewHtilcbu7ok1Fyb+RWZVupSolkYZRc/wAQPoKRrs6FbT2VuZLiWQ4jl8vG5e7etNtLb+1LhrSObyLZl27v4Tg8Ln1q3qurS3SCAKpnsz5cbqPv+p+lWk7XJlb4StI8Et1BHbQ+QsOJnRiWBYc4J7E1Rul1PxJdNdQQbFkl2FshSUHVanuJG0mzk0+0nae3uWDyu3DYzzimahfRaWDBYblR3ChMkhB/ER7mmGvQZqUtnY5kgjEgi/dqhOQTjGc98Gm3WotDFHbS2i+SY9uAhwzHGXI68VVnjH2i3FxDiGQBvs5HAx0yfU9aW1uTbPc308LERg+Uc5IOMcH0pXuUopFe7vJbhY7G0UW0b4RpOckep9aJJpLe0ldJIwFPkQlQBz3bPUim2UF7eXAMA+zB13Akj92nc1A8tnLqjypA7W9ouFjY5Xd059eam5XL0C1ikt7YwGUKXBw7L82OpI+tSwpcapqTyX8kiKIwBtbAVfT8qc8Fzd3qSzDYgQJHGDgrn0HatSSxRfIVsSXAz5hzkFvf6UivPqU44oppmlijmjtYh5cUkbHLn+nFbWnWXmwqAvl2rZdkBwcL6n3p+i2cqrcKubpouUhXoSep9K2xYzNKn2kIgd1Cshyq4/hHrjvT5epLl0K1jpyhY7qRlXzvl8pRkxoO5FaCWyv9nllZpraJi0aoRgY7sO+ats1vH58Zl23Kx7Qqjg9qu6PA0UEkaIGaRNpjYAEDsc9qaj0M3NrVj2ummlU/vEZuZgo5Rc8AVrMhuh5hikWAAbUXgsc9fpWbpiSwaqftMsUUoBCxlCcr35q5qWsGC9gtPljikAPmr0GD+gq1ojGSu9BLy3F4bcvDIVjHzRh+OvX3xWVq1k3l72lEbvIIvLXkMx/i9AOlbd1MVjllmki/dAhmJwHU9QMe1c497ptzc3EdxJNFpvlluCcM317U3YS5tzKERgNwmxYyOMI/cdQF9T2qte6hYi5gu0h8lgvlYnHdeTjHT0p/iVHiimm2PHIUSODad2D1BLDvjjFU0uYboLcTfvLxohGxwFUL3OKl6G8dbMhmlifUknh3NJLkKGBwGz2P0qK1y2mRSCEKVkMZZpO47D0yDStYS3SH7NcS4hDGNSw655I9qy7aW3NsIJSwcsCwUEbMH9TWMtGbpXH7WjgELqiuJCUbqdpPQ/SiSEJGzLtBQF/p7Cornfa6kzQkeWpyGY57U4zrMWDhfMwFwR2xWba2NknpYRoXLRkfOxXDIByDVaMyW1xFcWxGSfTIH1q0Y9zKdp2nJDdCT3pkv7smHfgf8s2PHBGamxfNbQp3kuL5ioUENng5Ge+ParFvMczJj7wGCvG01UmCTKDFnKdR6D61LpfL/Kx80ZAPZvShasH8Ish+ZgRhhwCKaZd0aA5ITJHbmiQMpaOSMpICGUn0pjPgHBG4noO4pMaYNNlApwSOhHWiO4VSVACs3I39jVW4L+QWjXKg4JrPadklQknaTQVa5vQSbs78suQSPWpJCdwkHU9B6CoRtFur9GlXAVTyv1qJZm37CAF7t6U2rEpk5G7IIGW6c1KEC4ycEDgjv9ahZsgAYJ9e1KzleDnaO1Iou2rlFdVLgt1x/WpVk2MoDLgjv0qrATKryblRkGMdM1JiKW13ZbzV+UADgCmk2KSsWo2AclQDsGQWHyn6VMhmunE0dq0gjHzbTkfU+lQXlzbQizjgkaY+X8/ybQpPb3q7Y3dxDG8FqxhW6PlttXOcjpVxWtmQ3pdF3RLGXUDLEYlZEHKhuTXXalc7NFgs7JvKYIobjBx3zXPeGh/Z8NzDCz/bJMoHJACD60kXnaleeRaZT+F13kg+pOfWt4+6rdTlqJzlfojSNz9n09zdypMAVC5OTk9/wrAvrotcbi6nzOMHgY+lauq2CWYlS4yJFIAwcCsC/DSy/O21UGHZQDge1KV9ioRT1IptUYR7DKGAJGwDG3FVxevIv7zBx0zVLVY1M4GlLcT2yEK0rAAhj7dxVMOdxVmZmHTtWclJHRGMbaGtDKkskhdgAoyKr3LLklxtPYY61QVmV949ceuKuRuXmVJRgN3A/lQiuWxTvw0cKlB154qu0rOg3rgdgBVyUGNSjjPzZAPUU2V1kbCRbQewpNpFXsVlXcwG8DOPmPapE2suCc9s0rIFhyM5Pao4sOQ3YcAdOaDOWoSI0fKccfhWRLKBNjGFYZIPatO/ZyctkkenBrLvrcs/zDB7YNPoKIxQNpBOR1+lRDCZDdGFLsBTazEbu1PeJVA6sen0oFIz54wxLJyBWNqEKKm7seoA5rpvL+TjscfjWZe7BG+4bfU4qjNnI3UIkBZup4ye47UVbuIiTgDKDoxoqkzJxuz6Nu0k/fxAhTKctjkIOox71lXJlkt45I1KLC2WIPzdMACrxQz6fK6kh3fYIx3weuahtrkRw3cMyBZ434RhzxSb1El2I9HfyLG6tn+YRgucjl89AfaqVvBF5MsU07LtXBYDOQTxV67jZHiliZhNMuHXOd469KqzSxS2uAWWZirAkYGc8/yoRT7l8hvNgtiHMCkNKqDChQOCPqaz2IFkb7YfLDmBI92CB3qxqVyzfbZvOMczKhK54LZxjH61UltwdPVFVMyyfeLZbdjkgVVyLFAB/sjxhWdmZVR2/iA5OPatWWMxS/aj5P2meMJDGDlR/tH0OBUk2psuiJAqq+xDbgjAJ5/T61UsYY/s9xdXsaLFE4Zctypxxx3pqyDV6sgUTpM93dmOQbi2wH5s46D2rPMwn8ma5/doW4jA4HfAFaMd6buEzRhVW4dmmkVcsqjv7Z9Kgjt2lIcK846JJIMKp+n0qW+xaXRlW9AmknnmJ3zKCu5uUUdBxVi1tEtIYkCMxIEr4HIYjgH271eFvA+oGa4wtqqAFxyMjsKu6bGiWN/cyxuQBzg/wnpS0bB7Fe2gmsY/MU77yRdyZ5ZWPfHtWnbaLcwWluSgF5dggITx/vE+9WvDscd8f7Qe12tZ25wD0bP8Rz/nip7G/nBlmnXfGEKxKw/I5p6bkXldpBZW/wDZ8KW8RUGJhJLIOhPb8B0rY09/tENr5GfMYfuzxgFm5PPFc34cmFxcvBdOyTyAqFmO1VXr+NdfDHP9itbd7eJlLNhguNg9QRVR1JqaMyjpVy00zWqPLJIzASMR0XrW7o812sx+0gueAylMMxA469hTSZYpm8ja8YTaEBztJ7n0pTeXOGhvGd3iZdsYx+8/EU0kjNycka0FhMl+s7T7tqYG8DIz1rKuUh/tp5JU835SkYbjkd/wpFle5njf97bxPwY3O4jHoe1TpdhYZJGQSJGQqAr/AB92Hrx3pt3ErozLi1DhjdwzBwd6lT09/f6VoPJb20Swrguy/caPIYnoWB71HqciX/2NoWkJUFnY/eU9RntVcWDXkhuLqUF872IPK9gB70a9B+phh7mRrq3ys8QVvKMjhAhB5YL3PpWTPC1xfBzCss5Xenlp8gboF/Kt8WVtfWmoQQJHEYskyMcys3oo/rVCFpbPTLeKB0BbORIPnTJzuPvUt33NV5blKf7JFZxXVm7Q3CS7JrcklgfQCsnV7Z/t73SxrubD7SNu0N3wKv67FFLercBnSWQj94sZQZA6j1rPS8LXUyToXlf5S0h5AxisZO+jN4LqiKAHyQJOVk6tjgHvUTpvc5wSflXBxSRTPbykR4IddrA+3GRTriIIg2NjoWwucHsaztoa3swZ3jgWNwNoOUweVx/OoLidZ02S/Pg/KSOQaazyRhi0eO24jpVGa6PJKjcD6UmWtR8hZZEKLnb1PTJp92iBFYHY7dVHP40yC9DAIXBxwOcfhSGREDNuIkBxjsRTSuTJ6jriSWR97kF9o5HpSooKYXJbuf61RvGjFyvlM5j29+vNSWV2YpSxUFSMFc5yKElfUbemg+ZAuVyCQe3Q1SkUHCjAx2qV5PMcsnAznHpTchpckfWhopFi1uSGB6MOmegqdG81SOMjJz61nsweQAEYU84qYzIj4GeBjmkFi1vwwHBxUplTerAggfwNWPLdCKVCThc80xL5ZbpggOwtnJppXLUWb7DDFZBtPenIS8RG/aqjoO9ZiTq9wpd34PXNSi4DEjf+ND0WgtTSOCijoQeSeuK1kuJPNicBmTOQw4yR39q5oTEHdknoOtbDyC3YbJlZ8DhDkLVoiUTYF0IpJHwrTMmV5ztNWdHlukZRCcSO2N3cGucid5HAILDqQOK1LB2UH51XzTwSeaqLuRKNkaF7bTxyhb+Uu7NyN2T7mprqRbmdLa0iRbWJcHjLH1J9adbwwiLbuLzOQCzPgY+tWraxKyrJbNEgRSzN5nSrStsYOQrHTVtHtYYl3vt2FhhkYfxVjah4YltJjsu4pmkBIYY5B7VbvIkaVSkrGZlJ4YEVLJb3lvb/AG28VjtxGu1RgD3962vdakxfJqmcHaiW0uZUYbWPHNWLe6ESGKdFaNm3K/cH0HtXWXNrFP5jyweYHj/duvHI9ax7TSoNQF0PtAikiGQjHgn0HvWLj2OmNZSWpl6hJbvhoVZCp6k5zVaaM7gU6fWmzQyrM8DqVdTgqeMGnoojhQ/dB4+Y96y3NGrDCSG2k8GlaNo8GMAZPANPCCYf6wAjgrinqQjKJB8o9KLEsZOAcPxkjBHpVG4VQnPPvnpV24hDlw+47DkdsismdwAVUEEdRRqSlcqug8xgWymKijk+fa7YLe1E0u3Axx60iKS6k4OOhzTTKktBU3fNgZqlqKsUAIG3tVu5kAdXX6EVWuw0gyckYpmbRiXYwd+0ADqKKkuUXyuT35NFO5nY94Z40u4YowFG04OcDjPWo/sIurG7nzlXXPmMcfMOOPb3qjPcxrJOs65kkHyk8bc/yq5LZGHSYVFwCruVMbNyo9R7UXIa2MW1kaKSzZyZJNxEiu/yqMVan2FwsYwNwyDycnkAVCiCO31CEqDKjqd3cg+lKkSyTyq8uXi2FSx6juP6UlpoaSV3cqSLPK12djMg5O4YYDtVnZcXkyyhVWGKMyMXPyq5HUVNqUxj0zzWUo91gIq9EAPert08NhbiC2USS3cIG3qqZ68Vat1MnfoYtvayyJAyk+RFkytHgscnk0pVNTtbxISFgU5DMeXPQfjVkSC2H2OAvvZSjbupz6/hS2cEFlOLdyEhGHwRkkVL8i9ba/IqxRSLphsoiiozDzAo5Az3PrWh/ZUt60EUcfk21qnPzf6xh/Eafp1tNdanJMrFLc/LGGHUeppVuWjjura2diJMp5ueN2cUA229CGaDzbW0tIWJhb940YPVj/KtaWwNpKtjJIsjTqrFIz8oHYGiza0gifYGYwKsbgc7ufXtV9IfNupJ2LK7KFUA9B2A/CqSREmNjhMM8trCytGGG6Fedwzzz2rUuobdrd5bchGicKkD9VzWHqKS2tqIoUVZpMfMqkkt/St6NI3EK3D7bhFEhDcblHqe5zTiyJLqU9Ojjy11PGZp4gwAKg5PpWlY3d0LNJiVULkKg+Vc4xTY7pLi7MESou7AKrztHcmpLjZv2RIBCCCiO/HoeP1pol6vUjkb7JC80rPEjAKu1sk/UVOvkn5HuUSNQDMyZJkPYVbktluvsltHFIPmJeRl+Ugdqke0iikZkwsUHyAMOWb2HpVWIcl1EspI9kpm+WzAWOEsMsc9eff0pwt9kIksw0yINgWVOcE/w1HbOEKQSMGkwSIgAQuB1x689aWW6aWYRkKXhUhtgwBnsKNhWuynqOq3NrNPb2kVutsTtViuee/PfvVWK8lguBNLGZSigKoT5VAP3/qas/YIIkR50EhkcqGL8DnPI7UQ2UEFvJPdSbi8+0fN8p9D6/hSaZd422MURG0klnV8XPmlkdfnPIzz71lXVw0ULlWuHWQDex4JPpn1rTuXkfUp8zvHbRD5THGBkHgnHbPNNupolht7cRF7ZP3iIAASM9WPf2rN6my+8zL2b+0YtlxcxpEnCRKmWzjue1YGqWb203mK33l24jPPGDnNbdxcwzTxedA6QkExRQ4Dn6tWNdbHszi4ljljOfLUfcTtk+tZvVam0NHoZ+JfJbcih1O7kdVPuaR5g0i+c208Ehe9S3MMeI/NmnZ/lxnnAqnJjLDAOSTuHBqbM0vcb9oOHDkuQTksazpmY5ONyjt0qcIxDR4Y87gB1qtKGbBU5xwx7UrNj5iJmELMyL1HRh096db3rQAiSPzY5Fw2RwPQ5qGU4kdXQZ7HPApqLKgdCcxsB07itIxJk7j7i42llxlwep7CmySqIRIrENu24HpjrVe/O3dKAeh/HHeufe5aYxneAB1APWhlx2OnhmJ3c5IHSpDMVbLkqPfqazLORlnVeTn7tWbkyFlklXCMcFu1DgNO5oMPLBBUcDdjHaoluY2OJSRkcUqQhnlPmkgqNi+tZ9yZXCIQMKeDjio5dS46ly5iLx4bBXqCOvvWeZXRljjXc2OM1qhs4Q4KkYPtWFqUzWtzkYx2PcVVi46ktneO0jxzNtdeNtats5Z8Dp9KytOtzqN+m1CzEdf8a6G0hkiidXAVVIxx0NWoXIcuXctl3ktxB5QByTkD5jWtpsKQ2KPJ8jkZ5HLVWuU+zSxyFyXdQ3A+77Vea+fb+6jTZ5ZjztzgH+tU0kZ3uPt8fMAitkYyT933Falq1rDbuDEkryJt3Ecx47j61HofhufUdKm1AzeVBESAD1Y1Y0HTjqLP9mdTcRsFeHJz+VEYyZnKcNddiAG4khKxRHbnBPpWrpdrAsri7Em0LnYehPpXT6Zpsts0UV3GnlZbcWHQ+tOeGy025kuEhluDL8qF+RWqpW1ZyzrX0RU0/wAPRXkcN7bkKImJAI6fSo/EsLxWkghkkYMoMkcuBj3FDC/hVY1inWWR8gbiF2Htj196XULaZbz95FIWI53E4/Gr6WM9ebVnPfbYftKhGlNvtGVxyDjmsy/sPLunlt5OG+bG7v2roZNOjl0+W9jY2txGxRCB8snriuSnluUt2EZO8H7x7VlLTdHXDW/KS38Ru41ulYCUx/N6kjr+NYEjNGqpLliDn5q0xLKX4cbiv7wgY3GovLInENwgYsflLelQ/e1No3WjKFuAbgNubbnt05q6jRnzVd8MvTI4qjdxLFcbbd2ZGORj1p9kj3n2ghhviGSvdqmzHJLcuTTszZmbcdoRSR2HSsfUIiqtszlhkEVdDmVWUemMnsaoTuRFtZsbTyf6VIkrGBGvQM2WySRVmPmME9qmeEBwyjHPfvUdw3lxYA/KiyuaMpXh2Sdck1XNwcnOc/WpLxgingnj0qlOdsA4IYDJqrCcdBbsBnUY4HOKKh8xpCsiAFcfjRVL0OdrU9hmgaK38hlBlxlS3X15q5DOv2dm3MzpHtR+ucj7prGeWWUXUrEZVQJMHBIqWxlJ06UynBIDIo4Jx0rO4OOhYiLTW7gqqNkRlV5bI70x/Lj0+F0cfaJHC7h098mprS8EQkmdgkqIWXjkk8UaWlmo3XqsYCXclG5DY6Y+tAWsTXE0c8YtyFRoyArHgHuSah12Vo7iI2LD/V/eI7Y5A9qr6dbvNaXBJGZAxAPP4+2K1LZ4Wihjmt0SJE8tyDktg5zz0NO/MrMm3K9CpbBJ4mnO0XKpuJcdO2MetVY7KdfLuzvePcEZ2PUdwK1lt0bXGaJR5VziNVzwg9T71YsYZW1mey3j+z1fbu25OKaVyeayZpbU/s51s7ddoKrIzHO0nutJbyWlvpsalUdJImZ0/wBscZrDa5u9M1SXTx88YO5wnO4dRir7xQm4ijhADEeZIoOQM9FHvVKdyXTSW+jKulWEkkhG6JVeYbo5DjI9/StlLSRtVeeZv3EZIZFOAcdlpLURJcQyOpaY5JAHGc4FXlYCGdHXMiMHfH8Jz6U1YJSdwSOSS4jLTI0IyUU9V57e4q1qaIUW0wWSQgoVGWz17+tQ6hc24urSOJPMDhXwDje2On+NadpaB4jKBveTO7acbfQD6Vdk9jFtrUqS2cVjdSXUURBlIDgA5HHOKWC3WW5SaGNIyoYiNzkg/wD16df27iVreVmnA2kbHOdx7AVWuHX7OrKzQEScS9+vTHtSY1qat5eXCw2yKdrytudOrAA+vvSXdwo1CJLdxHGy7cMvLEnmqdpMrSI0yzTNGdoc/KGXrxV2GdbjadqCUK2+UjGF/wBknvTV2TaxLqGqJbTyRCzzMExKxXoMcc+lV10qKHbcmRGLgEIzEhhjqfpVVIVhZ3kEixBxIQ3zFyD0z3qG9kdrN5YUVEmyh3Nk4z046D1ouNR6JjL+4EtuzwzFY4iZFAGFkI449aie7mSzDfZGaVxvRmwFjGMZ+tPjeZ3igxE0Swc45JHoT2FVtRvBcyPbxTYOwKxA2rj0Ge1ZNrdmqXRFGG5Ro5Li7U72IWRegZOnH1qLek947JsEccXyoD90Z4ye9Rahcm1jjtQWcOwUbBkOgPTP1qG/uISCIomWctsaPOcfT+VTsbJdTN1G5eW6bywEEagk5xg+tZUtvIUM5lTKgFlbOeT39c1q3EZdJn2j7wjXHUn6Vj6gNzpHG2IwOdxyRWTNlbZEc1011mSTbnbgYHygD+tUWuPJXLKJFIwA/pUrxtCXIHy4BwB1qrdu+Qwi/wCA1Wom0NWXB+VlG4cc9R9ar3D+WC2Qq5AAB6/hUqRsylkAG87SAOgqrPaxgr5MpZiDlWHTFaJaGLkMupJDFGJCGQnIIHSp4bgR5ZsEY4B6CqyS8sjjP+z3xVeSYx7o+Bu45HSqvbUtarUsanKj2E2ecKeR1/8A1VzMMYdYSqb9vTFaF5N5cLDJbecDPf2p/gyx+1astrcAYUnK5wB+NFrsd1GLudN4ts1hnsJgnlwS20ZDxnjdjnpU/kQ3mrJaSKI7UW4UOnKs+OGP17mqOrSGG4hsbpiYbdiVAIPWrEF4YYHhB+dl2Af7PXrVtrUlRbiikM28uAehKk9aiOcMTggHilBYu52/hUElwEyG288DPasGdEb2CYMzjaxA/iX1qtciKceW2Gwe9WU3bQAeMZDGqNzHumZy2Hb0pdTaOhfsI1s5VkR0A+7sJx2610trcSRW0kXGyRAHBGfpzWDYwefbpuIBHynjmtWMFBsByq4Aq+axlNFl2KrGxYsQMfhU6z7oAFI2nqOmaqNhsk9CMfhU1tGI5FGCUqLsEkd7YC+TwqttaSQZeWOVYXXDOWPAx3Fbvw2077Nd6rc3oEeoPMVZBwqj2FcdbyXEd5bzJLIQqjYzfwgdq62e+EtoJIf3d2zndIp5Zj0rqi1Y86rF6rudzJawecJ2B3pk/e4/KuOn1nbfTsBbrAsoYoWyWrG1PVbu5khsTMUYnZIwPb1+ldE/hzTLTTInmQuqDzJ5N33s96uLcnozFxjTtz63LMWuR3aTLasz3C9oxlT9CaQ30t1dE3cLxAYCoRyPel0+zkso4DZJ5lm/zgqoyPxrZuLdNy3DSukzAAHG4D8Kq3czbSbsjkp9OlRbuFZhux5nlduf7voaxLnSN0Hn27JNuyWj7qPcV3l3bsZQ7iMTtmInkA5HBrkYoLzTJzHcKvlJlC6n73uRUyib05nHvD5VwJUAxnkEcVc1aGO9tYJWAJK5+T+H61NqKMkz7drQSE8kfyqqFS3s1bzFmMynAXrER2P1rHbQ6eZuzMS3h8u8t1f5dkgUsfTNVr21ay1a4RSQokblT+Wa0LhW+ztLtJGc5Hei4gdoY7g4d5E3Mc8EVHkbX1MdUMu1CxBPIx61FdIyyuZiSQemK0Una3lZo9gJBXkZwD6VBqKp8sgJbK5PPepKvqYskjBnYoStVJZVdAoJANXbmPBZmB5GcZqjMzB8oAFIxyKEiyrOoljZAc96ydU/cwhcMzGtSNyk2zcFbB7VQvx9oQbc8Dn1qtxXsZtvMY4xvYA54GOlFMIAfA5A7miiOiM2lc9cj3StC/MjDONvHC96kuFDW0DLKrSTN/q14ZTmoJkeJ7VCTtG5iF+8PakkEUc8EwyQfmIHb0FYXaKtfY0rnMd80oG6NYwuCeMkc0x4iL1ZbDmOFMOG5GSKSI7ZxA0wEDIWMmO5FRW888LzwxPiOYgFsffUU/UheXQnt5ZIJY4XjlWQgj5hj8vWteyQXGqLFEPlifAZuCRjkGqhvI5dT85VwqKEWNuSvfP51Zt4A0FzdxXBM7Alx0zntVK3Qid92LDbs0eqtE7KID5kJzyG9M96ntL29sSl0HH2rYRyvXPc1l6QkaSNBeXJgjb7xfOFxzV27sZZLy3WG4DWxiMocjqR2NNXauJxSfKy/ptzbW929xJJi+/569QV7n61r6bbLfx3WonBkQCSKRcBQAO4rGt4LaeyeCRQLkEKqqcbs85rQhhfT9PuFtm2FZBC/wDe+YYOPUVabRnOz2HWMNzdzQrDJuuHlLKQeCo5zmrNtGI9SnifcZJZdzOBnd9KgVmtrKRrNxhAEyBznpmpAWht0upHVjkFir9G9D6GgT1L1ukfmTTGQLOiBE9eT1AqWMqNTcRszxsmZN3GD6596riVZYUuRJl1BdQRkD0ArNkkUyu1xPMqTJhmTnj0P41pczUb7mxey7b2O4sFJgXlyMg9OcVOl1ZXUC3FuF2Y2MrKSwP97FZWlzPDA9tAnmSo+DK7c7e2fpVuV5Ibcgwx4VwZJYz972ob6g420ZdtLyWa4hto4tiA8Fk5Y9SR6Uks1st48BWQbmLPvycr9Pas1LieaX7TaM0MoBxIzfJj+npT7K+CXk5uAjSMfmkbPNJyDlGwiS4vbl90kcSZZFJ5UZ4OO1S3DXSxQ3N0FSIKERCwBHPLkVblljFoYvLMaSndK45c98AHoKo2r2t9J9quEmVUfKKOeB0BH9aGNN9iNZgsU2Fk2uSN+cBU9/rWPcPBcy+XGyAIPLXA49Sc961NZdGs7mIEpvy5ZeTkdF9hWUipFaQJb2qyuYM5PUE/xVm30NYrS5AxMs8MhAjjjibynA+U9uPf3qotzJHMlxIiSy7NqIq4EeOPxPvSXcV0Yrd7ycTTdI4yflRfp3qpHETbzzMzHL7Q4bnb9KzbNox0uMvZTGimLdliWYg5wD/I1mFSYlHl5LEnJ7mrss5+zhVQpEBznqzepqhLMqJhTux68Kam92aWsinPL5SFkAZeuW5OfrVeO9jCuJVDKRjaDkmpGmAwv8I+8Kg+zxqHcsCuc5Azz6VcNTOb7iR3YmsinR0zgds1n6ld/aJEEZRSigBlH61pX1qrR7E2quN5x2NYDDbE/lhS2cE9q36anOrXBXLyu+TgCp5QTErOBk81XhZEZs5GR1Hc0spcgA4AHH1qJG8UV7iITRsEPyqM9OlWPBsBgkvbppDFIiFo2bncSen0p1tCQoGBz0yKtzOttZskShG5zx1qou2pUo3VjEL3VxqRMuTGT1POPeugS3d0gBABdQVUdxXPWT3LXS7ud52qB1PtXWwQeTcwr5bK0eGYP3Pp9KmOqKaszPuswsQGGVHPPQ1m3EakyeY53dV963b6LzGeRlUliW29qotYpIpmPG042+lZ9TWD0ILYsLVGb5s8AU8YO0MoLdcioXdo5fLTLMegrSs4d4+Vds2M7T3qlqynoWreEmASr0J+b/61XUzuBx8pHWobFDFbMJsnzGBUfSrYVi77QQhPftSnoZt3Y5SxOFUfMvJxVyyiPmIRg4+bb6H0NQj92uI0HIxmta0j4QoDvCZbn86mLuKTsi4l0GVGbcpRCo2nvWtBPH9rsFeQDcqpjHDE9Sa5Ni6MXGVQkkZ5qzpt3O15bMozIrgoAO9aKbMpU00dX4n05rbWQ1oPMCrvYD+VdUmpWuoWUMFxvXdGA8YGVPHU+1UvDd7BqGoTQ324akwbd6EelaM1mNLvfPBMkBXgMOh9K6o73RwTeijJbGtZrGLWO0iLBUQDcowPwqe7SYwbbYqsnQM3b3pLSeK5RZ4WyuMY6AVFNPc/2lHAkY8hly0meRVHO0QaonmWShuJ1+YHHBIrIEbz+HbqS7hzJv8AlbqTXS3YJgceUJF2/dzyay4GkGj3M00e1SpwlBSZ51qgAt1iaIARufnHXB9axTKsQmjPzREjk8d+MVrarcSENA7bWY5z6CsW9jWcnyQWjjX7x71jNHoQ2swvodkbQmQhwPTiqaTskCwTBdoJwQOxrRtoWns90vLFtijqSPWsaedUm2OBgAgVErL3jSDvoQ3ETRvlm+VulV0WTYS2NgNWri6WRIAQNw446kVTmYiUxq+Yx0FZPuaJNjLwKVGSGB5yfWsiYNu2gDk9c9K1HYFdpGe+Kzbpl25JG4dqaY0Zk4YyDOA2ep9ao6jMIYgMfPnk+taMwVUJOevXsKwdWllcDZ0BKnHpVLYZWRlkJAPGcnsRRVKAFJTv4BbrRTitCJOzPXTcSRyRSEH5jwCMnPelmkChMY+duR7VWmuppoYodiEozOGUfMxPvVaPebYNKjKckZNcrNUtTalgePT7WWFwfNdkdc8inW85sdSEVyrGNRlTwSB61SspnkWBXX92h5Iq3EIWuikoB25Ic9xj7tUtSHpozd0ddOuYroXG5bkozkn+Js8Y+tVlZrR41t2BdiC6N6jtWWodZbcRCQOTvDYJ29wMVqPexmI3c0aI4UgHPOe5qk76EONnp1LOqJKLiVJh80qDBx3z0I/rVqxmS1t4zM8m0uCyjnGOwrJsdQ8+WSe8EkhYbUIP3PTj6VtR6gUvYmtQE+QqY8A5yMc571atuZyUvhaLryJdqiW0IzGzTK4GTjsCfSkN9NdQwC4+SR+SexwPSokZLeSZoUfykUo8TttJY/zrUtbi3Z4wQGtNpCqRtKZHII6/jVbkbbEVvKJLLDxkJFJuC9yB15qSAWep/aWimEQ/iDjG4+n1qLT7wp5hS2MwRmEWTxk9QatwRwJpyT7WiuPMJlbhlJ9MUCe1x9qkRjjaNlxGMCEnp9TTYvLnBiO1UDZbI5T6UQzQTuymEqGAVpcc+/Hp0qpe2N3aXsbyq3lD5Y8EDB96H3QJX3JsbZxCiMI48kSL1H4dxV+CFLq3uN4V4xtbB479MVUikd4TEFk3OTiU8Bj349KjgWSKwJmQgOx+fackegqkyXG5duokhT/RmWREIUsRlV79O9LJ5ZRDANwU7mLcAfj71RSKcENIHQHlVbsPU0aZBLcPdXlw7sjthI1XO/6UCsS3E87amFSHEWNpAbjP+z/jTdXvpo7ZxZwtEoPlFc5JxTnuFtpJmKuqvhCowSgA5AP+FZ8ckhZZ71WKbspBs2+YvbJqH5Fx1FKTzxLbyPFGsjB5Npw2B2rM1G6Bdo7YyLCGAZx1VemKtzXYe8/ewgSPlY1Q5wP8KqK8DTx/aUWO1SQ4VDySO5qG1sbRTKt+8bHbGWDq2FUHJYHv+NV7iFrdzFNhWzyAcnNWIpRHKJVRWJJdWbsB0NZ12zTysxO8ltxbpWbNkuhWd2LsBuAHIz2qncHex3qCc54q1KuASq8Y61UjCbyzEgAUkNsr+SDJnaSM/MoPYUajcMbVoIQMFtwAqWaZFJLAjBzxULvHsLucEjIx/Wummkc03rdkV1LE1p5j8lFKlf61zcZ3EYwFOfrWhqOqJeW0CY2svysw7jt9azs+XJtVSCRg46Vo9jOCsxoct9047ZHarUZOANvA/Wo5ovLYLwrAYwD0qfB8sBMEdDis2dMUT27CRvmBCgZBzVh4/NBzzniksrQgCTdn2PatGC2BmVdpw5xUl2S1KWi2UdtqMM7AMsbh8deQc1v+LNTXW9ba4it47aIDnb3qFIGRLobQyghN3cU14w4QgcMMD8KpysrEOKlLme5TvV2xFIz8qnAI6GqclwixAkEAccDqa1J7MC0kcEBwQAvX61iy+e0CRbQMPnNZs1j5Fa8gaOVTuKyLyDjpT7K8ls7tGuNzhmyc9xV+8Sa7IZ2UmNRu45I9qyrtptqxlcr2PtTWhotVY7q4td9hb3acJIduewzUcSnJjYcjsaqaXqM6+HotPZMBJDIrDoR6VZkkeQ+YeJMYJpz5ehzxi1uWbR1SYMwD4H3T0HvViV3gmaSJly3AA9D6VQgCnHByOc+9WYXcSiRcBs+nFZJ2KaLKymZFRCFIP3W5zVm61GaTULa4WGNZLYKFCLgHHrVOWGR5N7MHB+9g4xUkd0it5U8ZaQEbSp7Vp6ktLc318QvJ4gXUliVZeAyoOMd663+07e8jS5DkpJIUERzt6dz61wht1MgjikXc4yinsfSrVvfzW0BtJnMSKd2VXIU1vCTW5y1aalblO/s1ELKYZVjtXPzRu3zE+1aiypzKY5GVM7W6j6VwrXcDCOXzJZhjAk28E1tx67eNbobK1ZkBw0hHUeuK2UrnJOmzdnS7Rp7lrkeVtG2Pb0rOurk2miz7BIZJBiJcZ4NZd3rxU5upwIhgnaOC3pVtNWtXU75jPLIuMMP9XVKxPK1ucNfWr3BM4yZgQpXsKzZpJYEWAAGJjyvvXeSqIo3KlHJ56cEiuP8AEFunmRpEfLuUYllJ+9molCx1U6l9CNZmtIHMuBIitnHXNcbfOTOJAR83JNX9Z1Qb3MrqXA2isb7T52DkZY5z3rnqPodlODWoXUwCs6ja55PtTo4kESGN2JAzz61FMnmA4PfOfWpYSFw248elZo1ei0HXA2Rqw+8R3rLuVdpRsXDEdKt3cgHzMe/fvWbfsEQyFshedoFNJEozLm4jCspb5QckCs++dFYLAdyEZBp92yugKKR3b6VTU7t425U/dPemn0CStqVmy0bNuXAbBAPJ9xRUZCrE0Z5kJ4NFWk2ZNnpS7YoWROX9fXipbcnhdxaMfMFY8A1FFIyyIhXPbPXJp6xuty0Mkm0DoR/KuM6EXmkislgl3KwJyyZ7+9KJEUnC7Dvzu7LnrVURxuqJ5e8g5Yjgn2qeGdoHkDIrAjGW6D3qrkNF+G5Blm3SYc4KMD0AqS41a2ltp7eOJRNtCBhzx3NZlkZLi8hjhiWSZgQvIrM3SQ31w8qgFMo23nkd6qL0E4Js6/w1JGL6GJosxBgGwOfbFaEOlRP4julE7LZAn95J1H5e9cjoupql2jecFUnO412OhXAmnLwHzZljZjk4B9x6n2rWFmrGNS8HdGnLaxrqDyzSAt8qq7DcCKheyFrriICS7/e3nA3Hv7CnKJFEMlwcFyd0TJygNXLuaCAKEkSV3XJL9QB/D7/WqkkYxk0VzLJpt6PKcmK4Ys8brjDegq6ilL0NImxZFOcg/MajTypLBPNj3Tscq7cgAdMelPOqXqwq9zxHGMooOSOfWltqO99iwIgiyeaxX5eNx7/Spt7TxNIjDyYQqnI+8e2fWsrVzLNDDL5oMssmXLDBPqPoKt6VcBTI09yIUBw0aDIOKFvYGrq5Evmuyy3cUrN5hyEPy7fb3q08jx2gmMwaUEukIGdmD0x9KzrjUNlqVBkk8v5l4PBqslyZUAlkCMSGUdPl75PrRezHyt2Zq6XPNqFzJcSyhEcbWAGWxjjrxVaSQxxL5Mpi6pgHkD2H9azb+5aVJYt7KzchAPlT6H1pumFrYu1zPmRABtK8sp9DS5ugKC3JYrm7nvibVWiEeY+RnAI5P1qdp5ElEQuZJiVIckDIz2omu42tYobCMSSH93sC8yMeSx9cVAlyYrx2aJA+OAnY+tLYu1+hKscHlXDOj/aiiwwjuq9yfSsSVhDt+QkIDjJ+83erMks376V5PmbjaTy1ZoZguJsNtHC9cVnJo2hFrUtvut4oldYzNIoc852r6D61VuZ87mCqFdeF/u0rfNIEmwp27ix5xntUVzG+TlUURpkgHt/Wo3KWjuUiTtBZuCcnHpVdyGY5Jwf1xUmDt+bjPH0pcZz0IHv1prcJFWKJnfOQzA96r6gpilfeQ3IDAdBmrgUhztGB1yOpqvqkeyzkDkGQkEknrW9M55u7MDxFbLaXAB2hOAuznP1qmqmOOXO4f3FB/nV/Xfn8vH7wIuX3nAz7VkqCrkkMAB8xNbzRlTv1NK3t2dSzDJAHBNaNvC5TeiZjBAJ9D6GqNsC7I0YKqvX3rYhYrbupJCsQcD1rnkdURqy7ZEX+IdQK2XTy4XeRWyeEPoaoW0AEzb2CnHBPf2q9cXMklsg2l3Un5uwH0qblPUbGwTOFPP3jmrSxSSgBI8YAAxx0qvsJsUYEbsk471diimS2bdlJCoZeeSKlXYMbboj748AKV7tzn1qpd26hUJwQh2kAdu1aul2gmMsbR7peE54KEnrTJoBBlQAMOVPOeVqlfqK+tjKCHCgqSQMdOoNUr6EPLuSMEZGV6YFb88kcd20kPKAhlB7Go7mzF3HPMhJRjyuOKdh81jJsumHJKhjjPFaKsinaylgejHjFQqCUjZwDtGOPQVPfyhx5o2qxA+TNQF2DFSpAGMc5FIjOY2UEeuabGw+zk7QGBBLZ/SmLPHuZWyG9B0qOpRciuYQyiQktwGB6E0+7MYljkQAY5GKoShCgcBccAilV8wMoXgdRmtU9LC8zYiu03EMu6QYIc9RVq+1aG+iw8IidFwSDjdisJb4m2EGTs3BunXiozJyAXyvbFXzEuCvc6Ww1jybRbdWCxdQO4NWDrGo2dosYnBhlJO1eo9q4+WU5woAJ46U9TIAFeQhT2PSnz2JdFPU24rp7kljkxxnJGc81t6bfQwDc7KpP3ieWUegrjYglujyRyZI/I1RvLx5PmDbSByBVqpbUl0efQ6Xxj4mW4u7ey0zfuzkle5rk9X1+ZLgxSLItyTgs9Zc9+9vcpcKApjHBHc1l3l9eaneLMyEYPJNEqiepcaPK0khZbWWfUUiuLoBGOeTwCat2cLRyyRpJvVSRkd6ia0lKEAZcnkmtC0UQRAMMMRjp3rLc32LJAKARZCnnFPBRQoPU8dKgD7SWDBgOPrSMTIQd2FHP/wBakQyOaVA3zZxnHFZF9L83ybgh4ya0pm56Dg8Cs65ZXQnJJBqkBlXMg8kovOecVBFE2wHYzO/yqijJJ9hWtp9idSv7e2h2iWZwgZuAPUn6Vmwmzn8VS2dtrEkEaOEtb0RHBlyAuR1Ubs8/SqUepEpXdjn5SyzlIw4cHYysMEN3GKKbdidL+6juw322OV1lBbJLgncc/WitYLQ55zsz0mzkLW8TLkOp3c1ez5x3hjgnOT3PpWLps7xwhZYtyn1FacEzxKcDKEEYI6fSuA7C5bSNvLtkFT94VJJ5ToQAWLt19PrVdUG0uGBUEHYKsqvmW075Cc5IHegGV5oTDPHIjNt6ccYNRxKI0k87LI45I5rQ3CRGEYJUdqfp+20mdzhx0+bkc0LcL6HJoqfaQVXYpzjBzjmtzRNZnsLgCLG7dwG70+G1ie6dm27ZGwcfwj2q3q+lyRpDNHGNhAXfjqfatFs2hScb8rOxv9Rmv47SViFlRNgUnnHv7U7SJHaMvcQh3Q4GR8oHrmsvT4mkjhUsquBls9WA9Kvw5Qy+RM+wjDE8BeeD9K05m9TmaUVyomOpwpMftAZowhwBxgn+lNu7hpZVyPKYsGAB+VwPaql4scq/uk5yAQOQ2OuKJJ1uHiTBUjoB6CkpPYfIt0X5tWkt3kaSRGVRuIK5HNP0W+twrSswfzXKeXyWXPcf4VkRF7h5TKNwYHjbtzRa2hZV+zOkdyXKgq+Dj/PehNpicE0dRJd2ktwbZEMfXc3UVTu7aDbJLHuEG3bGJBtyR1IqhpsMcUgSNnaWQcfMMe+akhllnEqOZJRGduSeP/1U27iUbPci0ye5hSXBcRnlQMZB9eaBfLO8a3MbfK2TIeCR6H60x5IoWVGw2AQJFGQxP1pzRbx58rB36hV5BNTraxppe5EJFF0nlJJHE5J3J1C+1WbkxCPMcrQqBu24yzHsKrNPhFdGBd+MdNvNNnjzukVy+zkEDHPeoK63Ibhoti4Dhy2Sx6/TFU5mCTERg7SQV3d6m3tcshYSMo+UFRjPtUckxSYMoyQuwFux9qllrQSUhpDIX3tnkjiql3JukDA8D8TUwOVb9R6GoHBA3FfvHFIZGnTPBHb1onYMwbACdOPWlZAdxUbVUfnUTHJIY8dqaExY5WRixwyqOAayb1hNbyl2wy4OPXmtGdfJYIMM5qvPbARQySL+7OefUCt6ZjJHPauJFjEO/CEhgWqmryOxR3GePpWhqrQXUa7QoVNxLZ6+grNswpCNhtxGWzW09jKOjNe2PC7Tlc54rVtTlgMEAetZNnPHGjpg+YpBX2rQspmebJPDZOfSuZo6VsbNsEeVC/3c9xmrNyvlIojO5SOSMetQRgWpjYESKyfMueQasKkcgAizxg4xUsa3BUUwOAGyHUfMPuitq+s54IS6sJOFbkfyqK1jSS4Z+VSZMqMdGHapxeXAVidpI6g9hVq1tTOTu9CXS2MVw97Mvzq6yuhPJTH+NUp4FuNXn3HyEZ/MHJOM8imgyx3KmQcDjbng55/EVrRSQxNI8qM5ckfKQNuORihO+hN+V3KIaOKQRzWqSRTIVLdwW7/gelVZFl0xmVA7IxIKt6e49affMfNXe+UPJHYZ9PxoivNodJSJNwwWPJHpQVYoII5IirDEpHGO1V5oxFErMynI4yc//qq7Njy9yL+7B4OKqOFbfn5lAyCaloq+pHC0axHJIYdAe9Vpl2neCACcDFTTcAIvfnjtVR5D5eMnKnrU2KRcRcxlV+/97PpUeVBBbdubjA71n29yBKyg4J6satLeRSEBhmQd16VorCdxJXIcBWyp647U85YBtwVRxx3pskkaAkJwxzwelIk0ZJRR17mi1hpsekuwFApB67jUomL4LDIHb1qjLMowQSWBwRTllwAQeT3oKLkkqtAFwxkBz6DFU5mDkhIzhepp4kOCSyEkduoqH7RtDAct3o0COhC9qk/TGPQ1DFFsVj8uM9Kmcq3Q7cD86Ug7VACkEc0tGVexG295AwJXPanSqwwxzxxg1Kx2HLjPbjtUckjspZzkA8HFMm4oiEcSsCAT2FVzJ+8baMBfXvT/ADmzswP61DIxXHAB75oEV5nJYgqfqKpXLmNGCjn61alY4Kjn6VnXLRoNrA5xnOeapITYlrfS2V3BNZnN3GwaJQNwdvTHv0q2uj3UWofbrfwDdJqRk8xEkvQbdH6htnXg84JrE0jU0sfEumSu8UcaTgs8pwqj1OOlFzoWnyX8znxpprIXJVpZJAxyc/NxWq1MJuxg6rJJbC6mvHb7YZXM27r5mTn9c0Vl61IZrvZPKrWkblfNXkSgHqPY9aKuxyyqK568qBhEynAU4yavyQ7pU2HcqjcccCqGXwjJjlsY7mrTExt5hI24ya4GekOKBELbcIW4PpViIkop25Ve/tVUTCdRHklM9MYqVQx3hiCgAzj26Uhl7IXdtUcnt1pgO13Q4G45x6Co7SUiNWBDcdTU8yNIrXCYZB8pbpQK9hixqWwo2gjjHerqSM0ajJKLwgPQGqiEeWN2RjJ/wqdndI9/DKo4FNaFPsattNgecu3cowQT936VoS3XnxlLeSNXlHQgVhQTvPGh+ZQc8cYBpy4VvMcYOOCvrV8xjyXdzU8q5s/3b4LYw4J6Z9KiaaCKQZRm6Ko6VGLmTgtKGUgck8mmyzLIVVWGUbggUm+w0u5o3D/2hcMUcQtsJ5PUegFVUhkDJH5iqdh2M3f2pZFjJVo3IcA7wT941mTuz3AKkHC4HPNFwSuW7NJbGQ+cfvdR1b/61a0uqR3McccFt5flghcHJbPqaw4xJK4LtgSfL34q4V8qARsg3KDj6U7voEopu7L0TReYu8hpUU428oCe1MQz3E23cFA+/wCg/wDrVlWweVXCIRxkc4qz9rMSiKBMyP8AeJ5/zilcHHsTx6a9zeyPE4McJA69Se49qzpmkZ5dzbo923IPGau3V1OlkLVQdrneVHGcetUfOZI4cIAAe4yM0NroOKfUsXN1MYIouBEi7RtHf1qhy7sp6Dlt3UmrDlim4OGfvUY+SNDtJYnqallrQjdyqkYBB5wPWnSgLbq5Iww4X3pmc7tu0noDmo2kIyHIwPUUgEQIrqs7EKRltvNQM/BaNeQeKlG0fM4yrHBHtUQBP3cc81aZLQyIb5HMiFiOSfSop3eSVAx/djgLmphkl1B2g8nHem2pYyMzIGAGNzH7p9a1gRYzNQs4VgeRf3ZBA24+97iufISKQYlJP8Q9K667Zr37R5rxqVXC5GAcelcjdvGFjIZ/OYYkDLjGK30sYNO5PAVaQ46jsetaunJlzgjPbPasS2bJUg/N6VowTFZc4PzDIrnkmbxdzoYWLDazYY+3WrkEgSYFWCt1I9az4pFkAIPb8qsp87IGPzKCMn+VZPctG3DPnaWU4U5IDcnPepkdgzyLl0J2k+3pWNbXG1lU/dwflParcMhRmAbIPJOaLi5Ualwz3kgddoIVVAzgYFNN0MpFIqkDOeMEH3qpDPh3y4A6D61DIQWL7sk8mi4uVdSeS4jkXy8AuG6kdfxqqAVLbwTjoQaXqQCuD6UyQ8AE546UXuVsKH8sHByo+8P8KgeQDIQioXkAB2t34qtPcqgKsKol6lqSXd94dB0qtK645PGOgqn9qDnC9qaZWfO445x0oQrkMqKzlkyM9M1CjOrHqPpU8kqmRFc4A4wKUOgGFI3+h7VViucYkp2nuM81IJGZ+PlWpIY02k4wW61K8cYUEMvfOByKEhc5VYsJFYLnPBNTr5YKnJ25qvLKQoxnb64qDzsDO7K+1OxaZdmlVYzjCgniqTSttfbnHTJqNp1YAbu/Q0nBLLuK47Ck1cadidJNwww+lWkbbGCeWzg1St1wylQck4ye9WEYNy+MmhITkTxEnJPU889qSTcSMtnNIZAF5cAY61E8m4YBGRRYz5hrEDczHOOaqTSGQs2QcdT6VM8qbSZQTkYX61mS3CoMActwaaQcw+VgpbbkEDNYt/MxJOckt0J+9RqF6VjxGc88k9vasO5meWaOJMmRh/CenuK1SvoZynbVl+x8Sx6XDJG+kaZeKrlhNdRbmH+zn0FVj43E8hb/AIRjw75KnIDWxJY/nWPfrbpbrDLMszt85VeMNWRp1skl7ClxceVAzBXlI3bFz1x3xWiVjklPmLFzcG/unlliiiLuzCOIYVQTnA9h0oq5cw2MN00djdveR84doTERg+mTwetFWokJnrdnJvH73lBgZHUGr8jeW6rKU2McEAZGPX61kw8oAgbeCc4rQZDJCgwMrg4rgZ6j3HMpjC7WU4Jx2pyE+YSDu+XP1pjhSpY/Pg8j1FRmXyyCBgkYwazLLMEm/kqRnjCipo3aGPyUZirHcwPSq5umXayBY3HynA6+4p6I8iZz0JH50D33LSyReUSAcn1p8Tu8BjbaRiqiQSElYQCV5IzVKW6vbaUo0GOe4p9Lit0N+3ZgirGpLL2PStBbSSezSdnjUBtuM4/GsiGV/s6MxOG9PWpreZ/IaPcSuckk8U15id+hphlkZUdVVQAM+n0qAWywytsJKO2eeSaignMSkOMegIq1HtDecz5PcZ6fSgVmtSV0/fJvUg5ACgYINKNPW3D7stgnOR0PpTHujHOij96cbt2OambMavLNvZT8xGe9AtRVSR0LzEKoXKDPT0qtBKbjCx7mcnBYjPFPinW5yGO4EjPoorS1GayURrbRFCgx5mMbzTWwm7Mo3TIBiOQLGp27Rnr61FDLsjd1UHIwGHaox5W8RqeCe5pZIndRhguTtBB4FLcvYgkvCpXaG80tkccVJFC8rqhyGZxkds5pFgcM8qlDGo8s+9Mt38t2IYnHHP8AOls9R77FzUIHs5HhZVRcjpzmq08pDhcFsDAPQEfSogTK7M+5gO7Hg0SPnZsBIHNAlpuQlH2uy/KfSkaPeFYncT/P0qWacsAvG3HI9aj42kRA+/1oAZ95BgkL/CPeljTORjEhHJIxihZWyVOFcdB6GplMgklJYZYDccZxTWpEmVgzHKqeenSm2rhIZIiAVLZLN1xVlYUw8sEhUgY21WaNuDPt4xkjt/8AXraOhN7oY1qGy6AlR1PcAe9ZWuxw3MsLNGF8vAZlHUV04KLMsSozLxtHQH61BcabvmlR1XeeRtOVrWNzN+ZwFxF5cxCk7Oq+9PgZgwLEgit/WdNTCxxxtlQQWz0rn54ZIUHDbR1z0aiUbkxk4mvY3PVJDkVq28uDuLVyqSqhQgMoPc9a1Ir4NgFsHFYSiaqZurIsjKQMMRjNWUdXO3GW7YrBiuMsNz8eq9atfaW8wEFdp6gVFi0zSLEsy5JyOuO9TCdduwBhx+FZwvEdmDkgj+6etMFwgbdu46daOUXMajXBICnGVGRntVWWYq3BOe9Zkl4iSZLkDPPtVWXUsysM/N/DjvVchLmkaU04VcoOPeqMt2xBUgMOmMVnHUVZXDuQ3TaOtSRSSKQTGwjzy3UVagS6iQAuCDggfxY7CrAuMgDjd2qGSO7W1WcwkRucBs8Hmoc3AkUGJv8AeA61apsz9smWSuHHzbg36Go/KRn+VjuHNV55WiRzgghsE0w3ahA0ef8AaJ60uRlKpc1Udogu5gTjvSiVsnjOfTvWNNO4AkeVSDyAKcty2FO4E9OvWlysfOjSa6+XGNuflas+R/3hHO0dBTHZwQBh1Jz70sZTYC7/AHepBz/k01EFUQxhuwXIweOnSpkk2wgH9D1qBpFmGyNiIye/rTTNgrjGMnrRyj9oaCSqEGSPl9KQXWThD1HWst5mZSSQBnkimmVidzEjtSsDkajy71HmHCgYAzUMl3tRsMOuPeqZmwxBBKg45FUJ3VJWTOWHpVcpPMakl8SwTPB6H3rNuboAsH4OdrHPeqxLGEuGVecgH+lZdzdIQECGR17t0PvVJLqZyn0Q+/lILkkIgBbOc/5NYM17K0o8gMiDkN/ET70S288zofM2gtyueDV6K0wGG07hVX6Iyd3uQeFNPh1PxVpdlqBYW804WTDY3/7Oe2en416BpOnNp4slHh21/tPW9QcSWM0Jb7NZodpxnlR1O6uN0HRptT1q0sQwi8+QL5nXYOpP1GK7C6ttHuJdEuYptaWG/lmsJLp7jdMcEKrey5IJX0polqxyF7Z21tq97FDKHtY7h0iOeqBiB+lFMvIP7O1C5srkb5LaRoSQOCVJGRRVpiPTFUIpkjL+hI9atRM7qCSfLXjHvVO3cHzArgBuQTmrKH5slduFx7Z9a849V2JWVxIpiyUYdcdD3FR3MwRWRkJjblHI5BqWC6MabT9zPJ9ai3iRPKmG9ASRzjGaLIeoqDIQOcEc1bicAkMTk9RVaJBIkiMApx8vNWraBnibcMKgxuP9KSiHMkWrWcROGYLj0PerWpyLeFJMrhUA2gY5rLVAitt+bPHzHgVJEGCscDC9RQpNaDcU3cuFUMa7edo6UkEIUlhuI6jNMRUKIzHk/pUiyMRgYYA9qL3Cws8cgi3nk5yfb2qzalPKLOmSDnrTQ6OvlscEdPxqEIFyocgA+vJpWswvdGmXgEamNGZ2HzdiBUEitNbKSxCbvXtUZmCuqE/MeeeOKnjm4LbdxI6Zp3JtYctukWYrTJHQHHJpiwTbR5u5lY/IO5pYZHjjUw7jMT6YwPXNV7m5cSbG5cHjBz+VNjRpxwRqvmYJk24Ue9VXWRcowQMx+8f4aYhZETcAFPUjrQZvNusk7FByXxkCkJK242OPBZN+cHg9jTxFGwEe0bhySp5NLdK+dykEP9w5BOPeo5UWByjS7m4BZRQFxJCpUjIRAcDHf3pmEVJZHZcAYGe9Nu2Ck7MlR3NRHAQKFOeuDQMYzJ57b+Gxxig7Utj+7Ykvy/tT9qlWcn5xkYphDeQuckf3KA0SJoI4JbhA2UUtkkntSpKWnYKxFruKrn0qrGgnU8lUHBGOlXhErhIo42CopyT3H0q46GTtcWESOHbcoCjI4/Ko/JR0iGCzs2W9KtwWyG2L5IUk5z+lPt7J0KnG4Jy2R0rRIhtD5LWa3aNGkAx8wxzn2qy0crpGzgQgHk4wSK00jWWOKfyzIx4EYPLGoZFF3O+4YAGxx12//XrdGTfM9TCuoYvlEZIVsnLdTVMaTDcWMhkcJMpwse3Pmepz2rS1O2ljkiMSfL2PfHuKtpb+bYt5svbPA/SmnqKS0PPdS0JoZSIWGzB2qxzz7Gsh4J1XMsO3nG4ntXp62sU0QO7DjKqcZAqK70lCiqIS6qCG3DAz9aLX3J5rHmquYsbiyN/dx1qRbqSTyxCrMckHjgV076dcyXixbFMa5AYr7VHeaZc2cBEaI+TtMQ6gdzS5EO8jIm8+AkzKuW5Azzisq51dbabbGrMAOoGRXUz+HyxiuJZmAI5jJ6emKrto0cMTzBTIP4cLz703FAn3Zyh1GeWLEcQyx+b3FKsU0wRjJkjqB1rpbHQTcRSTRrjZzj61Yh0hISOQxB5OOfpUMq6WxzlnYvu3Fdx3Z+bvXS6ZaeYZLVzIUOGCIvQ960Rpm2YOi5jQjgDp9avyXMFrMsqnBI2sw4GO4qYqxM5XMxrWJo0tbMSMy5D7jkH0wOxqzoYmW6e12LI2NjI3BX3rWslsYJWvDKQsj5AVc4OOBV94DPqMVwLcI0sWN6nAOOmTWq7nPKV9LHL6zpMcVpLd3NvtjiJIixlmx2Fc2umGU+fPGU8xQ0UfTH1r0TUJbmfUVt5Y1aJQDlWyBWXdqst/5QUNInV2PGPSh6hB20Z5/qsGZoo4QMudhIHAI7Cob61FtFDCuDKGGOud3eu8OmAW6JhXnLF9/oc9qoapZiC92DawVPmlb9aBqRxc6kTNLKHRSMBhxzWeszwybY2ZkJ3c88111/aLdwQfZgBbs+Nx5yKpyaQBNHgDyweT04pMuLM4mMIi7yI1ODnueuaq+YWdVJ/dA/dHUVvS6YJZN9vCREq53MfvGp20U2yKzp80gDY7ik2OJhGNkXd5gDuNwXHTHalaF4wmAzDq2e1b0OjOZ2PDBxjk/d96vJpqrlI0DnG0896dxN26nLFX2s8hDJ129Kr7CIWZkZSowHA5wfWuz1DS4/KEONxVcnjGKp6bZRvHLhg64wFNFxJ6HHCxbAfhlxxjp+FVm0WR5TIEGcZzn9K7uxs4ZEk8yEqqdGI4BqmwQtKrfe9B2rOxondHGx2qKpDRHejfNx29qkjsi0vzkjByrDoa27xGeCRoiu4d+2Kpx/v1K7sqR1HeqvYTjoZ2ki6i1q1h0tib9Zg0OSBhu3J4/OvRBba4kEQh8I6dFf2rvNCTdqyxSNyziPdwc84PAriNLurOw8QWN1dIWWCZXdQMnA/i98da17Ox07Ttaj1afxbaTW0c3n/IWNxLznbt9T0PaqTuZtHK6zpuo2N+v9swvHLcFpPN3Blk55IYZB560Vs6zdWNx4bs7e0ljeae9mvvJTpaI3Ajz6n0FFMlxuWLe9IIYjaQ2GGe1b6XbEiN13RYyCK5SyDzO4I+XpirkVxcxOEKEoOK43HS56t7m5cSiLBA+VuAPSlRcqxGce9VkYMg2gnPJqYy91yB3qLFlhUkdFwSVXqRVp5pAkcchwAc8eprPtJ2B+V9ocEHjrVuGUFFXdv2+oqnoLW5KpdMjrH609XZZjsXcvTPeo/MTzQQSSDyKtqQWYhcA8jmoGx/zlOD7AYp1irRoBIfnOelMQMjkyHAC9D3NJDITgkjI60bAWipYkhcEYx7GpFA3pvA4PWoA3yklstu6e1SRSodwYDIOcg80xFqOVHl3GNZOwqN7kR3W0KVPUY5pkThNwjBxw30qPcZFyCOD972pDLEF2kyFc5n6qPWpVuZPNZ5UQORgEDpWZIhh2mNV3EfeB61ZhU7U807jnkelVfoLl6l63mVXyqkvg7T15plxdLKiqsQjK8yYP3qhlA2blwoI+WmGA24JklDg9SOaVw0HRux/eFdiHgHHWn9XBb5Vxz3NRZkk8sFsIOBnsKR352hiy5wM0hjHyxJDfKex70MSZAG5AHXpQ2za25jvH3RjimqCykO2MDJzTEOJaQqgxgckZ71MmZ0UyD90AQPw9KgHygqCue/0qVPNZiQikD8MfSmiZFmCF2VFQLgHzHGMcD1qdZGa7cgKpdQMZ7etQG9dITbkgFyOdvJHvT4X8kA4UNnqewq7ojlZdt5IzIsfltLHFyRnAya0raHyrSdHUSSyjO5jjFZlqpWRYwMsxDNnpj3rUiVHmd7ifLD7oPRRWkWYzRctFJW3PnAlVwdowE9qkcrHbiGNV3s2/3B9TTDeJZ2UjbSeeqrk1Us0kuIzK+8SzAkDHRa2TMrX1Y9vMWT97i4ZeVCDjn3pZrMKolnY4H8J4xV+wjit7FEaPzJTkIxbgVK9tHHFPJcAuuMsD0X6VRk5nPXwNvbwyonyTNyF7Y6Go7t5FceYd2WBbB4xWnM9rLDEbMb4x94r3qtdxRq0keGAYbk3HAU/wBaLWLUk9yGRFMQIbaSDg4zgU+xskW12SYaZMu7EdVqOC2lCwmSQeWjZIU/eqxeXETeaYg4DDqernpj6Uk+pMuyMS4gXUFVLYAiLLls9RUZkS1geFApeXGGxyPUVpaRarFDI0hC4J3ZOPpgVSEUTJPOUBZOQx7fhSsUhLSBYzshwFK7pCcfLVfT9LlluZmaTMSEtubjPtWpLDYHSXCTFrl8FgOGB9qqyvPa2ywpG0x6lye+PanYjm6ocNO2343yFbOQZDDr+NLqVtAYEtDCM5ykv9c1NOim2gkurjBAyq9vpTZnlmmLNGFjj6ejD2oJu2VLYtpb3SXio8aDBPX6EVqQTXc0SrBGRDIPvEdPpRDGzTyyGJJVZcLuPytRJDdQXEMiS7IM5aIeuO1JCk0SW1ukVl5Urh7gseccmsnyRbzXUrJmRF6kcCrsF4kt7fz28MvnovlKHHyg+oqoJZFsYBNFI25isp3dST1p2JTMmWR44rK7lkXiUuFHcelUWtJ57hbqV2EUgI2kdOau3tut7fwpysVuC2B0A6D8aZdyTC2SSVgzYwEU8hc4pbGkUU5T5KLBujNuQSeMFT2rNnLrFJMBwo2qN39Kt30UJgkkUfKQATn09KqRW4cFyxweinripuXGJfsjhR5mDGASRVwsJJo/MG5WwB7VWtnh8o7hkdPrVhisUQYqRkfLUtloWONXkVB9/B5qeyTZEI2JmmVv3bjjn3qO3UxgIrDzH5+g71pwLFwIGOU6M3rVJkSVihqEV3MGRCqyl8FjyKq21jJPE7GXyJlYqNuCD71rXCC+mEcNw0TIMuy1AuktN5PlXpSJ2IOByaszsUXtWjtYUMm+TrLx1rLu7KA3BkjiyxH3q6dbOGGeW13NIzDiQmsWaEOrKp5U469KxmzpppGFNbxwSGIKAr9azJ49m7YNijIGBXQ3EQb5WI3joxrLuIzsZZRgnpU3NHEoeHrKK68S6bHer5ls04Vg/R/RT7E11llqN3JFYSPotk0w1JrK6hWzAaJTjYenBGT164rndJsf7R1O0sDIYGmkCmTHQeo9+OKvNq+i6fd3UsF/4iSS4JWaRJEDSgcZOf8A9dXFmUonEazA1lr9/FvWXbPIC6jAc7jyMdM+goqaVIGllMJYxbmKFzlsZ4z70VomZ2LULtBtYZwW5Nalrd+YgWVRuHcdxWNtfd8xLYOcVfhuBsCqoBBzzXItD0HqaFpKFLAE47ChBtdy74ycgGqhnYR70Gcn9aikeTzFLhiFPT0qGi0bAl2BAhBB71ZRk2DqHxyP61kRsXdXjGVzkj0rUikjkXnOOnFAMtAosQOAS3fNSpJiHk8jvVVV2qDgMuMZ70LcGJwzwh4iMYxRYZqQuXPzvlWH502LyrUSeYzYxkn096iim3tujQgY4FSW+/y/3gJbJIpWFctRMJE353BhlSO9ORURPL29Dkt3NRhXMgKH5cc8cA1PErl2IAYY5JoGCglSpHXj61LKoULGgw3YjpioonMig8kZq4sDxqwmADNgA+gosJuxAsaGNWzkDtnoaJozuARhyeWNO8sxjzN27nAAFKH2/MMlm45FMdx5gHlL+8BH8WOtRFwrrhc+2KA5RhGQDxTXmIzsUfLwSO1FxCSy4yWxtGe3WovMYjcFIHWp/s3yRyyq2113AZ60kxWQsAPlJGPaiwXXQrvkuozgZqeLLSFFQOScZ9PeljUAO6gbweh9KdbbljZQdu/qfUU0hNkkQURn7igZO5hndSxys0+6AZUDjIxSyM7EAxgYGFUd/c06ESBRIwCrnaBnmm0SmJCrRAzum9m4RcZ59a0USJLRGuQCQc7QKz45mVtxBJJwoHar0iPKER/ml4Y84CiqiQ902T2k3nlI4rUgsSSf71ag0wSQsZygk3AFVPA9jUmkQedBt25AG0MOMGpFWTZJEQjOnTHetYKyOec7tpFswxsiKzruDD5RjaAPenaiZ44lNt69VXmmLbL5Ko5AJGVbvWiGzZqjO26IfdH8VbWVjFyaMOA/Z5HlmdnDcbD2P0p9xLI6ODMWjIz0yPcU9CJw0ko8sA8s1Z1z5sNwyRyh7Zzvye2e1LYLpmlocdra6bOuR5JGcj07isjVrRtQuLSWGVVVG25LcEGrdtGYtOu7YlWgZMgp29jVC1tYY7HyJHbeSGVi3T2q73I21LwSGGGNpAGeP5QQeCM1iavemG4jCphJHI+Xsf8ACtOeMvDHtK+ZEc5DfzFVZ/LtrXzZlVojxluoJ7ik+wKQ+V4RYlnfCDA346mobB4owfM3jf8AM/GQw9MVX1Kz/tbR2tbNjBn5kYdMipLGO5hmS5ndXZEAaPH3iOuaOW5DlbckiFhI0rqdrZCpgDoOoNVtRSVIGi04qJ+M5b86ZE2m6pLM8J2KeSF4wQeaBLbQzhkUtKxwSvzcetA7k/lRy28cUzBmT5lY+vfNJ5dzqFvgnDRvgEN+XtSWNzHcQylLVyrkqQ4xx3q1A8NqiQFWQPwoycqe2aVu4c1thzPeRJAltbjBO1nLYCH1qO1u5xe3IumUBCUQsfve4qSzNzb6PJDdypNKMsRnG7/69FrGjWZ3xlM/MFPUEDpVpIh36mZpt5NcW13a3TPDcRlg524X2Oe+RT5BNOkUg+SyiT7w6u1W4UbVFKT20iI3Dbhg56Yq3fQLbrHBaqqxMNhB7fh2pNhFanOyNDbWUkoWQsybXUA888Vn3gd7uINtEYHzD19BW3qd0uyWKLDSD5VUfw/WsOVmu8MoMUrAAhx93HWs5OxvBXIJ2zcKkW1Yx/CfWqsr4V5MgBiVA6VPd7XaQKNygYz71mX0YWZGlZtpABXsKi5s7rUsfalh+SSM/Lxgd81tCNmZGLh1ReB1rnPtAkkR3UiNzg8cjFblpBM6qYJBsIIKn+lG+gn3LluSXeZEBfOxd3AAq7tWG8jQN5gIDbU7t6VScl4lSNgJIsAgDr7mtrT0t/sqSEBZWb5S3UY6012FP+YY8MskpiiAWTG5we/tWhb2U32dnkhFu8f3B2p9vcbknnjVZc/KpXqDVwTyCEieOQhQMZ65rRamUrlK5iTdAskY85lIZsYGa5XUNJ8qXzkOFLnDKfvfWu3vIJpLiOadgYmQkKv8PrVC4trOOxbAfYEymeQWrOSNYOxwV6oIbcuCelZEx3kq6NuTpnvXV6lawskDAncBkj0NYd2jBS6AMN3IrDZnXujO0aFJdf0/7SkhhaZQyoTn26c9fStjUJvEH29zP4VspG3nOLAvn05zz9ar2drpzp5l1q72U6v8qpEzFfQgjpU0sVixKnxhep7iOTj9a0izKSODvIQLi4LRCJy7b4wMBTnkY7Y6Yoqe+QGaYeY0qbjtlxgvz94/XrRVIjlKULMsYLHc+MHB7VYhmWQAY2r0zjnNVLdhuwAevOakUmNsoCV96xOovo/kNhm+U96vlopyHGAEHb+KsVJzK/zDj0q9bYA4OAP4aL9BtdSzboBIRHnYeea04H3hwiYOORj9aqRksoZQu3uO9OJYMhRnTjkA9R6VNguXEba7Ki4C8kmrEcu5PmUFuuCarw+Wx7Edx3p0YkD8D5B0z1qS7lu3JC8qQPUVNmUMBCeMZJNUYbtld1bll5xU6XDO6hQAetAIvLI8fUgjvjtUkU+5wyZBHHTrVaJyNxzmkWdWG0kg55oA1jMmRGRs78dQaYzEMS0pcdfmPSslr+OK42E5zgZ64q4pDKGbgf0oFYsmYvIUTJXue1BRhJgnJz07VCjO6HYR8vUCnL+7OZDlj79KBkomcK6IMj1x0piMSeeg5I9aXznZcRqQrHpSkgrtwOf1ppCbG3E7v90HHQH09qiAlaQBRlT+lOVBkhDhR1JqdG2xuVU4JxuoE/IiP7xsLhFHcnrVuIrNIzu2FXAUYxn8KTyY1ikkkc+irUfLryQu3gE1Wwr3LkM7hiQoLY49Kjhi37fNCh2O7JOBj2qaFYYtkssm8Lz5Z43Gl8wSAjYDuOcDsPSmSTBkhaNY0WRhyMDNWLS3WSNpZ3O8tgqOtQxOvnpk7WVsYHUiriDbDJJ96TduXmmiZaF+JpPMCbmiVDuAAxn3qxBcG2kBk2sJCSpHUH1rNn83yY5CxLtgKD2qa4URhGwQcdPetEYOxoedHJal3dgpOM/jV2zuPLhbDqwI5JOWP0rDt2t2XbKGXggBTkE0JKY2EUIwD0J6r61qmYyXRD9Q1EW0SeY3E7YAbpUbzyJBG4jJUH5lC9BVLXYk1MrbyuweJxIhHGMVKlyI7jMzkx4ywXoPen1uT0Ker3jpqVtFZudlwPmA4IxUxthK9xbXTebG6feU4K/Q1TvcXN+JrUNJ5ZyrDqB3qGz1Oa71R7SZcPGMcnAApg1dFu0RkiCQOrvGuxieo+tTW8sj6e0V95TDkE4wDVbTYbMahcSrKQ8vDruygx6U8JCLmZXlM1nMpXB4waZmyaSFLe3jeGRlhI4xyM1Vt9VmhgEcyolxICoXsw9aS4iEFmILWYmMAlEfjJ7Cs7zkVob25TbLjy9rHIUnjNAJIsO8VhdxRxxMrzPhio+XkcmnRWf2JBDbzowVtznOSMmqd3MIb5ICSJGG9DjINFwkrHbHgzyAFmHBwO9C1G9DY+2BXSKMxh+Oo680+ysZvt1xJJKjIx3qp6rUAhjIVS6M2OOzZ9TVrTIjEkih2d/7/U/Sp2HbqTGx2zn7cdzr8wcHgVFcWsdyY5objypUBCksdrVZEN+kUfmqkkLtzx2qPVmtVjSEnBQ544xSbaHZPQtWBaN1S+uIlgC5B759KWSydJZpfPMreXiOMngf/XqlLKllG7gCSFwCFbkr3zShWuvLnSVgn3mKdxVXIcNblYQ/aLZJlgBfnzEYYYn+tYs27zWO3YSuwZ7GupiWJZf3UjlpRtDN2FZFzGPN8k/PJv8AnZRwR6/Ws5G0G9jmrhXt38nG5i25j/dqhPCtwHJ3Haa272JVYpGAGz8x7kZrKvSVt28g7RnnHWsr6nSo6WKbQC2JMfIPUZ6GtO3ef7ATavtkU/KGHbvVW+ZBLGYOVZQckd/Q1a06ZXYO0gCt8hApp6g46GyyMunxvHFslZQzOO9aun3dsnkw3EYDMmCG559RVC3RpIzCJfuJge4onRftEE8ZLwrhGPf3q09bmW+jNvSpLiGWP7LBE1sXO4Z79q20lvG0+R3hUO0mMseB9awkktlBXTndljbdjHOa1Fl85R5EExR1xKrN3q0ZuN+hJrMKWzWssrnZKCjbPurWU9wEtZbWBlkgjIJDnnHtU91BNCIY4j5qycIrHOPas+6cwTTQXVsgfbg896iT6m0Y30M2/EZkEi4CuOAvOKw72NFmdARtx1FbE8zRKWjQABdvTtWM0oliJZSJQ/4YrnbudMERWehX99E09lArwZKkl1Bz+JqCXwnrRlGbRcdMecn+NWLCBL7VrezYlY5ZNrFTyB1OK0hZ+GnitJWs7sQXVy1uC1wflcYxnHY5FXBEzbuef3FvIk8kUq4KEqQDnBBwaKvX0JgvbuGVRCYnZCgOduCeM96KvmIscvG4ifO3g9KvIkJhyHGSeaz9yhCCD061IjoQWDEEY4rM0J0A83BjJUd+lW4onzvVeQeR7VTfcSpDMB3NW4ZmAb5iV+nWkhitPOFzFnA6gVcS6Z1Qldp74FV2lWTaqKC2PpRC7mUqPu4xSKWxpLwFO5R3I7mpi7MygkjIyM1ShkQqdwIYHirMkjeWNvztjik0OLvuW8jamAN3UnFSxvhxgDPqe1UoColwWO3HT0qxG53ErjA6e4qSi5GjtKFLAL2zTsDLKyjIPJ9ah3Ngszg9x7UpZnwS4Bxk4oAtCKGFCUjDZ67hmmyykFWRW2gfdAqMPsh3k/jUwdmwTuGR0AobuCVh45RQoPIzToclXzzjrnvVZScEI5YdA2OMVKknlKMHI7n0oGy3b3RcFFwdo5qQSxxRPviJY9D6fSoFkDRjykxnq3rSLITIQTuIx1poza1JFJUAcjIyc96WcOMJkAdcVIMk72ABHTNMJAUsQSWPWnYVxyR7nUBjuA4Gc7jSzxgBY2UvIT0B4FRoTuBVsY6mppflkTy8qMZz3PvQF22Tw2pcF2IEScEE1dAimkDRjBBCrj071ltulJZmIVRya0YhLFbLNvX5uAB2FVEmb01Y9yqzRPCMNyoz6etTJO6BUKBt4wvHU1nRj94XZyCvQCtE3KGOBVhdZs8O3pVpGc3Ymeeb7UqMyMowcKOh9K05CJrZ1lcGVlJXaM9ulYs0krKq2cRC7t7HuaLqd7WRZnLRbvug981cVYwk7k2hPPFbEyRgtjBL9VNV7yOWDWEbeSssW5COmQasndGsc2W2bcsPaobyCOdEmglb1APTHpVohsoDUHlu7pHZleMA59R61o6UTPYSrqEiheRE464IrMuCkkjTIn79YyuOxHvWYYbufRvtCP5LiRSQTwBmqREtdzQihurS0zZsJJl6nPBFWUkjNyrmEG4kQZ2nrSFvKWFdxBdcg9KxNNuri6vpEjUecJWX2wO9PVbC6G7YSQxm6ZIAS0hO1h0/+tS6Nb5jmS6bcplLqV/hX0qHT4HhvJDczblkzjaPumr9ralbmVI50LHIKkcAHvQk2TJopW9qlnNcvNIbiLdvjI5IHpUUtr9scS7vkYY2EcCm3d1PYJcJelGEXzAoONvaoLUT3CSTSkJG4BQLwce9JsuOyJrqNprNDcgKIXyuxuT9asQtbuqtFIrTMPkOP61GY5WKBAJIyoBX+9UDCOKGNvL8vaduPT2pcxTiXlgO4XTRhZWG045GKtASvaM1oQAvBLVnwyXMUCR20uYt+XST0PfNacu1oDHDJsbjJUUmCuizHdbdOkFzMU8s5L54I+lRJtls0uVzc7yQpUcBf61EbCWTyxMqm1KkbhySfp70+2me0ixZAJHG+1om6AU/Un0J50T7Ak7N5QQBmJGaIJ5XsGihkEYkbO4DqKYyTSvCVCiBj86d/pWvBbwX7mIWslusI3RhxySOv4UA7lWRDb24Mybty8EjHzdqz7mPy4o5NjxyFSckZBPpXbLpks0DO7I6hMeWBkg1kXggvLRo5Va3mt/kUEfePpUyRcJXPPrhgx83B8zknPaqEgB5KZHUV0OsW7RXjRkdRggjH0rHlt3VCDlGTsR96udndG1jGlyJPmBCntUtt8kuBtA6gVYmhU8sck8/SoI1Ak2AgljwTQh2Oh024h2M1wjkkfKy1ZgEhhAtlUYYkZ6NWPbylGbPHGBirVtIUT5ivH3QTz9a05kYuGpsQLOsUsrhI4zySnrVwz+ReR/ZbxnVkwSB1rDhmV0w0jBCeRng1a+1edEItixonRu5p8ysCiXLkyQ3JRiRHx82ehqleBsF3kZmU5z7fWprYvL+7dsxng5qO6gRZGiMmFHGCOtRfqVZJ2GPHthY3RIhZSUA6k1zeGm4UHh8ZNbU1wDEIQ5aP09Kx7ySOMNtJUg5FTuy43RFZx3R1SJbFMXolHlkdmz1rRt57lNcu7TOkyvJL58QdT5PnjAHl+h+vGRVTTdQltJobqO2eWXzfl+UnzOOVHvirH/EstnN5Hp+uSyI4eO0Nvgbgcgb/TNaRiRNnC6zcTfaZvtO77QZG8zd13Z5z+NFUr+6uL3VLma7+SaWVmdP7rE8iiq5Acl1Mg5HBwQefpSIy7zzt461FI2YyNxzVdg5VSjAH0qbDuaUdyzOAucdxWnEQUOGO7+77VztvcEkhx8wrStnIQMM7sYyahqxRbWQq33cNnANWA7yFWjGAvJrPVncBeozzmrVtgow5GOtIpovBsnkZXqeaninVJNu7g8VmoSobBBHbJqePItlBwD1J71Nh3NMgxOSr5zyPSp4pdiLk5DenasgO/Q8h+/pVlJo4VCB/u+vekM1DtyoPCn361Knl+WcEDnv2rKafcQTuAPSlSUDKs+89vY0WGaSb2JBDbB09DU5kKjLNnA/GsxbiXdhVzjrVwMUBxkNjJBoC5LHMzqSDtYnG2lU+YQjjjuRVN7htuXyCT1qzGDEoVyeen+NIdy9GRGME/KPfpU3mZZmjjz6gfzqhbK87AJ8wz19K1bWMxF08wE1cUZzdh2yUQ7pNoUgE0EbUUgkDORn+IUrTJsHmJgqeQaTCSOCRgA54PFBKfcs+QirGsr7Yz8zYpmVYNsB25wuT2qJx5jMiglm6dhRLhYwoPzDr7UMZObcl0ZmKqG4/wD1VbNwW3COMsFGMn/Cs8TyYjVtxHb3qV5jFN5bPgsN2R39qtIzlLuP82QMMryzYzjgUQE/bbk3MhdkUFCTwKrzSfZTmc5P3sZ9aqyec0sbQ7Sh5YnuKtGUmbX2lYilv5oZjyCvXntVXWfNuLALKCViYOufrWaLgT6uk+3mFCCV4Gewq3NeJqqvEspXDDfgYxV2Mrvqa0txCYVAcoXXaFPSm2z21nEltLcEqvyqx7k1l3n7yM+SQskONuTmq1us17bRT3YCHfuCHjGD3q0QzZNhHa3Fwqy+bvGf/wBVZ1zbx3tskLySbA2fl4xjsaLe4ub0TSQRYRW2q+PvU5S10kkbMIZFOMtxn15pBe/Une8gMkFp5YZlHBB7VFpsT2mo3JX5hN8yKeMH0qu7m11AMgYM67AwXIFMtmutkiXGw3By0ak4pq4jSQSzrIs4aKRgWOOcY96pxxypdrLaSBGPyyFudwqcNcW2lySuDLcqv3QKoXP2pnt5bXZh0+eP0agE76GjJi4AimVS+NrAnqKW9u5LcxwiAOjEIT/dFVrad8o17GrOowdvGKt2+2TcJmEiEkgDqKm6LsXWgjjkBhkO4AbTniopis/mLLAcqOHHc1X+zRtiGJXEfUHOOavQCZXRJGAGepqWylETS7WSa2lS4xkHPyd6pao8iw+QI5WjkIG5Oqe5rWiEnnl7f7wBDD1FQ3M8sNqCIjJz1A4pJjaLgacW0MUQYg4Ac/qatX9nBb28d1IHEsgxwOvuajW6sx9nuzvA4UheefStqBzPZyvOQYpD8gPVRV2M76mVY2iXEMQdmDA7g2cVt6Mf7Uu7hJQ8KQgqWHBxVSx0yS3dZ7YmSMsCys3X/CtrSbp7i4u7e4t0hOBtPt/WlHzKns7Es1osRW1sblvm+ZmZsfSqd7aloczyL5ok3EDnNXDBbxztdl2MYTCgHqR6+9VLGRrq7YizeHK7ixbI/wD11TJjocjrUJuL+WRi7DPB68YqtqAN3ZK77Q8SYPHJHate9229pNaLLkyyMyn0FLp9vbPp6wOm3ILIM5y317Vjy3bR08+iZw+xS3PJ9cVVa3CSghAT3zXU3NkTNKVQDywflqgtoxRdyEBu59KzaaN1JMxoFCyASAgVKUdWBI4xWqtn5hxgBgMjjg0qWMomEUg+YYP0FFmPmRQiVnBVTj6+tW7BPMXywGMnbNa89jAYGJYeZkEOB1FZ8r/YiHRgznr3quWxHtOYsK0jQbJEARThmX+E1l312/nuAysDwe+aLi/ESSfPgSHJ9M1iXd4q5ZGBY8g56UPyCKd9R2o36ptJIGOCBWJqOpxhTvYZxkAVmazq8LOy7t0hHJ9DWC88s5BdvYfSqhBthKVjsNI1KW7vtPsIbu4iZ5wVaLkxsRgsB64rWjvba51RbCHxvqvnNJ5aN5RCM3oG3eveuC0y5uNL1W0urUBriKQMikbtx6Yx3znFdq2jizm/tS38J3A1CE+ctq1+jpG3Xd5Q+cgdcV0KFjmnPscv4o077JHHfWl895bSzvFI8keyWKZeWVx79c0Vm6troutIt7KOAo/nvdXUzNkzzN1IH8IA7UVqooz9oZ0UivwcDio2jCsWU4qMAAgdvWpEKsNpPArjeh0piIPnyKvw3BAGPxPWs6aIsQA5Qe3erECrEgXcMipZaZfMig7h1Pc1LkrGWkIx6g1niXLDIx65q3Dc5DfJuHpms7GlyeF0ZVDE4znjvVgmNjuBZQOnvVPz8lQq7amP7zO48H0oFcsRzl2ZY2x+FSqyyS7Sudo/OqsLbQojzu6DNWHJGMf6zufWhoafcsxsTIARuGccdqmMWZThhj0AqtHIIrcSZx/PNHnuWAXHPJzRYV7lwyNbjYr5ZwOlTqvnOJJFZmUcZNMR4lZHUpvA6+1MuLoISYcsx98UWHc0LVA8wypYD9KtTFFdfm3D+VZIeYiPa21h1INWY95JcAZ9aVhs0VKQFhFnPTir0RYoAsZEgH3+tYkM6hxs3Ng/Nu9a2FlKqGblm7CnEmQrscJuGQT+tWiFIQOpwDnAqGEo8i70G3tmiSQDzFiP3Ofxq0jJysSTL1ZeCvSmq+2N9+C5GMdapSXMmNzEjsfeo0lEo3Lk9sCixV7IuJcjf87bigwOelTJMhUuQQT0z2qp5C2tq1y7ZeQZ2Cmm582Jpdm0lePSteSxh7RPUfqoe6tGCH5+m41atwYo1Vjlto6Cs7UrkHTk8s4yyhqltr9XaaMuAwXAHc01Gxm5XKwkS31SaHyziYgp37cn86NGZUuLkLg73+U56+tEZiUG6KsZ9mFP9Kk0ZoprdLh1VCcnaOxq0RIfayouoXkZc5DLtqe0uheXU0N0Nscb7dw4BrLiSZ7y78krtU5DNwc1duZZ5Ypo41G6NNxOMfNimZtmktytpeGzjc+Sq+YCvvWdqeoI5FqgzPI3G09s8mqdswaAzp+8meEK+D0qfTooGhjuVXL7flPoKRpZF65Ba32WknIxjI6Cs+R5G1WGRwdiqQWJ6H1qSK8haVzAhBI2svp706Z/MbJwIAMNmpbsxxjzFm01SeechAJLID7/AKnuKsRQpHNMYTsMnzKM5qnblUgRbaIBCeoNNIguHV4XfdETuC9iO1JyZSgtieC4kZmjuotrk4J7cVIZQl0qyRlV2/K2ep9KfbyJIrM6ktjFO8+VpUSRSYgpzkVNy7FiymnvJCHZEkU4BB4xWh5cz3QXduO4FWHes6MxH95AgQdOOtXdJlXckMxlaQElGI7e5oSuNpolhknhupJNgG3171rwbZVyhAaTOYiOB9Kz0uYlExzlVbhcZzVmPyZIFm8wxKp4NLYbVy5bw4uvsrRrEEG4ZOQa0LZrZtPFvd4Dhv3cg7j0qrbNbzRvJLKWwvGO9Rwz2tm8DwswdiS24bgPaqTsQ43L0crw3MqXVuSoGUCN09M1civ/AD2M9vgOg2lXGMCsy41R55fMmU4YHbIi8k9qhm1BZGR0haOc4xlsKSO9Fw5bm45jvE+0eYxRQcpjABx6ViXmqlQYJXfyCMxrj5s/WqT6ut5LN9uuvImRSAFHDVzmoar9olDeaCoXA9QKUp22KhTu9TpDfW8UMjXjESqpMaEcc+9Z0OqMbdlgAVuisewJ6VzxvFkViW3t6mq0uoRoPM3bVHvWbm3sb+zSOtg1EtMyBVBOSSe4xzTU1O3aHayEhEKquOpzXCz+I4cbUXa5P3vanLq0flGRHxt5GTyTTTY/Zo606lGi7UwrDGc9fpV231FXJmuBlVB29seleYJq0sl2ZP4i3y1eutQugD+9yH4IHrTuwdLQ7BtRU3DNEx2t1XHArPv7zZAVz8zc1zz3v2QBwxc4zz2NVLvVQdrSMuD6dqEmw5bEepahI85iDZNZd5PIIwBJz0+lVL26SS4LQE89zWdc3hIKr361ShcblYrSbnncFs4qxGQqjH3h3NVImzk85NSE/KATyOtdEVY5JyNXw9qkWmeI7C8ugTDDMrSEDJA9R9OtasOlCz1yHV5/EumizhnFw12lzmV1BzgJ97cemDXJJZaheq8tnY3dxFnbvihZxn0yB1qXw/o2qjxFpkk2j3wiF1FvL2rYxuGc5HSqvYybM3XtSjutUvLmBfLinmeSNP7gLEgUVU8TFT4j1chQFW8mCqowAPMPGKKLoi1yS2umZAJBgjocVYtsFmctz6VShcCPLLmrCupwynFczOpMuIBIxyxxT3Vd/Gc+tVhOCrBeopRL6c4qGaJ3J5GxFnPzHtSR3ix4WIl2PbHAqIupxv4GOtWLV02gKFA9QKNLDuyzECjZf7561NHKyq20YGcE1BcJ5ibvMxg9KeuUhxu5Y8mpZUexpQsCq9dw5BqRHK7mkKjnIHrWdHJI0e3IBHQ1Ye4/doMYcdcDrUFlmRTPFn7pB4NODOYeuccZ71AkwkyJTjHQetWrdk8vKtnn5QaEguJEXMbZGEx1PWrVkoMewgt6560xyQoAA2P2H86cnloEEZJOfmPrRYHqWwpBVACq/wAXrVpA64GCPU1EGZlITkDvVqFtnyMQdw4JqrBew4lUjyCS+ecDr9Kt20wcDggHuaqxAQR7bl5JCOdzdT/9aljImjZgw9qaRDl3NXeERQvzAck1Vnl3AsOEB3E561XecLEsalW9TmqWoXWyycxEE4xtHWr5Ohh7RJFyMyXcJaM/uyecmiCSK1ChDlue/WseK4ubmGK3tT+9bqOmB3qTTx5F9PNOCyooCD3q+RIh1GzekuYG0ecTO5vMbFjXkjPeq3mJDBDb/MoKYJ7k1DKYS/nbju28kVh6pdSW15bSj5kdvLBPQe9aJ3MbWWhsNeW1raMXYyOzY2EcVUt5WMszRKDM/IB7CqOoXIhMbOoZN2M4qa4uIkuopkcRkjaQO5puIlI17cOZFS4YBChy2ehqijf2d5pd2a3jGcnvk1WtNVVt6kCRpG2fN1/CnXzrPdJZxklWQkg9qaSE79TR01/OiuiSUWRi0ffimwyTx2k0kkpFw4JCH24q6jwpapAAFKDCkD86yrO8aS+nyoZosBc/3al7jSL2mukFhGWY7iNzirMVzDbWDtCNgGWrHNvc3N8JGYRxch1PAxUcixCzaJ2YQB9p57elIaLGmXKL5ewktKd7t7V0AmQjb5e5W5z6VhM0UKi306MDeuAfQVoRmWSyaNDg4wMVEjWOhNvWyd9rM/mtgL6VZsIoQrGBtm/lvc1mW8cyXMYILALhmPatSKHyo/8ARlG4HPPpUtmkVrcZDAI9SkZnZRtAKk8Vrowd+gYHhecZ+tQPlyweLa2MliOtN2MQpjfbj7wx1qGy1EtxBZZEUna33cVdtgsF4HYjjAxjis3AAXk8HNWN0bDzfMJK8VNzRo0rd8yTBBt3njPFOguZLSGW3YDef4WXIPvWV5ykgklj1BHap5L6OSLEjtu6EmncEjUiNuLCNJCQ+cMqdcVMlxYQKqxedIWUqd4xtPY1hx3i26sU+bdg8jpVC81gGTlByeeetFyeVtm5f6yI4ESV2KKm1doHX3rCvNeaaJEmlJRBhR0rntV1WLLbBu5yBmsGe+eUsBnB7Cmk5PQpRjFampqWqkykxsQehNUFvJMMWZiO9UhDOwLbSFPensjZEYYH1GetbKl3E6nYtjVm8soByR1rOubqRsjdx9akaNiR8oA9+KglTLY+U49KpU0L2hAxPAYn605VPl8sTinpFkdeRzirMcSAKyYBx3o5R8zZUhJHJO30rTikcmPJbjnJ6VWfHQqBUbTbMDLe1HJfcfMaOoynyCXYHmucubgOxCdPSrN3KWxknHpms+THORj+tVGJLkMlZVhVedx6n0quSRwaezgZ44zUcj7skjpwKq1jNzuCHjA/OkupBFGSaiaTy161m6jM1wwRW47mnexlZydkWLfxHqllH9n0zU7y2hzuKQylVz3NSHxR4kdhjXtSAHYXBq/4V8M6fq+n3s82sfZJ7VTLJALYysYh/GuCM+4HSrUWh+Gdwz4rO09/7Of/AOKpJN7m8cPb4jlWV5ZWklYvI5LM7dWJOSSfrRW9DaQM0ojcSIGIVyNu5QeGx2z6UVpyWNLRWljCWTYAe1SwTIWIPTNZ8O7dhzn2NW0AHCjHqfWuM5ky0oGG2n5jVhPukdM1mxxuJN5c8e9XlfeeKTQ4seIfMjy5zU8YQLiMnAqvEWViueBUyShSBsGM9aCky2CVQbweemacGO4FgCDUMk+7qeB0FDSAR55NQ0Wn1LRkABwx3VJGRgluWPrVJHzGCVwakjdjwWOKnlNVIuRs6gcdevtWlEIiu1m+fHasuOQgYJz05p+/GChOc5qdhvU1x5armM4A7ZpYZGhdU4KnqxHNVYiUi+ZM981OkoITeM+1PqJFyBiJ2CHCnrV6N1GGIJwetZ5woEicYPI9qsGQEAZ+X0qkiJSL7yC+fahIQcc02RktoHjCA+X1IPJrNsG2zyBWK85H0q1YzTSPNviBbJ259K3jFHNOT6CJJGsIkwPOfll9Kp3FzGjuWUjI4OKrAStfNG67N75J7ADtU+rKDGrHawA+XBrS3UychsTJbWzXcjmKXHyge9R2F5Jd9f8AVJkNnjJpNQfzbFImcZ4OarrKuzEZ2o2cgdzRdvQnrc0Y9RSS1Z5PkiGcDoTVbU2jlsY22BQv3fUn1rLUCeY20vyon3AKvT3CKqxFN7r68ihA2OlRZoRBKT8oByao+VJLIUVvljkDZzzinmZpGLM6rngbjS2d8kV9+7RZdhBb39qpJPclto1mtIUaKaM9eB659abdRbGRYp9sn98DnHpUeo6jHGJJ5MKW5AX+Gq0Ehktkd3wzcjPWpbSZUdUbDzuqlWJCkY3dzVW2by7xyOFKjkmop7kRW5UfvGxjcexqtaxvAXkuC8hkwRjtUp3NHE1oLvz4ZlZyXBIpTLCttFHOhYuegX+dNt18uFyigFuSTVuzUSwg7gpHGT1qZOxcYsmZHN1A8SARkc+v0rUjUAjA2heoqkC7xmMsA3QN6VYtQUO3eztjOT61m2axiKqSGdpPNAU/dWr1pI8YOSH3dqhRGKk/KG64qeEfuwdwHPIqGy0i1JNkEBs4657VGC8jMd4EfWqszb8jlcnlgKeZ9jAYzSZSL8YRdrdeP1oEhjTPkrg/rVFrnagyMEngUwXOw5diwxwKRRbuJlXd5QAJ4IFVTexw8FV9TuNZd5q0ERIVcvjOQa5zUdTedsLwM8VSg2K66nQ6hrSBWVXOfasC41KSU7cn1zmqEaO4y4IGetWbaIRncwB9jW8aNtzOVVdBbdPtLsXk2nHpyatrFDFtaNhj+Ivzj8KSPyojuz1/unmmtcwAuPJLj+EE9K3SUdjBybJj9nfIdnfB4K9/rULPaowKxu7DsTxUEj5DYwikdBTA6iPt1pN3HZFie5aRSzIoU8AYqpvUqAQBzwaV3JGWIwO3YVAGBBPBApNj0Jc4PzHj2oEgycHjFU3lJPWlB2/NnFId7EplJJHVvftULyEElz09KikuAobaAT0zUDMzAKep61dg5ySSUOQRn1xVa4Zi2GXgdqnkxHjjmoJZEXJJHPWmkQ53IHO1QpHPWq9zMioMnGeuKguLo7iE5NVWR2bL0b7FU4SnogkkaYgcgA09Yc5AxToYSe3FX4YAPvDFOMbnp0aCgWtD0fWpQLzR7O/baWQTW6McEjDDI9jzV1fCeuDj+xNR6cAW7Vf8NX93ZPcWtrFcXMF3GUltoWYEn+F1I5Ug85/CqeoL4jsIme6GrwoBy7+YAPfNV8Jo079DFd2s52ikUo6EqysMFSOCCPWis6V3klLOSzMclic5PrRUOpqS6avqZ67Scg8j1qSPhjk9aiRlKgAZPrUqlGUFu3c1ynkkwBB9qlQiLlSTnmoVKuoAzj1qWPaqjuKQ0WIyQCyr19akU7lIP1po+UDJ+Wo1DeYAo+XrSKVicDact+FLvIGcE0y5HmfLnAFOUELhaLDTsWUZSgJJOKeqM5LDgdQKgAYLnA5p0bMpBLYWk0UmWVk/eBSBg9asrKFfII24wKzsAHzA27n1qdF5yCTnmpcS0zWtpNxxuJPoelWHUptDcsOfpWTCxhYnk5HSrUF0Cx6k9waBOVti6t0+4YBLehptlLNiR5/XjHaq13cIySeVkuBjA9amsIpLeyE0h3Y5PPStIpmMpalmymLfvLobAThQOtW55ZI1LwtnccDnmsHUr0yohhXncFGO9XUkEMCrLJ8+Mn0q0Yt2I9Tu5GmS1iy0jDczelKIJJYkMpCuSCB6Csm6uDbq91CS7MdufartlP50bST7t3RV9qom4sjG482EOAytgHtUMkqqoUEFgdoA6+9SRbFkcxfU/Ws23tHa4Nzn5cn8KuJk2Tm5WXVJGj+Qqm3n19ai+0k3BMm75fvN2qvdgwXixbP37d/606YPFbukoBwcn3qmmtwWuxcSNJLZXOWw+7caRZ445yFGC3JxTbGV5LC4dUxGp61DcSILZXQ5mY42j0oaS1Ba6EsVzHdrLG4yC3U962FMaonPFc/agQsCeo5q3DJ8p8w8ZzWT8jeK1NOV485GSD2q3ExWAKpGO1ZcUyEYFTq4JyWGKy1NTWQApyRk+9WLd9oCqgHrzWRFMhYbWJ9eatJIoIYEgUmik7G3HdKq4k4NTtLuQbW2571z5lAcPyQexqyt7HuALjpxS5S7nQRTDaACSB6jrU4kXG8dfSucOohEwXODzSSasuNykAjsKXKylI6M3AHL/dNQzSx54bk9B6Vyv9tFXOcEDnrVO51RppCQ2N3oapU2wckjpbrUkjZlZhhfTmsWfWJASIXyvvWQzksTv684pi4wMHGeea0jRXUh1Cy0pkJZiSx6U5AA3AP0qGN9nIGfrUyzRseWG6t0kjFybJwxCDGVx3p5HGTu9jmqouEYbQQDSif5QNwPtmlrcdibzNqkZ4qGaXy13HNR+YcE8e2arvdAc5B9eKbQkm9i55xYbsfKRTPNAbJ69qpG6XbkBiB7VXkuyzfu42J6Zx0pFqEn0NGWceWAT35qubhT8qnFUJYp5CN7474xTltsA7WJNKzZssPK2pZdmYAA8UjOzDqfTFMijm2FRzVq3sbyZj5aDPY01fsRKi1voQQou0Mxy3f61MAI1LudpPTdWpbeF7yTG+UqDzgCpbvw1bxRAzyyOR6mrVzF8idmzmpLkMxC5kf0UVWS2nnfBQqPU12tla2kVv8Au40GO+Oax9RmVXKpxV+ztq2FNqb5YoxGtYbYZHzP6movKMj54z1q2IC7ZI+961ct7VTx70b7Hq0aaiilDAeDjGBzmrihT7Y7etTTR7AAOPrVORiqnnj09KeyOuKudh4fkup/C81n4fu47bVTcl7hfNEUk0W35QrHHAPUZpmk2Pi3TtThuNQv3s9PRw1w95dq0bR5+YFSTuyM8AVlWEWl2fh8arrFnNfm4uWtoYEmMSptUFmLDnPPApD4esrvUtI1DTWlutCuruOCaKZsyWzk8xvjsezd6xkzKUUr/wCRyeqyW0mrXklihSzed2hXptQsdv6UVY1i2jg1jUbeIbYormSNFz0UOQB+lFZGbdjl1ypyD+dPVsx4JxTWbPfg+1IExhiM1Fjx7kokMSrgk55q3G5baD1IqoCJGHHA6ZqwySOMpx70WC5YUuzfMcL6VbjIKDnOO1UYuFIJyfWlhY88Y7UmUmaCSRsSM8ikZwTuJ6VVAIzgYOKgjWZmZy34Uhl8zEdOfrUi5eLDECqcW8D58HNTRgkjBxjtSKTJxsXALGrJ3nBjO0CqSOrucdRVlZNy57ikVctecV54J9hViCRSEOB7+9Z+9QN4PP8AKkabkBSQ/U00ricjXjlj8xokHIGc1A3mLG6s7Bc9KytKu2e4mbdkk4FaqsWB3nnOarYz3JWRVljc9hwvoap3U0wnZmUmMcYp0Mjz37fN8ijjNXJJQM4xjoTVozkZLXe5xbJF8vUmrFpKY5efvE96gN3Gtwyou5iecU5ZVnnKKvtn0qrmfUmuBMtwfKYASjB9qIXeELECML19zSzyLlUBwy9ahuiqqoQ/N3OaOYOXQdcbZLhpZRukXoR2rOv7gyPtU8k1aWcwQuDgs/8AFWbLIN/3SfenJ31HFGhFcSwWjWwYBZDk4qMSkNgdRVW2inv5ljXjmvSvD/h+1SEC+iBwM7sVSi5bhdROR0/TLnUZQIlJz0Aq+uiTxFkmUhxwQR0r1wWumWGm20mmxATg4OR1qjqiCS8jmeELgglscH2q+WMTanUv0PNG0NygGSv4Yqs2lzqCQTgV6r4muoL77P5FusbqPmwKwpLX90SBkdxitOWLWx0wSe6OBFrcxkhM03fdI2COldo9qqjIxmoZLNDklRmo9lFm3sl2OU+13CnGzio5pJiu8A59K6drOPGAoyaQWMeD8vWl7KJXsEcm09ycFhkCnJJI454zXTnTYmbAAB+lMm0pQQMflR7NESomAI5+2MVLbWktw4UDrxWlJphjzsY/jU2mE2848wDjoa0UYnPOnNK6LsnhG8gt42mGN4yDioW8LXG0nf26YrsP7cN9FHFM4+UcCtLTIPtkyxowye5rVwhbQ4Pa1I/Ejz6Twrei337ifbFZcmjTJJ84bjrxXtV1btbkwybeB1FVTZwyHLqpP0rN010Lp4xrdHkP9m7Co8puR1NNFiqOSynJNevTaXbyJjy1z9K5u/0VVugqHknpUSg0ddPGRlo0cQ1nnOB+FPjtEAxsGPpXpll4YhMQMnzMR1qX/hFYM8Din7N2uN46ktDy57UYAC8dcYpBYOx+VO1esReGLRc5VTVqHQrWMjCAmk6bZLzCC2R5KmhXEmHKHaBj61q6X4ZN3Lyu0DsRXpk1tDDCQFGAKr6OI9z8Z5pcijuYyx05L3TCt/BtvGoLDJrSttFt7YDagBFdE+0YPSqdy4WNmGCKrS5yOtUnuzFuY1XIVe1cl4jVhCV6V0OqaikSMF5Jrj9RuJZ8l2/Oquup0UaEpO5hwSS5KDP1zVe4j+Y/xN61akYxkkfeFVnl3NkjB65qG2z2aNC2pHEwB+ZfpirAYY+UEVXDYZiOW9aQzKEw3BIyfammdnsxtxcDJyMkelU5JskgDH1ptw69VPFVPNGTzkms5TsbclkbenapdW+mX1gogls7jlo5kDBGxjen91veq+ga7faBqDXGmSJlsLJE43xyAHI3D+R6itTwraqtmL2WO2knmaTyvtQJhgjjAMkzgfexkKF9TU+kXceu2kzaulhLFHIiOYbcQT26uQqzKVADKGIyp7Vi5XOeUlqrepyt7cPdXdxcyoFeaRpWA6ZYknH50VY1C3a2nmtZdvm28jRvg9SDjiinYyZxpZsDYOvSpI2bhWFR2nQ/Spl+9Unh3LQ2BMKR7VIkxXAPSqKf638asr0agL2LeBncvemvkMCBj1qOLtU1z/qlqWVFjmlAAA4NCJtyd2SaYOq/QVYH+sX6VJdiujyM7Ky7V7Gp4m8tQSRn1pH7VE/3qAJ4ZEMhVeKmcuq4T7xqpEORVi1PD0APjUlcyc1Zk2iHK45GOKrXB/cn/dp1l/qB9atEydhdKtRDEW2kZPJq3vLEmPkDrT0/1BqKH/UPRuxdBmnZmuJXII5wKltN73FwxOI09e9TaaB5I+tQy/dm+tUZvchgg8uSSXbkseKmR1iGWUBz14qOT/Vp9KQcyJmkyrCOMO0pzk1WMpkjJ7itPUuLaPHrWYP9SfpQPcrRTFlYOCCKftMjKu3r6VEn3WqzZf8AHwtWtNSFqbGjqLSdGOM9ea7ux1F5lVSvyk4rhk/4+Y67XTf9RB9aqMm2W4o6kMkyKPuFQMVV1PUnWJUKhlQ8571Yuf8AVR/SsS75Az60SLopN3Z02jW8mot9pMaLkBQprQ1jSGsbdpCE2MMY96bo3ywJt46dKh8VyOYcF2Iz0zVp6Gik3UsczDZGaYxqw6Zz1xVO6i8pzCeWHFb/AIdA/tPGBjZWHrny6pKBwMngVSelzuptudiP7OBCZGHaqj5OCoGK0pP+PFarxAZk4H3aGzojsVEZc4A571IDhuQMHiqsf3vxNS3PRKm5o4oc67shelVpEGR8v41LF96j/lofrQmS4Ir4ZDuU81dstVuLWUOjHcO9V5fufjUI7/hV3MKlCElqjo38STSODISzepq1B4hUgAgg1yTdRSdCcUmccsHT6Hfw63Cxzu5A9ayJ9TB1BpMkr7GubQndTcnzOpqubSxh9UjF3PSrHWoPJXc4B9CelaC6jEw5Yc9Oa8xticdTWlCxOMk9fWp52c88LFanfJdpyNwP40rXKg8EVxEMj+evzt+dbCsxRskn8aiVSRlKgkybXdWSGE4OT6VR0PWIc8uFLGue19j52MnH1rFiJW6iwSOe1RzN6s1jTXLY9f1i5gtLJZUlDt9a5C71eWXcFYhaqFmax+Yk89zVGXqa1erua4ehHqNupmbJJHFZM8rH3yatXh/cmqMXQUpHs0acbFaXb82QMk1m3LBCOmfart79x/rWRL98/SpbsehSgmOSYjOap3c7EnHJ9RTj0P0qnJ1rGU2bcqHbyRjp3pwTBBzmoz0qXtUJmcjovDepwrarZXE0EMsLSNA1yCYJkkAEkEhH3QcAhuxFaKmw0mBzPDp9jbMyySQ2179rnu9h3LECOETcASTzxXDHvUeAC2BjpTSOSdNNtli8upLy7uLqYr5s0jSPjpljmiq5+8aKq5gz/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory papules are present on the nose.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40346=[""].join("\n");
var outline_f39_25_40346=null;
var title_f39_25_40347="Echo in mitral stenosis";
var content_f39_25_40347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Two-dimensional and Doppler echocardiography in mitral stenosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that echocardiography should be performed for the following reasons in patients with mitral stenosis:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Diagnosis of mitral stenosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Assessment of severity (mean gradient, mitral valve area, pulmonary artery pressure)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Assessment of concomitant valvular lesions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Assessment of mitral valve morphology to determine suitability for percutaneous mitral balloon valvotomy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Known mitral stenosis with changing signs and symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Assessment of the hemodynamic response of the mean gradient and pulmonary artery pressure by exercise Doppler echocardiography when there is a discrepancy between the the resting Doppler echocardiographic findings and clinical findings, symptoms, and signs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of usefulness of echocardiography in patients with mitral stenosis in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Reevaluation of asymptomatic patients who are clinically stable to assess pulmonary artery pressure every year with severe mitral stenosis, every one to two years with moderate mitral stenosis, and every three to five with mild mitral stenosis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40347=[""].join("\n");
var outline_f39_25_40347=null;
var title_f39_25_40348="Causes of neuromuscular disease";
var content_f39_25_40348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of neuromuscular disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Spinal cord",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demyelinating disease (multiple sclerosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disc compression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidural abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringomyelia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetanus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transverse myelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Motor nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyotrophic lateral sclerosis (ALS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical spondylosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Critical illness neuromyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poliomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diphtheria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guillain-Barre syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic (porphyria, diabetes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mononeuritis multiplex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phrenic nerve injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxins (heavy metals)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neuromuscular junction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Botulism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypermagnesemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lambert Eaton syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myasthenia gravis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications (neuromuscular blocking agents, aminoglycosides, anticholinesterase inhibitors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organophosphate poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scorpion sting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shellfish poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Snake venom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acid maltase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic abnormalities (hypokalemia, hypophosphatemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malnutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitochondrial myopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscular dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myotonic dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymyositis/dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhabdomyolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40348=[""].join("\n");
var outline_f39_25_40348=null;
var title_f39_25_40349="Diagnostic studies for pediatric respiratory distress";
var content_f39_25_40349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic studies for evaluation of acute respiratory distress",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Bedside testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulse oximetry",
"       </td>",
"       <td>",
"        All patients with respiratory distress",
"       </td>",
"       <td>",
"        <p>",
"         Normal values despite hypoxia seen in patients with severe anemia, carboxyhemoglobin, or sickle cell disease",
"        </p>",
"        Falsely low values obtained in patients with pulse oximeter not correlating with pulse, poor peripheral perfusion, venous congestion, methemoglobinemia, certain nail polish colors, and in patients receiving vital dyes (eg, methylene blue) during surgical procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        End-tidal CO2 (ETCO2) measurement",
"       </td>",
"       <td>",
"        <p>",
"         Confirmation of successful endotracheal intubation",
"        </p>",
"        <p>",
"         Noninvasive monitoring of ventilation in intubated and non-intubated patients",
"        </p>",
"        Noninvasive monitoring for sedation in children",
"       </td>",
"       <td>",
"        Measurable in non-intubated and intubated patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Electrocardiogram",
"       </td>",
"       <td>",
"        Clinical suspicion of cardiac disease (eg, cardiac murmur, gallop, differential pulses or blood pressure between upper and lower extremities)",
"       </td>",
"       <td>",
"        Typically combined with chest radiograph to assess heart size and pulmonary vasculature in order to determine need for echocardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Laboratory testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Arterial blood gas",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Determine PaO2 for calculation of physiologic measures of oxygenation (eg, A-a gradient, PaO2/FiO2 ratio)",
"        </p>",
"        <p>",
"         Correlate pCO2 with end-tidal CO2 measurments",
"        </p>",
"        Measure pH and correlate with venous pH",
"       </td>",
"       <td>",
"        End-tidal CO2, pulse oximetry, and venous blood gases may be used as less invasive methods for ongoing monitoring of oxygenation, ventilation, and acid-base status if they correlate with arterial blood gas measurements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Assesses for the presence of an anion gap and renal dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Electrolytes, blood urea nitrogen, creatinine",
"       </td>",
"       <td>",
"        Patients with metabolic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucose",
"       </td>",
"       <td>",
"        Altered mental status",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ammonia",
"       </td>",
"       <td>",
"        Altered mental status and other findings suggestive of urea cycle defects",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carboxyhemoglobin",
"       </td>",
"       <td>",
"        <p>",
"         Smoke inhalation",
"        </p>",
"        Altered mental status, headache, vomiting and possible exposure to carbon monoxide (eg, blocked furnace flue)",
"       </td>",
"       <td>",
"        Pulse oximetry is falsely elevated in the presence of carboxyhemoglobin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methemoglobin",
"       </td>",
"       <td>",
"        <p>",
"         Cyanosis in the presence of a normal PaO2 on arterial blood gas",
"        </p>",
"        Exposure to agents known to cause methemoglobinemia (eg, nitrites, benzocaine, aniline dyes)",
"       </td>",
"       <td>",
"        Oxygen saturation by cooximetry identifies the presence of an abnormal hemoglobin if specific measure of methemoglobin is not available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D-dimer",
"       </td>",
"       <td>",
"        Clinical findings suggestive of pulmonary embolus (eg, low oxygenation, pleuritic chest pain, wedge-shaped infiltrate on chest radiograph, and predisposing condition [eg, sickle cell disease, thrombotic condition])",
"       </td>",
"       <td>",
"        <p>",
"         Pulmonary embolus is a rare cause of respiratory distress in children",
"        </p>",
"        Imaging options in patients with moderate to high clinical probability and elevated D-dimer include ventilation/perfusion scan, ultrasound of extremity veins and deep veins, CT pulmonary angiography, and pulmonary angiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lateral neck radiograph",
"       </td>",
"       <td>",
"        Clinical findings suggestive of epiglottitis, retropharyngeal abscess, or ingested foreign body",
"       </td>",
"       <td>",
"        Croup can usually be diagnosed clinically without a radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest radiograph",
"       </td>",
"       <td>",
"        All children with significant respiratory distress and those with focal lung findings",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Forced expiratory or bilateral decubitus chest radiograph",
"       </td>",
"       <td>",
"        Suspected foreign body aspiration",
"       </td>",
"       <td>",
"        Hyperaeration noted on the side with the bronchial foreign body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unilateral decubitus chest radiograph",
"       </td>",
"       <td>",
"        Assess whether lung opacity is due to parenchymal disease or effusion",
"       </td>",
"       <td>",
"        Loculated effusions and very large effusions may not show evidence of layering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Echocardiography",
"       </td>",
"       <td>",
"        Assess cardiac function and presence of structural heart disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abdominal radiographs (supine and upright, or cross-table lateral)",
"       </td>",
"       <td>",
"        Significant abdominal tenderness and/or distension with concern for intestinal obstruction or perforation",
"       </td>",
"       <td>",
"        Other testing (eg, ultrasound, upper gastrointestinal contrast study, abdominal CT) may also be indicated depending upon clinical findings and likely etiologies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Computed tomography (CT) of the head",
"       </td>",
"       <td>",
"        Clinical findings suggestive of increased intracranial pressure or intracranial mass lesion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40349=[""].join("\n");
var outline_f39_25_40349=null;
var title_f39_25_40350="WHO criteria for contraceptive use in cardiovascular disease";
var content_f39_25_40350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization medical eligibility for contraceptive use: Cardiovascular disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        COC",
"       </td>",
"       <td class=\"subtitle1\">",
"        CIC",
"       </td>",
"       <td class=\"subtitle1\">",
"        P/R",
"       </td>",
"       <td class=\"subtitle1\">",
"        POP",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         DMPA",
"        </p>",
"        <p>",
"         NET-EN",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         LNG/ETG",
"        </p>",
"        <p>",
"         Implants",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cu-IUD",
"       </td>",
"       <td class=\"subtitle1\">",
"        LNG-IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Multiple risk factors for arterial cardiovascular disease (such as older age, smoking, diabetes and hypertension)",
"       </td>",
"       <td>",
"        3/4",
"       </td>",
"       <td>",
"        3/4",
"       </td>",
"       <td>",
"        3/4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        History of hypertension where blood pressure CANNOT be evaluated (including hypertension during pregnancy)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adequately controlled hypertension, where blood pressure CAN be evaluated",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"9\">",
"        Elevated blood pressure levels (properly taken measurements)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Systolic 140-159 or diastolic 90-99",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Systolic &gt;160 or diastolic &gt;100",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vascular disease",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        History of high blood pressure during pregnancy (where current blood pressure is measurable and normal)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Deep venous thrombosis (DVT)/pulmonary embolism (PE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        History of DVT/PE",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute DVT/PE",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DVT/PE and on established anticoagulant therapy",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Family history (first-degree relatives)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"9\">",
"        Major surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        With prolonged immobilization",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Without prolonged immobilization",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Minor surgery without immobilization",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Known thrombogenic mutations (eg, Factor V Leiden; Prothrombin mutation; Protein S, Protein C and Antithrombin deficiencies)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Superficial venous thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicose veins",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Superficial thrombophlebitis",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Current and history of ischaemic heart disease",
"       </td>",
"       <td rowspan=\"2\">",
"        4",
"       </td>",
"       <td rowspan=\"2\">",
"        4",
"       </td>",
"       <td rowspan=\"2\">",
"        4",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"       <td rowspan=\"2\">",
"        3",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 3",
"       </td>",
"       <td>",
"        Continuation: 3",
"       </td>",
"       <td>",
"        Continuation: 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Stroke (history of cerebrovascular accident)",
"       </td>",
"       <td rowspan=\"2\">",
"        4",
"       </td>",
"       <td rowspan=\"2\">",
"        4",
"       </td>",
"       <td rowspan=\"2\">",
"        4",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"       <td rowspan=\"2\">",
"        3",
"       </td>",
"       <td>",
"        Initiation: 2",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuation: 3",
"       </td>",
"       <td>",
"        Continuation: 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Known hyperlipidaemias (screening is NOT necessary for safe use of contraceptive methods)",
"       </td>",
"       <td>",
"        2/3",
"       </td>",
"       <td>",
"        2/3",
"       </td>",
"       <td>",
"        2/3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Valvular heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uncomplicated",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complicated (pulmonary hypertension, atrial fibrillation, history of subacute bacterial endocarditis)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    1: A condition for which there is no restriction for the use of the contraceptive method.",
"    <br>",
"     2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.",
"     <br>",
"      3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.",
"      <br>",
"       4: A condition which represents an unacceptable health risk if the contraceptive method is used.",
"       <div class=\"footnotes\">",
"        COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Medical Eligibility Criteria for Contraceptive Use - 3rd Ed. Available at: file://www.who.int/reproductive-health/publications/mec/summary.html. Copyright &copy; 2006 World Health Organization. Revised from: Medical Eligibility Criteria for Contraceptive Use, 2010 update. Available at: file://www.who.int/reproductive-health/publications/mec/.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40350=[""].join("\n");
var outline_f39_25_40350=null;
var title_f39_25_40351="String technique";
var content_f39_25_40351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    String technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 227px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Loop suture around belly of hook and wrap ends around index finger. B) Grasp shank of hook with opposite hand and depress firmly. C) Pull suture until taut and jerk quickly and firmly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_25_40351=[""].join("\n");
var outline_f39_25_40351=null;
